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Abstract 
 
Human pluripotent stem cells (hPSCs) differentiated into complex three-dimensional 
(3D) structures, referred to as ‘organoids’ due to their organ-like properties, offer ideal platforms 
to study human development, disease and regeneration. However, studying organ 
morphogenesis has been hindered by the lack of appropriate culture systems that can spatially 
enable cellular interactions that are needed for organ formation. Many organoid cultures rely on 
decellularized extracellular matrices as supportive scaffolds, which are often poorly chemically 
defined and allow only limited tunability and reproducibility. By contrast, engineered synthetic 
matrices can be tuned and optimized to mimic the embryo environment in order to enhance 
development and maturation of organoid cultures. Herein, this dissertation primarily focuses on 
testing the hypothesis that using synthetic microporous polymer matrices can guide key 
interactions guiding stem-cell decisions for the reproducible generation and control of organoid 
cultures. One study showed microporous synthetic biomaterials can guide the assembly of 
pancreatic progenitors into insulin-producing clusters that further developed into islet organoids. 
Immunofluorescent analysis showed the scaffold culture facilitated cell-cell interactions by 
significantly increasing protein expression of ECAD compared to suspension (42 ± 5% vs 21 ± 
4% of total cell population, n=4; P<0.01). PLG scaffold cultures supported cell-mediated matrix 
deposition of extracellular matrix (ECM) proteins associated with the basement membrane of 
islet cells as well. Furthermore, hPSC-derived β-cells cultured on the PLG scaffold showed an 
enhanced insulin secretion index compared to the suspension culture control (1.3 ± 0.2 vs 
0.43 ± 0.06, n=3, P<0.01), indicating the development of functional β-cells. By modifying the 
stage that cells were seeded on scaffolds from pancreatic progenitor to pancreatic endoderm, 
xiii 
 
islet organoids showed increased amounts of insulin secreted per cell. In addition, seeding 
scaffolds with dense clusters instead of a single suspension minimized cell manipulation during 
the differentiation, which was shown to be influential to the development of the islet organoids. 
An engineered insulin reporter further identified how mechanistic changes in vitro influenced 
function within individual cells by measuring insulin storage and secretion through non-invasive 
imaging. Human lung organoids (HLOs) were also evaluated for in vivo maturation on 
biomaterial scaffolds, where HLOs were shown improved tissue structure and cellular 
differentiation. We sought to examine the contribution of polymer degradation to the number of 
airway-like structures with the hypothesis that faster degradation would permit more HLOs 
fusing in adjacent pores, thus, support larger airway-like structures. Investigative studies 
demonstrated slower degrading 85:15 PLG HLOs had significantly smaller airway diameter than 
the faster degrading 75:25 PLG (224 µm vs. 333 µm, P<0.05) confirming that scaffold pore 
interconnectivity and polymer degradation contributed to in vivo maturation. Polymer 
biomaterials were also developed to modulate local tissue and systemic inflammation through 
local delivery of human interleukin 4 (hIL-4)-expressing lentivirus. Microporous scaffold culture 
strategies improve organoid complexity and exert fine control over the system using engineering 
solutions, thus, allowing the community to build more realistic organoid tools. Taken together, 
the microporous scaffold culture has the feasibility to translate organoid culture to the clinic as a 
biomanufacturing platform.  
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Chapter 1: General Introduction 
 
1.1 Motivation and objective 
Regenerative medicine has the potential to cure untreatable illness by replacing 
dysfunctional organs damaged by disease, age or trauma.  Being able to develop human tissue 
in a dish, from its early development to its organogenesis or adult stage, would be a key 
breakthrough in modern biology. Two dimensional (2D) monolayer cultures are prevalent in cell-
based molecular investigations, however, 2D cultures often fail to capture the complexity within 
native three dimensional tissues1–3. Significant drawbacks in these systems include an inability 
to achieve in vivo-like cell-cell adhesions4, considerable differences in gene expression 
profiles5and cellular morphologies6, marginal nutrient and metabolite gradients7, and an 
absence of extracellular matrix (ECM) interactions8. In order to attend to these problems, three 
dimensional (3D) cellular models9 have been proposed and developed in diverse fields of 
developmental/embryonic biology10, drug discovery11, and regenerative medicine12. Of these 
models, development of multicellular three-dimensional organoids that closely mimic the native 
structure and function of organs has received a large focus.  
The tissue engineering triad for organoid development comprises a combination of cells, 
scaffolds, and biologically active molecules13. Scaffolds are three-dimensional constructs with 
the prime function of being able to mimic the physico-chemical properties of the natural ECM13. 
In addition to structural stability, the ECM has been shown to provide tissue-specific biophysical 
and biochemical cues that are required for tissue neogenesis and homeostasis. As one of the 
crucial players of the microenvironment, the extracellular matrix is a dynamic ensemble of 
proteins and proteoglycans, which surround cells, provide anchoring sites, and control growth 
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factor signaling14–17. While the influence of soluble molecules and growth factors on cell fate is 
very well understood, our knowledge of the impact of the physicochemical properties of the 
extracellular matrix is only just beginning to emerge.  
Scaffold-based platforms can play a valuable role in advancing our knowledge of the role of 
ECM in regulating various cellular functions. Our synthetic polymer scaffolds can provide a 
tunable niche, as their material properties can be tailored to mimic those of native tissues. 
Investigating the influence of an artificial ECM can help evaluate what complex and dynamic 
roles the ECM plays during organogenesis. In addition, when organoids are destined for 
transplantation, they should preferably be able to establish a functional niche during culture in 
vitro, and then continue proper engraftment in vivo. To avoid the need of disrupting cell-matrix 
interactions established in vitro, and to maintain physical support against hemodynamic shear 
stress, it is preferable that the matrix used for in vitro culture can also be transplanted together 
with the organoid to promote functional maturation at the ectopic site. Furthermore, the synthetic 
scaffolds have the potential to be functionalized to present factors that can promote cell survival 
and function. 
Investigating the influence of a supportive matrix using scaffolds can provide new insights 
for a variety of tissue engineering applications being developed to treat diseases, like diabetes. 
Type 1 diabetes (T1DM) affects one in every 400 children and, approximately, 1.5M people in 
the US18. Pancreatic islet transplantation has emerged as a promising therapy for T1DM19,20. 
Despite impressive initial improvements in metabolic control, few islet transplant patients 
maintain long term insulin independence21,22. Furthermore, islet transplantation therapy is limited 
by an inadequate supply of donor islets, a problem worsened by islet loss post-transplantation. 
Thus, the field has turned to human pluripotent stem cells (hPSCs) as an alternative source to 
generate a limitless supply of islets due to their ability to self-renew and differentiate. While 
multiple protocols for differentiating hPSCs into insulin-producing cells have been established23–
25, these traditional culture systems can generate heterogenous populations consisting of 
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polyhormonal endocrine cells in addition to monohormonal β-cells. Moreover, the development 
of hPSCs to mature glucose-responsive, insulin-secreting β-cells is inconsistent, and not all 
transplant recipients return to normoglycemia24,26. During pancreatic development, the 
progenitors congregate into structures called islets that are surrounded by a dynamic, 
supportive extracellular matrix27–30. The microporous scaffold provides a 3D environment that 
physiological represents the architecture of the native islet environment compared to traditional 
culture systems, like air-liquid interfaces or suspension flasks. Thus, one objective of this 
research is to develop microporous scaffolds that support the differentiation of hPSC-derived 
pancreatic progenitor cells into 3D islet-like structures, which will lead to maturation of glucose-
responsive insulin-producing β-cells.  
This research can also be applied to intestinal organoid models derived from hPSCs, which 
have been one of the pioneering organoid models in the field31–36. Intestinal organoids have 
been used to model infectious diseases that are specific to the intestine37–40. Matrigel is the most 
common matrix used for the culture and transplantation of intestinal organoids, however this 3D 
matrix is derived from mouse tumor basement membrane and consists of extracellular matrix 
proteins and undefined growth factors41. Since Matrigel contains undefined materials and may 
have tumorigenic affects, it cannot be easily translated into the clinic. Also, the properties of 
Matrigel cannot be easily modified. For these reasons, another objective of this research is to 
define a scaffold matrix comprised of synthetic polymer materials suitable for in vivo intestinal 
organoid maturation. Scaffold technologies can also be paired with existing immunosuppressive 
therapies, or with emerging tolerance therapies to prevent rejection. In order to translate this 
technology, scaffolds should be designed offer the necessary signals to achieve the goal of 
regenerating complex tissues that can fully integrate with the host. Thus, our last objective is 
focused on demonstrating that polymer biomaterials implanted into adipose tissue have the 
potential to modulate local tissue and systemic inflammation and metabolism to regulate 
immune tolerance. It is in this context that the work presented in this thesis is concerned. 
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1.2 Thesis Outline 
The cell culture system microenvironment can facilitate and/or promote three-dimensional 
structures and cellular organization by recapitulating the native environment of the tissue both 
physically and chemically. Biomaterial systems, the focus of this thesis dissertation, were 
developed to direct the cellular organization and influence the cell phenotype within the 
organoid cultures. Chapter 2 is a review article that summarizes the current applications of 
biologic and synthetic biomaterials utilized for different 3D organoid systems and discusses 
mechanical and biochemical material properties relevant for tissue formation. In Chapters 3 
and 4, microporous synthetic scaffolds are designed to develop early-stage islet organoids then 
investigate their maturational heterogeneity using a novel fluorescent insulin reporter cell line. 
The in vitro differentiation of the pancreatic progenitors to early-stage islet organoids on the 
scaffolds will be compared to suspension cultures. Chapter 5 then investigates the physico-
chemical properties of microporous scaffolds that influence late-stage human lung organoids to 
form airway structures in vivo. Chapter 6 focuses on local delivery of immunomodulatory 
cytokine Il-4 from scaffold implants that can be used to regulate a specific set of immune cells 
for tolerance induction after organoid transplantation. Finally, in Chapter 7, a conclusive 
summary of the thesis research is provided along with a discussion on future directions and 
potential challenges that must be addressed before these strategies are tested in humans. 
1.3 Significance 
Our research will use microporous scaffolds to create a 3D environment for the consistent 
and efficient differentiation of hPSCs into functional organoids that can help transform cell-
based therapies. The 3D environment provided by the scaffolds can be easily changed to 
recapitulate the native environment to promote the maturation of progenitor cells in vitro and in 
vivo. The cells in contact with the material can obtain signals from cell-matrix interactions, while 
those cells not in contact with the material will receive signals from cell-cell interactions. This 
organization of cells into a tissue, rather than a collection of cells, would also facilitate direct 
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transplantation of the scaffold without manipulating the cell within the pores of the scaffold, 
unlike cell aggregates which are dissociated and reassembled before transplantation. Thus, less 
manipulation combined with maintaining cell-cell contacts and providing ECM signals is 
anticipated to improve organoid survival and function post-transplantation. An engineered 
fluorescent reporter tool provided non-invasive assessments of maturation and function of the 
organoid cultures, as well. In vivo, insights on how the scaffold pore interconnectivity and 
material degradation rate influences organoid tissue growth and maturation can be utilized to 
inform future engineered matrices. Scaffold cultures also offer the potential to create 
controllable environments with the appropriate immunomodulatory cues required to promote 
tissue viability and function in vivo. The biomaterials, thus, provide a tool that may be capable of 
directing tissue formation from organoids for the purpose of modeling normal development, and 
for enhancing cell-based therapies.  
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Chapter 2: Designing Biologic and Synthetic Scaffolds to Guide Stem 
Cell-Based Organogenesis 
 
2.1 Introduction 
 Advances in human pluripotent stem cell (hPSC) biology over the past two decades has 
led to many new and exciting opportunities for engineering human tissue from hPSCs. The ability 
for hPSCs to self-renew in vitro and differentiate into cell types from all three germ layers makes 
them an attractive source for generating a wide variety of tissues. Continued advancements in 
differentiation protocols have made it possible to obtain fairly enriched or highly pure populations 
of hPSC differentiated cell types for tissue engineering constructs, including neurons42,43, 
cardiomyocytes44–46, liver hepatocytes47,48, and pancreatic endocrine cells23–25. In recent years, 
several examples of various organoids derived from hPSCs provide an alternative strategy for 
direct engineering of tissues from hPSC sources49–51. Functional organoid tissues are inherently 
comprised of multiple cell populations that interact within and between populations as well as with 
their extracellular environment to dictate tissue form and function. These heterogenous cell 
mixtures are organized in three-dimensional arrangements that can cover multiple scales and 
ultimately work cooperatively together to carry out specific functions.  
Organoids are physiologically relevant and can allow the study of biological processes, 
such as cell behavior, tissue repair and response to drugs or mutations, holding great promise in 
both basic research and translational therapies. As a result, there are a wide range of applications. 
In terms of developmental biology, organoids derived from hPSCs that retain features of their 
developmental stage can help in studying the process of embryonic development52, lineage 
specification53 and tissue homeostasis54. This research can also help investigate the development 
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of stem cells and their niche. Organoids are also suited to study infectious diseases affecting 
specialized human cell types. Lung organoids derived from iPSCs from a healthy child carrying 
null alleles of interferon regulatory factor-7 gene were developed to study influenza virus 
replication55. In regards to personalized medicine, organoids derived from hPSCS derived from 
individual patients could allow ex vivo testing of drug response56. Tumor organoids, for example. 
can be employed to assess the drug response for individual patients.  
Despite these significant advances shown by hPSC-derived organoids in different 
manners, organoids are in an early stage of development and need more robust and dependable 
culturing practices. Substantial differences that set them apart from their in vivo counterparts 
indicate the need for technologies that improve organoid generation and reliability and that allow 
the development of key tissue- specific features57. Influencing specific stem-cell signaling 
pathways that drive organoid formation requires a precise niche environment. In vivo, the 
extracellular matrix (ECM) plays a critical role in the development of the complex cellular 
phenotypes, while abnormal changes within the ECM have been considered a driver of 
disease58,59.  
Given the essential role that the ECM has in maintaining the physiological stability of the 
microenvironment and guiding tissue-specific function, biomaterial scaffolds have been designed 
to mimic this environment in an effort to enhance tissue development.60 Compared to traditional 
2D culture, the novel 3D biomaterial scaffolds create a more satisfactory microenvironment for 
stem cells by including both chemical and physical signals across the ECM. Based on the design, 
scaffolds can be used to directly regulate cell signaling and elicit lineage-specific differentiation of 
stem cells through chemical cues or cell-matrix interactions.61 Furthermore, the cell adhesion, cell 
transportation, cell differentiation and matrix organization can be modulated within the scaffold to 
direct stem cell differentiation. Hence, surface, mechanical, morphological and chemical 
properties must be precisely considered when designing a new scaffold for in vitro stem cell 
development.  
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For transplantation, scaffold designs largely depend on the site of implantation (e.g. 
tissue type to be repaired or type of stem cell to be delivered). These design parameters can be 
manipulated to mimic the native ECM and consequently function to promote new tissue 
formation and stem cell engraftment (Fig 2.1)62,63. On the most fundamental level, biomaterial  
scaffolds should define a three-dimensional (3D) space for tissue formation, as the 3D 
architecture can support the infiltration and assembly of host cells into structures and induce 
gene expression programs associated with normal growth or development. Cell seeding and 
infiltration of the scaffold can be facilitated by micron-scale porosity and/or cell-mediated 
degradation cues introduced into the design. Furthermore, ECM derived adhesion peptides, 
protein fragments, or native proteins can promote cell adhesion leading to a number of specific 
cell processes such as vascularization, bone regeneration, or the creation of a tissue-specific 
niche64,65. Trophic factors may also be necessary within the environment to drive cellular 
responses leading to stem cell differentiation and tissue formation. Finally, tissue engineering 
Figure 2.1 Design considerations  
 The hydrogel design for delivery in tissue engineering applications is dictated 
by the biocompatible polymer type, porosity, mechanical properties, 
degradability, and signalling factors in the microenvironment. 
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and regenerative medicine may be nearing a tipping point based on recent investments by 
industry and an increasing number of clinical trials. For translational purposes, the design 
approach should consider manufacturing issues such as availability, reproducibility, processing 
strategies and generally the issues that will be needed for FDA regulatory approval and 
commercial viability.  
This section will provide an overview for how to design scaffolds to guide cell development 
and promote organoid generation. We also discuss the scaffold design parameters that are 
available to enhance transplanted cell survival and appropriate interactions with the host tissue. 
We highlight engineered material systems for culturing organoids with the aim to establish 
organoid cultures as powerful research platforms. 
2.2 Scaffold Designs to Promote In vitro Organoid Development 
The in vitro organoid model is a major technological innovation that has quickly become 
an essential tool in many basic biology and clinical applications. This near-physiological 3D cell 
culture system facilitates the investigation of a range of in vivo biological processes including 
tissue renewal, stem cell/niche functions and tissue responses to drugs, mutation or damage66–
68. Organoids offer a valuable bridge between traditional 2D cultures and in vivo human models, 
as they are more physiologically relevant than monolayer culture models and are far more 
receptive to manipulation of niche components and signaling pathways than in vivo models. 
Much importance has been placed on the self-organizing nature of hPSC-derived 
organoids, while the surrounding extracellular environment has been largely regarded as a 
passive matrix in which a pre-determined cellular program can play out. However, these mini-
organs are currently imperfect models, which would suggest that their native tissue counterparts 
depend on both the self-organizing potential of the stem cells as well as complementary effects 
from the microenvironment niche to establish complete organization and function.  
Biomaterial matrices are often used as a 3D culture environment for organoid 
development in order to recapitulate the scaffolding support provided by the native ECM tissue. 
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Both biological and polymeric materials have demonstrated the ability to establish a complex 
microenvironment for the cells to develop. Hydrogels made of natural biologic materials, like 
reconstituted decellularized ECM, present sufficient cell adhesive-domains to promote cell 
attachment and can be remodeled by enzymes expressed in the developing organoid. 
Alternatively, engineered synthetic matrices are a suitable alternative to conventional organoid 
culture scaffolds because they provide better tunability, are fully chemically defined and can be 
easily produced with minimal batch-to-batch variability. Designing the appropriate biomaterial-
based strategy is advantageous towards optimizing organoid growth and controlling the 
geometrical, biomechanical, and biochemical properties of the organoid's three-dimensional 
environment. We highlight systems that have the potential to develop organoid models suitable 
for different types of manipulations and high-throughput applications. 
2.2.1 Biologic materials utilized for organoid development 
The intended function of an in vitro organoid system determines the design specifications. 
Modeling developmental processes in tissues to generate functional organoids dictates that 
closely mimicking the in vivo tissue is a top priority. In that case, recapitulating complex niche 
components and interactions will be crucial. This niche environment should be designed to permit 
the cells to mature, remodel their environment and undergo self-directed cell sorting. As the 
complexity of the native ECM cannot be easily replicated, a growing body of work has examined 
the use of scaffolds derived from decellularized tissues for stem/progenitor cell culture69,70. 
Biologic scaffold matrices derived from the ECM, like reconstituted decellularized tissue, help 
provide this complex extracellular microenvironment through the retention of compositional, 
biomechanical, and structural properties specific to the native ECM. Increasingly, studies have 
investigated the use of ECM-derived scaffolds as instructive substrates to recapitulate properties 
of the stem cell niche and guide cell proliferation, paracrine factor production, and differentiation 
in a tissue-specific manner.   
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Techniques for tissue decellularization have been reviewed previously71,72, but commonly 
include enzymatic, chemical and mechanical steps to destroy antigenic cellular material while 
preserving the construct and composition of the native ECM as much as possible. In addition to 
being utilized in their intact form, decellularized tissue can be designed in a variety of modified 
ECM-derived biomaterial formats including sheets73, hydrogels74,75, microcarriers76, porous 
foams77,78, and 3D-printed scaffolds79. In order to closely mimic the in vivo microenvironment for 
cell maturation, DeQuach et al. designed a myocardial matrix consisting of a nanofibrous and 
mesoporous structure with re-assembled nanofibers approximately 40-100nm in diameter80. They 
used this method to generate tissue-specific extracellular matrix coatings by decellularizing 
skeletal and cardiac tissues. These decellularized matrices facilitated the maturation of committed 
skeletal myoblast progenitors and hPSC-derived cardiomyocytes in 3D culture. In a similar study 
by Rajabi-Zeleti et al., 3D microporous scaffolds derived from enzyme-digested decellularized 
human pericardium were shown to enhance the survival, proliferation, and differentiation of 
human Sca-1+ cardiac progenitor cells in comparison to collagen scaffold controls that had a 
similar porous structure, as well as intact decellularized pericardium81. 
 Tissue-specific ECM provides a good scaffold model for organoid development as they 
have been widely hypothesized to promote lineage-specific differentiation in vitro. Flyn et al. 
showed that decellularized adipose tissue (DAT) established an adipo-inductive environment for 
human adipocyte stem cells (ASCs), inducing the expression of the key transcription factors 
CCAAT/enhancer-binding protein alpha (C/EBPα) and peroxisome proliferator-activated receptor 
gamma (PPARγ) in the absence of exogenous differentiation factors82. They then tested a variety 
of DAT-based bioscaffolds to confirm that adipose-derived ECM displays both adipo-conductive 
and adipo-inductive properties by improving the in vitro differentiation of human ASCs in 
adipogenic culture medium and by promoting adipogenic differentiation in proliferation medium 
that would normally inhibit adipogenesis83. Thus, decellularized organ scaffolds have been shown 
to provide structural cues and ECM components for 3D tissue morphogenesis.  
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Another commonly used biologic scaffold material is Engelbreth–Holm–Swarm (EHS) 
matrix, which is a reconstituted basement membrane harvested from mouse sarcoma84. The EHS 
matrix, also known by one of its trade names Matrigel, consists of a mixture of many different 
ECM components, which provide a complex environment for embedded cells85. Matrigel provides 
a physiologically relevant microenvironment of soluble growth factors, hormones, and other 
molecules with which cells interact in an in vivo environment86. Matrigel has been widely used as 
the gold standard scaffold material to provide 3D cell cultures for a wide range of cell types. To 
generate cerebral organoids, studies have used Matrigel to demonstrate the feasibility to derive 
complicated tissue patterns through a process involving dynamic patterning and structure self-
organization in 3D hPSC culture52,57,87. Recently, Sasai and colleagues recapitulated aspects of 
eye development in vitro by culturing aggregates of mouse embryonic stem cells (ESCs) in 
Matrigel and minimal growth factors87. Their studies showed that mouse ESCs were able to self-
organize into a bilayered optic cup-like structure when cultured in 3D. Beyond the morphological 
similarities, the outer and inner layers expressed retinal pigment epithelial (RPE) and neural retina 
(NR) markers, respectively, indicating that cell differentiation followed that of the developing retina 
in vivo. Using a similar approach, they have also generated distinct cortical neurons88. These 
studies have laid the groundwork to organogenesis that may be used for therapy of patients with 
neuronal disorders. The organoids can also function as an in vitro model to understand the 
intricacies of brain function in a culture dish. 
In vivo, a variety of extracellular matrices provides support for epithelia and significantly 
influence epithelial and stem cell behavior. It is therefore not surprising that the choice of 
extracellular matrices in three-dimensional intestinal organoid culture systems matters a great 
deal89. Sato et al. showed the self-renewal and differentiation of Lgr5 intestinal stem cells (ISCs) 
is cooperatively controlled by signals from the underlining mesenchyme matrix as well as cells in 
the epithelium, specifically Paneth cells (e.g., Notch and Wnt signals)90. Thus, isolated ISCs were 
cultured in Matrigel along with medium conditions that permitted the self-renewal and 
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differentiation of the stem cells, followed by self-organization of the generated cells, which 
collectively led to the establishment of intestinal organoids. Ultimately, there studies found 
Matrigel to be indispensable for epithelial organoid culture. 
While Matrigel has provided key insights for the influence of a 3D scaffold matrix on 
organoid development, the disadvantages associated with Matrigel are commonly occurring lot-
to-lot variability during manufacturing and the complexity in composition, which are often ill-
defined, making it difficult to determine exactly which signals are promoting cell function. The 
mouse tumor basement membrane-derived matrix might not be ideal for cell therapy and drug 
screening applications also because of regulatory issues (animal product). Other natural gels 
such as fibrin, hyaluronic acid, chitosan, alginate, or silk fibrils have also been used for 3D cell 
culture; however, these natural gels have less versatility to promote 3D culture than Matrigel.  
2.2.2 Synthetic polymeric matrices developed for in vitro organoid culture 
The ECM used in stem cell-derived organoid cultures is in most cases a ‘one-size-fits-all’ 
type of matrix: physicochemical properties cannot be controlled to accommodate dynamic tissue-
specific needs, nor can the course of the morphogenetic processes be manipulated. Thus, 
researchers have started to utilize synthetic ECMs, with compositions that can be customized to 
reflect organ-to-organ microenvironmental variations. This synthetic matrix could provide better 
control of vital cell niche cues to direct stem cell fate decisions within organoids during their 
formation, thus steering the overall development of the organoid at will.  
As an alternative to biologic scaffolds, vital signals from native ECMs can be incorporated 
into synthetic polymer matrices with specifically tailored compositions. PEG hydrogels, a class of 
synthetic biomaterial scaffolds, are highly hydrated crosslinked polymer networks that have been 
constructed for a wide range of applications91–94. Several key characteristics of PEG hydrogels 
make them particularly well suited for mimicking the extracellular matrix, namely their 
biocompatibility95–97; their permeability to oxygen, nutrient growth factors, and metabolic 
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waste98,99; their tunable mechanical properties100–102; and their tissue-like viscoelastic 
characteristics103,104. This tunable design allows for engineered biomaterials to present features 
similar to the natural ECM, like a multitude of cell-adhesive ligands. Peptides, like the fibronectin- 
derived peptide sequence RGD105, the collagen-derived peptide GFOGER106 or the laminin- 
derived peptides IKVAV107 and YIGSR108, can be incorporated into synthetic biomaterials to 
provide cell-adhesive ligands and to influence cell phenotype. The concentration109, spacing110,111, 
patterning112,113 and timing of ligand presentation114 all impact the behavior of cultured cells. For 
example, RGD ligands that are presented as pendant groups from a PEG matrix lead to 
statistically significant improvements in MSC viability compared with RGD peptides that are 
confined within the matrix115. In  another study, the MSCs required RGD for survival early during 
3D culture on PEG scaffolds; however, the removal of RGD ligands at later time points did not 
cause a decrease in viability114.  
Signaling proteins can be engineered into the synthetic scaffolds as well to render these 
otherwise bioinert environments permissive to biological processes, like degradation and matrix 
remodeling. This process occurs via chemical/enzymatic crosslinking through adhesive or 
proteolytically cleavable sites. For example, cross-linking PEG with cell-signaling components 
and oligopeptides that are susceptible to proteolytic degradation endows the resulting 3D scaffold 
with biofunctionality, making it permissive to cell migration, proliferation and tissue 
morphogenesis116. Cruz-Acuña et al. prepared hydrogels for growing human intestinal organoids 
using 4-armed PEG-maleimide (PEG-MAL) monomers containing bioactive ligands (e.g., laminin 
and RGD) that were then cross-linked with dithiol (bis-cysteine) protease-degradable peptides117. 
For investigating organoid growth within these hydrogels, spheroids were encapsulated in situ 
during the hydrogel synthesis, and the organoid's survival and development were systematically 
evaluated in a variety of hydrogels with different biochemical and mechanical properties. 
Hydrogels with low polymer concentration resembling the mechanical properties of Matrigel 
showed high organoid viability117. This was also observed in gels with degradable cross-linkers 
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and RGD adhesive peptides. The organoid viability achieved with the optimized materials was 
comparable to that using Matrigel, while organoid formation was strongly dependent on the 
mechanical properties of the scaffold material. Similarly, enzymatically formed hydrogels were 
used to demonstrate the importance of the hydrogel stiffness on the expansion of intestinal stem 
cells and organoid formation by the Lutolf laboratory31. While more rigid scaffolds (G′ = 1.3 kPa) 
encouraged the expansion of stem cells as shown by the activation of mechano-sensitive yes-
associated protein 1 (YAP), softer hydrogels (190 Pa) were more suitable for organoid growth, 
highlighting the influence of the 3D microenvironment during organoid formation. By tethering 
microenvironmental signals such as ECM components, soluble factors, and cell-cell interaction 
proteins to discrete locations, an array of artificial scaffolds can be generated to support organoid 
cultures118,119. 
While these defined synthetic matrices offer the means to control organoid formation, 
current scaffold systems have largely focused on control over the bulk properties and have not 
provided spatiotemporal control over local mechanical cues or signaling gradients. Interestingly, 
a recent study used bioengineered scaffolds to provide controlled positional information to guide 
the formation of human brain organoids120. Fiber microfilaments comprised of poly(lactide-co-
glycolide) (PLGA) were used as floating constructs to pattern embryoid bodies from hPSCs. This 
strategy facilitated the shaping of brain organoids from the inside at an early stage. They also 
found that by increasing the surface-area-to-volume ratio with these microfilament scaffolds, 
reproducible induction of neuroectoderm from micropatterned embryoid bodies was observed. 
Another study focused on generating extrahepatic cholangiocyte organoids (ECOs) to generate 
biliary tissue suitable for surgical reconstruction and found that organoids seeded on 
biodegradable polyglycolic acid (PGA) scaffolds formed tissue-like structures retaining biliary 
characteristics121.  PGA is one of the most widely used synthetic polymers because it does not 
induce inflammatory responses in surrounding tissue, is biodegradable, and is more flexible and 
easier to process than natural polymers122. ECOs were seeded on PGA scaffolds where they 
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attached to the PGA fibers within 48 h and continued to grow for 4 weeks until they reached 
confluency. The cells populating the scaffolds retained expression of biliary markers such as CK7 
and CK19, demonstrated no evidence of EMT, and maintained their functional properties. Thus, 
PGA scaffolds were shown to guide ECOs formation towards a bioengineered tissue resembling 
the biliary epithelium. These studies demonstrate the potential for bioengineered synthetic 
constructs to guide and control organoid self-assembly. 
Similar to biologic scaffolds, the structure of the synthetic scaffold is another major design 
consideration for 3D organoid culture. Scaffold structures can be designed using a variety of 
techniques, such as 3D printing123, particulate leaching124, or electrospinning125. Alternative 
approaches include gas foaming, fiber meshes/fiber bonding, phase separation, melt molding, 
emulsion freeze drying, solution casting, or freeze drying126. These fabrication techniques are 
utilized based on what structure is needed for the 3D scaffold culture. For example, 
electrospinning is generally used for fabricating fibrous scaffolds whereas particulate leaching or 
solution casting can be used to create porous scaffolds and 3D printing produces scaffolds with 
a more defined shape and geometry. Of note, cells grown on fibrous scaffolds typically adhere 
and elongate along the fibers, which means they are often not considered to truly represent 3D 
culture127.  
A challenge that comes with the prefabricated design of porous scaffolds is uniformly 
distributing cells throughout the scaffold to promote effective regeneration of highly intricate 
tissues. While encapsulation strategies allow for cells to be uniformly distributed during initial 
fabrication, microporous hydrogel designs with a tunnel-like network could diminish the ability to 
achieve heterogeneous cell distribution. Several seeding techniques have been established to 
improve uniform cell distribution, but many are lengthy and restrict clinical applicability128,129. The 
most common method for seeding microporous scaffolds is static seeding, in which a 
concentrated cell suspension is passively introduced on a scaffold. This technique, however, has 
several limitations that result in low seeding efficiency and poor cell penetration.130         
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To improve cell seeding efficiency, Tokatlian et al. utilized a two-phase hydrogel technique 
where μ-pore 3.5% hyaluronic (HA) hydrogels were formed and then seeded with mouse MSCs 
mixed into a thin 2.5% nano-pore HA-MMP hydrogel precursor solution131. Due to the fluid nature 
of the precursor solution initially at room temperature, the gel solution flows throughout the pores 
of the porous hydrogel and distributes the cells uniformly. In sharp contrast to the classical 
approach of seeding cells on a preformed hydrogel, 3D bioprinting can simultaneously seed cells 
while fabricating the hydrogel to produce highly organized cellular constructs132. This strategy 
helps to overcome obstacles derived from low cell densities, uncontrollable seeding positions and 
a heterogenous distribution of cells throughout the scaffold. Kolesky et al. recently demonstrated 
a new bioprinting method using cell-laden GelMA inks as a bioprintable bulk matrix to build 
vascularized heterogeneous tissue constructs133. These 3D microengineered systems consisting 
of vasculature, multiple types of cells, and extracellular matrix are able to generate an 
environment for cell adhesion, remodeling, and migration.  
Clearly, organoid cultures on scaffolds represent a valuable approach to achieve tissue 
and organ morphogenesis in vitro. Strategies using 3D matrices to help organize stem cell 
cultures will provide critical information about dynamic local interactions during emergent 
organogenesis, in a complementary manner to in vivo studies. With continued efforts focused on 
developing efficient protocols for hPSC expansion, differentiation, maturation, and 3D cultures on 
scaffolds, organogenesis can be an emerging resource for tissue replacement. One of the major 
challenges at this current stage is that this integrated approach requires a comprehensive 
understanding of spatial-temporal signaling networks to engineer optimal 3D environmental cues 
that efficiently regulate stem cell fate commitments.  
2.3 Scaffolds as Vehicles for Cell Delivery 
Tissue regeneration following disease or injury may require exogenous inputs to augment 
natural healing programs and suppress inhibitory processes. The delivery of cells has most 
typically involved the injection of high-density cell suspensions into the target diseased or injured 
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site. However, such direct cell injection methods often have a poor therapeutic response due to 
a rapid decrease in cell viability, low or modest engraftment of transplanted cells, and limited 
control over cell fate due to the local environment134,135. The delivery of transplanted cells in a 
scaffold comprised of biocompatible materials addresses these limitations by initially providing 
protection to the transplanted cells that can enhance survival and prolong retention at the site136. 
Moreover, scaffolds can often have physical properties that are similar to the native extracellular 
matrix, such as their mechanical properties and water content137. This mimicry of the niche 
environment can have a considerable impact on cell fate by influencing the morphology, viability, 
differentiation, and function138,139. The two main strategies in utilizing scaffolds for cell 
transplantation are non-integrating approaches that isolate cells from the host tissue through 
encapsulation within the hydrogel and integrating approaches that allow for the transplanted cells 
to directly contact host tissue either immediately through a microporous design or over time 
through biodegradation140. Several examples of systems designed for delivering cells in a range 
of regenerative medicine applications are listed in Table 2.1. The number of systems investigated 
in pre-clinical models is large and cannot be listed exhaustively, thus, we have focused on 
relatively recent publications that are approaching large animal or clinical translation. This section 
will discuss considerations in these scaffold designs related to the survival of transplanted cells 
as well as their ultimate function. 
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Table 2.1 Cell Delivery Applications In Natural and Synthetic Hydrogels 
 
Hydrogel 
Material(s) 
Cells Delivered Delivery Strategy Target Application Ref 
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Alginate Pancreatic Islets Laparoscopic implant of 
microcapsules 
Diabetes 141 
Adipose-derived and 
Mesenchymal stem 
cells 
Injection co-delivered 
with BMP-2 
Bone regeneration 142 
CAR-programmed T 
cells 
implanted into the 
peritoneal or tumor 
resection cavity 
Cancer 143 
Polyethylene Glycol 
and Alginate 
Ovarian follicles Encapsulated scaffold Ovarian Function 144 
T
is
s
u
e
-I
n
te
g
ra
ti
n
g
 
M
ic
ro
p
o
ro
u
s
 
H
y
d
ro
g
e
ls
 
Gelatin Adipose-derived 
Stromal Cells 
microporous 
microribbon hydrogel 
injected into cranial 
defect 
Bone Regeneration 145 
Collagen Autogenous 
chondrocytes 
Porous scaffold matrix Cartilage Repair 146 
Alginate Mesenchymal stem 
cells 
Injectable, void-forming 
microporous hydrogel 
Bone Regeneration 147 
B
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Collagen iPSC-derived 
hepatocytes and 
endothelial cells 
Encapsulated 
polyelectrolyte fiber 
scaffold transplanted 
into liver 
Liver Tissue 
Regeneration 
148 
neonatal astroglial 
cells 
Transplanted gel into 
lesion of spinal cord 
Spinal Cord 
Regeneration 
149 
Hyaluronic Acid Cardiac Progenitor 
Cells 
Subcutaneous injection Angiogenesis 150 
 
Neural progenitor cells Injection into stroke 
cavity 
Neural regeneration 
from stroke 
151 
Gelatin Cardiac-derived stem 
cells 
intra-myocardial 
injection with the 
controlled release of 
bFGF 
Cardiac regeneration 152 
Polyethylene Glycol 
with degradable 
peptide crosslinker 
Adipose-derived stem 
cells 
In-situ injection with 
encapsulated siRNA 
Bone regeneration 153 
iPSC-derived 
endothelial cells 
Injection co-delivered 
with VEGF 
Muscle Repair 154 
Fibronectin and 
Agarose 
Cardiac stem cells In-situ injection Cardiac regeneration 155 
Fibrin Human embryonic 
stem cells 
Epicardial Delivery of 
Encapsulating Gel 
Cardiac regeneration 156 
adipose-derived 
mesenchymal stromal 
cells 
Patch applied to surface 
of skin 
Wound Healing 157 
 
20 
 
2.3.1 Cell Delivery in Encapsulating Scaffold Biomaterials 
The key role of an encapsulation device is to create an environment that allows for normal cell 
function, while acting as an immune-regulatory barrier through isolation or modulation of the local 
area for better survival of the transplanted cells158–162. This function can be manipulated by the 
structure as well as material composition140. A common encapsulation approach is illustrated by 
the TheraCyte Device, which has a porous vascularizing outer membrane that promotes tissue 
integration and an inner impermeable, membrane that protects the transplanted allogeneic 
islets.54 Neonatal pancreatic tissue was implanted in non-obese diabetic mice, survived and had 
a response to glucose levels for at least 50 days164. While this original device was not successful 
in clinical trials, the general strategy has evolved over the course of several companies, including 
Living Cell Technologies, Beta Logics, Viacyte, and Encaptra. This Encaptra device consists of a 
single membrane that is immunoisolating while permitting oxygen and nutrients to pass. ViaCyte 
is currently carrying out a phase I/II clinical trial using this device with stem cell-derived cell 
sources to assess the safety and efficacy in humans165. Other encapsulation devices that have 
reached clinical trials have been recently reviewed in detail166. While these devices provide a 
clinically translational design for encapsulation delivery, they are still limited in their ability to 
provide enhanced transport and more tunable properties. For example, in a hydrogel, adhesion 
sites and biomechanical properties can be manipulated within the gel to enhance cell viability and 
therapeutic efficacy. Scaffolds are now being developed that utilize the foundational delivery 
approach provided by the TheraCyte design while offering tunable properties for not only the 
exterior but the interior of the device to enhance cell motility, viability, and function. 
Alginate is a natural polymer derived from algae that has been extensively investigated for 
cell encapsulation due to its biocompatibility, low toxicity, relatively low cost, and mild gelation by 
addition of divalent cations such as Ca2+ 167–169. Alginate can also be modified to improve cell 
attachment and motility. A double-layered alginate hydrogel system consisting of matrix-
metalloproteinases and RGD peptide in the inner layer was designed to allow transplanted stem 
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cells to proliferate and mobilize to the outer layer following the inflammatory storm caused from 
surgery170. Following transplantation of neural stem cells (NSCs) into a rat brain trauma model, 
the double-layered alginate hydrogel promoted survival and differentiation of the NSCs. This 
overall approach focused on NSCs, which have a reduced risk of teratoma formation compared 
to hESCs and iPSCs, but the design could be easily adapted to other types of transplanted cells. 
Alginate-based biomaterials have had great success in rodent models; however, the translation 
to larger animal models such as monkeys and humans have not been immediate successes171. 
Although there were no detectable inflammatory responses in human blood63,64, the limited 
efficacy of two clinical transplantations of human islets in barium-alginate and calcium/barium-
alginate spheres has been partially attributed to a foreign body response after transplantation.65,66 
Recently, fibrosis has been reported to be reduced or eliminated based on the diameter of the 
spheres 176. Alternatively, alginate has been functionalized with a range of chemical groups in 
order to screen for chemistries that would avoid a fibrotic response177,178. Vegas et al. recently 
identified chemically-modified alginates such as triazole-thiomorphiline dioxide (TMTD) as 
scaffolds that resisted fibrosis around the implant in both rodents and non-human primates179. 
The TMTD alginate scaffold was then used to transplant hPSC-derived β-cells into immune-
competent STZ-treated C57BL/6J diabetic mice. The scaffold showed no observable foreign body 
response and supported the engraftment and long-term glycemic correction (174 days with the 
mice still euglycemic at the end of the experiment) from hPSC-derived β-cells in immune-
competent mice180. These results lay the groundwork for studies in autoimmune animal models 
and future human studies using formulations that overcome the immunological barrier inhibiting 
long-term cell function. 
Materials derived from natural polymers have had a long history as scaffold delivery devices, 
however, synthetic polymers have become a popular substitute since they provide a more 
clinically translatable model and more reproducible properties. For these purposes, non-
degradable polyethylene glycol (PEG) hydrogels have been widely used for encapsulation. Also, 
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PEG’s tunable viscoelastic properties provide a tissue-like permeable membrane with minimal 
inflammatory response. By applying a conformal coating around islets consisting of PEG and 
Matrigel, Manzoli et al. demonstrated a strategy for long-term reversal of diabetes with allogeneic 
islets transplanted in the epidydimal fat pad in mice 181. The incorporation of Matrigel into the PEG 
coating provided supportive ECM interactions while keeping the permselectivity low, which 
resulted in a lack of immune cell penetration and T cell allogeneic priming. In addition to 
biocompatibility, PEG-based hydrogels are also utilized for their structural support182 and ease of 
functionalization183. Studies focused on artificial ovarian tissue delivery have shown encapsulated 
immature ovarian follicles in PEG-RGD hydrogels can enhance primordial follicle development 
and graft survival compared to non-encapsulated follicles184. After a subcutaneous transplant of 
encapsulated ovarian tissue, ovariectomized adult mice showed restoration of the estrous cycle 
within two weeks.  In contrast to islets, ovarian follicles are avascular and relatively resistant to 
hypoxia, allowing them to maximize the benefits of immunoisolation methods. 
For cells that are more dependent on graft vascularization, a PEG hydrogel was designed 
using lithography techniques in order to develop an encapsulating gel that had microchannels for 
vascularization. This encapsulating strategy combines encapsulation with printing systems to 
generate microchannels in pre-defined regions of the nano-porous hydrogel.185 The scaffold 
architecture presented here can be designed to improve the transport of nutrients and oxygen to 
encapsulated cells. Furthermore, the network of larger sized channels could facilitate the invasion 
of the host vasculature after implantation or be employed for pre-vascularization in vitro. Their 
studies revealed that transplanted islets in these gels had tissue and vascular in-growth within 
the microchannels, which promoted normoglycemia after transplantation and sustained glucose 
control over the two-month period of study until removal of the device. Collectively, numerous cell 
encapsulation systems are being developed for the treatment of various diseases. Current 
advances in material design, immunomodulation and encapsulation strategies will be critical in 
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addressing the many challenges that are involved in transitioning these cell-based therapies to 
the clinic.  
2.3.2 Cell Delivery with Tissue-Integrating Scaffolds 
Scaffolds are also formulated into either a microporous structure or are made degradable in 
order to facilitate integration with the host tissue (Fig 2.2). The integration with the host tissue can 
be advantageous for vascularization to provide nutrient transport necessary for survival and 
appropriate cell-cell contact that can direct differentiation186–188.  
 
 
Scaffolds with an interconnected microporous structure can be seeded with cells, and 
upon transplantation, host cells can infiltrate for integration with the transplanted cells80. The 
microporous structure allows for nutrient transport and waste removal, while also providing a 
substantial surface for cell adhesion and space for tissue growth81,82. Compared to encapsulated 
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designs, porous hydrogels can encourage cell migration and cell–cell interactions, which can help 
with regulating cell proliferation, differentiation, and the organization of some engineered tissues 
(e.g., cartilage and liver)192,193. These cellular activities can be inhibited or delayed when cells are 
encapsulated into gel scaffolds since they are entrapped in the 3D polymer networks. As a result, 
the incorporation of cell living spaces that are larger than tens of microns in diameter in gel 
constructs can support cell spreading, migration, proliferation, and then vascularization for the 
establishing access to nutrients and other systemic cues194.  
One recent innovation demonstrated that the shortcomings of human lung organoid 
maturation could be overcome by using a combination of synthetic, porous scaffolds and in vivo 
growth in mice195. Prior to transplantation on the scaffold, these organoids contained many of the 
cell types that are found in mature airway epithelia but, notably, they did not contain mature goblet 
cells (the cells that produce mucus) or a number of other secretory cells32. However, they showed 
that incorporating a porous PLG scaffold into the process of culturing the organoids then 
transplanting into the epididymal fat pad encouraged organoids to develop tubes that resembled 
the adult airway. Moreover, they contained a wider range of mature cell types than had been 
produced before. The PLG scaffold served as a physical niche to support survival and maturation 
of the transplanted lung organoids, which displayed enhanced epithelial organization, morphology 
and differentiation into proximal airway lineages. This result suggested that the scaffold was 
required, along with in vivo cues, to support organoid maturation. 
Cocultures on scaffolds allows organoids to receive both a supportive microenvironment 
as well as cues from missing human cell types that have been shown to influence functionality in 
vivo. Aurora et al. showed human intestinal organoids (HIO) cultured on scaffold matrices 
developed multiple epithelial and mesenchymal lineages that are found in the developing human 
intestine196. However, while the HIO possessed many of the key cell types that are found in the 
native intestine, they lacked an enteric nervous system (ENS), immune cell lineages and 
vasculature. Recently, neuro-epithelial interaction in HIO-ENS co-cultures was accomplished 
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through the use of enteric neural crest cell (ENCC) spheres, which are 3D progenitor cultures that 
are capable of differentiating into the ENS lineages, along with hPSC-derived small intestine 
seeded on poly L-lactic acid (PLLA)/polyglycolic acid (PGA) microporous scaffolds197,198. The 
coculture was transplanted into the intestinal mesentery to aide maturation. ENCC 
supplementation with HIO transplants established submucosal and myenteric ganglia, 
repopulated various subclasses of neurons, and restored neuroepithelial connections in the 
organoid. This study showed improved organoid complexity by introducing an ENS and porous 
scaffold platform to begin studying human intestinal motility and associated human ENS 
neuropathies. 
A common caveat of the microporous design, however, is that these scaffolds are formed 
into a specific shape prior to implantation, which limits the ability to target a specific site199. 
Interestingly, granular materials can be used to generate injectable yet porous materials by 
injecting microscale hydrogel particles and having them assemble into a bulk granular material. 
The first example of this approach was termed microporous annealed particle (MAP) scaffolds, 
where microscale hydrogel spherical beads are injected into a cavity and subsequently annealed 
to each other to form a bulk gel with the space between the beads serving as pores in the gel. 
While the void fraction in MAP scaffolds is limited to approximately 20% rather than 80% for other 
porous hydrogels200, MAP scaffolds have a continuous micron-sized porous structure that allows 
both transplanted cells and surrounding host tissue to infiltrate the scaffold without the need for 
material degradation. In addition, MAP gels have the ability to conform to the wound shape and 
promote integration to form cellular structures within days after injection101. As a result, MAP 
hydrogel injection into skin and brain wounds have shown lower inflammation at the wound sites 
101,102. The microporous injectable hydrogel design could expand the applicability of microporous 
hydrogels through its injectable nature.   Recently, another example of granular hydrogels utilizes 
particle jamming to avoid the need for particle annealing.203 This work utilizes the phenomenon 
that jammed granular material behaves as a solid.   
26 
 
Similarly, a cytocompatible fabrication process was recently developed for generating 
microporous scaffolds with encapsulated cells using gelatin as a leachable porogen104. The 
scaffold was designed with a wide range of porosities and pore sizes by crosslinking 
oligo(poly(ethylene glycol)fumarate) in the presence of mesenchymal stem cells and varying sizes 
of gelatin microspheres. Encapsulated mesenchymal stem cells exhibited high viability 
immediately following the fabrication process, and culture of cell-laden hydrogels revealed 
improved cell viability with increasing porosity. An alternative technology is based on using 
microribbon (µRB)-like gelatin as scaffolds, in which the ribbons are building blocks forming a 
macroporous structure.145 Their results suggested that enhancing cell survival and proliferation 
using a μRBs microporous design further promoted the paracrine-signaling effects of adipose-
derived stem cells for stimulating endogenous bone repair. A commercially translated 
microporous design has been utilized for NeoCart® (Histogenics Corporation, Waltham, MA, 
USA), in which autologous chondrocytes are cultured on porous bovine Type 1 collagen scaffolds 
for the repair of cartilage defects in the adult knee205. While the 3D matrix bears load, its open 
structure allows for influx of MSCs, which ideally differentiate into chondrogenic lineage206. A FDA 
phase II trial comparing NeoCART® to microfracture showed significantly better results in all 
clinical outcome measures in the NeoCART® treated patients.146 Histogenics recently completed 
patient enrollment of its NeoCart® Phase 3 clinical trial in accordance with the Special Protocol 
Assessment (SPA) agreement with the United States Food and Drug Administration  (FDA).207 
The efficacy of these novel design methods for microporous scaffolds demonstrates the promise 
of cell-based therapies for enhanced long-term tissue regeneration outcomes. 
Encapsulating gel scaffolds that are degradable can initially function as an 
immunoisolation barrier similar to the encapsulating gels of section 2.1, yet their degradability 
over time can allow for improved cell infiltration and integration with the host. Scaffold degradation 
can lead to changes in mechanics and swelling over time, which will in turn affect cell behavior208. 
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By utilizing degradable reagents (i.e. peptides, ligands or proteases) to form unstable bonds, 
scaffolds can undergo degradation through hydrolytic or enzymatic mechanisms209. A common 
principle is that the degradation rate of the scaffold should match the rate at which the tissue 
grows or infiltration is desired. Recently, Lima et al. used biodegradable alginate to fabricate 
beads encapsulating rat mesenchymal stem cells and fibronectin and implanted the particles in a 
calvarial bone defect in order to evaluate their potential for bone tissue regeneration.110 The 
hydrogel’s rate of degradation could be controlled to permit accelerated bone tissue growth while 
preventing cell loss and any toxic exchange of molecules with the surrounding environment. 
Many natural polymers are biodegradable; yet their utility in tissue engineering 
applications can be constrained by the intrinsic properties of the materials.  In contrast, synthetic 
polymers provide an opportunity to control degradation through well-defined mechanisms, such 
as controlling the crosslinking density of such segments211,212. For example, the hydrogel can be 
crosslinked by reacting the backbone polymer with a peptide sequence that can be degraded by 
specific cell-secreted proteases endogenous to the wound healing microenvironment, such as 
matrix metalloproteinases113–115. In a recent study, PEG gels co-encapsulating chondrocytes and 
MSCs were crosslinked with an MMP-degradable peptide in order to match the resorption of the 
scaffold with the rate of matrix production by cells during cartilage repair116. Relative to non-
degradable hydrogels, those that allowed for cell-mediated degradation showed significantly 
increased GAG and collagen deposition, which are key markers for chondrogenesis117. Another 
design consideration utilizing degradative properties evaluated a two-component synthetic PEG 
hydrogel macrodevice for the delivery of islets to an extrahepatic transplant site218. The hydrogel 
consists of an inner layer crosslinked with a non-degradable PEG dithiol and a degradable outer 
layer crosslinked with a proteolytically sensitive peptide to enhance localized vascularization. 
Encapsulated islets demonstrated high viability within the device and implementation of a 
vasculogenic, degradable hydrogel layer increased the vascular density around the transplant 
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site. While normoglycemia was not achieved with the device, suggesting that parameters like islet 
load require further optimization, the results highlight the benefit of degradable interfaces for the 
promotion of engraftment.   
 Another application for biodegradable scaffolds is as injectables, which have an unparalleled 
advantage for delivering cells to specific sites with minimally invasive procedures by undergoing 
gelation in vivo.119 Injectable hydrogel polymerization can occur as a response to temperature or pH 
change, ionic cross-linking, solvent exchange or crystallization, or simply thickening upon removal of 
the injection shear220,221. One of the most common polymers used for these biomedical applications is 
Poly (N-isopropylacrylamide) (PNIPAM) due to its lower critical solution temperature being very close 
to body temperature222,223. A recent study evaluated PNIPAM-containing hydrogels used as carriers 
for intramyocardial delivery of brown adipose derived stem cells in rats with myocardial infarction224.  
The hydrogel displayed rapid, subphysiological phase transition temperatures and was capable of 
noninvasively delivering a liquid suspension of cells that gels in situ forming a cell-loaded scaffold, 
essentially isolating treatment to the injection site. In addition, engraftment around the transplanted 
cells was significantly enhanced and therapeutic efficacies were augmented in the myocardial 
infarction. This research provides new treatment opportunities for diseases like cardiac ischemia, 
which have seen limited therapeutic success in part due to poor targeting. Gaffey et al. addressed 
this concern by developing an injectable, shear-thinning HA hydrogel that delivers endothelial 
progenitor cells to ischemic myocardium225. The hydrogel was designed to flow through a syringe 
with the application of shear force and then re-assemble at the injection site. In vivo improvements 
from this delivery strategy included enhanced cell retention and vasculogenesis, limited adverse 
remodeling and improved cardiac function.  
These injectable biodegradable scaffolds may also be modified with trophic factors to 
enhance cell survival or function. VEGF has been incorporated into degradable PEG hydrogels 
encapsulating islets in order to promote localized vascularization.226 Transplantation of the in-situ 
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forming injectable hydrogel at an extrahepatic site supported engraftment and reversal of 
diabetes, which was not achieved without VEGF. Xu et al. applied a similar approach by using a 
basic fibroblast growth factor (bFGF) release system to increase MSC survival in a 
thermoresponsive, biodegradable hydrogel.227 The incorporation of the pro-survival factor bFGF 
within the hydrogel improved MSC viability after intramuscular injection, as well as increased 
blood vessel density, limb perfusion, and muscle diameter. While the functionalization of these 
hydrogels enhances both oxygen and nutrients to the target site, the hydrogel’s ability to promote 
neovascularization is still being investigated since the process of angiogenesis typically requires 
days to weeks. These recent studies demonstrate the critical role that local degradation seems to 
play within tissue engineering constructs. 
Scaffolds have received increasing interest as a leading candidate for engineering tissue 
due to their superior biocompatibility and inherent similarity to the natural ECM, in addition to their 
conducive framework for cellular proliferation and survival. These recent advances discussed 
above highlight important considerations for designing hydrogels for effective cell delivery. 
Encapsulation approaches can potentially eliminate the barriers preventing transplantation of 
xenogeneic or stem cell-derived allogeneic cells. However, hypoxia can occur at the core of the 
scaffold and limit the duration that these cells function. Meanwhile, scaffolds that promote tissue 
integration through microporous structures or biodegradation are challenged by the immune 
response but can enhance vascularization and in vivo tissue growth. Also, incorporating 
therapeutic molecules and particles into these scaffolds is another method to guide transplanted 
cell behavior and function. With continued research in these areas focused on incorporating the 
benefits of both approaches, scaffold-based tissue engineering will continue to make advances 
toward clinical restoration of tissue function.  
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2.4 Conclusions 
Some of the primary defining characteristics of a tissue include the physical assembly of 
multiple cells, heterogeneity of cell phenotypes, and higher-order organization of tissue 
architecture. With recent advances in design, scaffold properties such as porosity, cell-mediated 
degradability, and tethered bioactive cues not only provide structural support for organoid tissue 
development but also influence and direct cell-cell interactions, proliferation, migration, and 
differentiation. A scaffold delivery system no longer represents only a mere static structural 
support for cells but rather a dynamic and versatile environment. However, several challenges 
remain in controlling the dynamics of the scaffold in the complexity of the tissue environment in 
vitro and in vivo. Currently, no universal material fulfills all the mechanical needs to improve cell 
survival and functionality during the different phases of tissue generation and transplantation. 
While some material mechanical properties, such as stiffness, may be optimal for enhanced long-
term retention and differentiation, these same mechanical properties may inhibit the progression 
of earlier regenerative processes. Regulating the cellular processes and guiding the development 
of new tissue growth in parallel with the dynamic changes of the tissue environment would be 
pivotal in determining the outcome of the regenerative therapy. A number of scaffold designs are 
being investigated to achieve this control as well, such as self-assembling peptides and peptide 
amphiphiles that provide for controllable gelation, degradation, and presentation of cell adhesion 
motifs228,229.  
A promising future research direction is the development of layered biomaterials that can 
recapitulate the zonal organization of native tissue in order to fulfill multiple mechanical 
requirements throughout the multiple stages of in vitro and in vivo organoid development. A 
layered scaffold consisting of different ECM proteins as well as mechanical properties could offer 
better delivery properties to direct cell fate and regulate processes such as tissue maturation and 
engraftment230. MSCs and chondrocytes encapsulated in multi-layered scaffolds with spatially 
varying matrix compositions and mechanical cues have demonstrated promising results in zonal-
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specific differentiation231,232. Another useful functionality that can be incorporated is the ability to 
increase or decrease hydrogel stiffness after initial crosslinking and implantation. This has been 
achieved through stimulus-triggered secondary chemistries between functional groups or by 
incorporating a secondary reaction mechanism that occurs at a much larger time scale than the 
first primary crosslinking mechanism233–236. The stiffness of the hydrogel can therefore be made 
time-dependent and can be tuned to the different stages of the regenerative process. 
Recent efforts to study the host response to implanted biomaterials can use these insights 
to design materials which can proactively direct the immune response upon implantation to be 
favorable to the regenerative process and the survival and functionality of any co-transplanted 
cells in the material. Examples include the tuning of material properties which can increase the 
presence of pro-remodeling versus pro-inflammatory phenotypes of macrophages in implant site 
and can also control transplanted stem or progenitor cell behavior and differentiation237. Finally, 
with emerging technologies such as CRISPR, transplanted organoids can undergo genetic 
engineering to regulate the immune response as a means to prevent or avoid rejection238.  
In summary, organoid cultures have the potentially to transform drug discovery and 
development. Three-dimensional cell cultures would have enormous potential to model 
development and disease, as advanced cell models under development may fully capture the in 
vivo functions of organs and tissues. Scaffolds offer great promise in designing suitable 
environments that provide not only structural support for cells and new tissue growth, but also 
control over organoid development to promote differentiation and improve therapeutic outcomes. 
The optimization of organoid cultures for scaling-up cell production would improve quality, 
quantity, and efficacy, thus making cells as therapeutics a reality. As these scaffold design 
considerations continue to be investigated, this system could provide a promising platform for 
organoid cultures for a wide range of applications in tissue engineering. 
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Chapter 3: Microporous Scaffolds Support Assembly and 
Differentiation of Pancreatic Progenitors into β-cell Clusters 
 
3.1 Abstract 
Human pluripotent stem cells (hPSCs) represent a promising cell source for the 
development of β-cells for use in therapies for type 1 diabetes. Current culture approaches 
provide signals to mimic a temporal control of organogenesis to drive the differentiation towards 
β-cells. However, spatial control may represent an opportunity to improve the efficiency and 
manufacturing of β-cells. Herein, we adapted the current culture systems to microporous 
biomaterials with the hypothesis that the pores can guide the assembly of pancreatic progenitors 
into clusters of defined size that can influence maturation. The scaffold culture allowed hPSC-
derived pancreatic progenitors to form clusters at a consistent size as cells differentiated. By 
modulating the scaffold pore sizes, we observed 250-425 µm pore size scaffold cultures 
augmented insulin expression and key β-cell maturation markers compared to cells cultured in 
suspension. Furthermore, when compared to suspension cultures, the scaffold culture showed 
increased insulin secretion in response to glucose stimulus indicating the development of 
functional β-cells. In addition, scaffolds facilitated cell-cell interactions enabled by the scaffold 
design and supported cell-mediated matrix deposition of extracellular matrix (ECM) proteins 
associated with the basement membrane of islet cells. We further investigated the influence of 
ECM on cell development by incorporating an ECM matrix on the scaffold prior to cell seeding; 
however, their presence did not further enhance maturation. These results suggest the 
microporous scaffold culture provides a conducive environment that drives in vitro differentiation 
of hPSC-derived insulin-producing glucose-responsive β-cells and demonstrates the feasibility of 
these scaffolds as a biomanufacturing platform. 
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3.2 Introduction 
Type I diabetes (T1D) is a chronic metabolic disorder characterized by autoimmune 
destruction of the pancreatic β-cells that results in the need for life-long insulin therapy. This 
disease represents 5–10% of the diagnosed cases of diabetes, corresponding to more than 1.25 
million individuals in the United States 239. Several secondary metabolic disorders can arise from 
this disease, as well, such as retinopathy, neuropathy, nephropathy, stroke and heart failure 240,241. 
Although exogenous insulin injections have decreased mortality, severe hypoglycemic events and 
macrovascular complications persist 242–244. Thus, recent research has turned to cell-based 
therapies focused on replacing lost insulin-producing cells. Enthusiasm in cell replacement 
therapies for diabetes was driven, in part, by the progress in allogeneic islet transplantation with 
the Edmonton protocol 245–249. Recently, promising results from a European consortium of islet 
transplant centers showed excellent glycemic control and absence of hypoglycemia reported in 
approximately 80% of patients at 1 year and 60% at 5 years 250. However, the widespread 
application of islet transplantation has been tempered by the lack of availability of islets and the 
need for life-long immunosuppression 251,252.  
The lack of available islets has led to the investigation of human pluripotent stem cells 
(hPSCs) as an unlimited source of functional β-cells. Initial findings from the Kieffer and 
Baetge/D’Amour groups demonstrated the production of pancreatic progenitors and, 
subsequently, insulin-producing β-like cells in vitro. In the Kieffer lab, these cells could further 
differentiate following transplantation to normalize blood glucose levels after approximately 3-4 
months 253,254. More recently, in vitro culture protocols have developed hPSC-derived β-cells that 
induce normoglycemia over shorter times after transplantation 255–258. Additionally,  suspension 
cultures utilized for aggregated hPSC-derived β-cell production provide procedures that are 
scalable to generate sufficient glucose-responsive cells 255,257. While numerous protocols have 
been established, the in vitro production of β-cells can result in a heterogenous population 
consisting of polyhormonal endocrine cells in addition to monohormonal β-cells 254,259,260. 
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Furthermore, the increasing culture volumes can influence the size of cell aggregates, which has 
previously been linked to apoptosis-related cell loss, cellular differentiation, and heterogeneity261. 
These challenges indicate the need to further investigate approaches that can promote maturation 
of insulin-producing β-cells.  
The current stepwise hPSC differentiation approach aims to mimic a temporal control of 
organogenesis observed during embryonic development, and spatial control may represent an 
opportunity to enhance the efficiency and consistency of β-cell maturation. In vivo spatial control 
is achieved with cell-cell and cell-extracellular matrix (ECM) interactions. The ECM forms a three-
dimensional (3D) environment and offers a niche for cell adhesion, colonization, proliferation, and 
differentiation262–264. This 3D environment has been shown to enhance hPSC differentiation and 
promote the assembly of functional tissues23,265. Recent advances in 3D cultures have generated 
tissues called organoids, which possess several advantages including cellular organization 
similar to the native organ while possessing the specified cell types32,34,52,266,267. These same cell 
types cultured on plastic and allowed to self-assemble are not able to form the same complex 
tissue architectures that are permitted by 3D cultures.  
Recently, porous scaffolds have been utilized to provide a 3D environment to facilitate the 
assembly of hPSCs into multicellular structures, or organoids268–270. In addition, culture on 
scaffolds represents an alternative manufacturing platform that has shown translational 
capabilities with other tissue engineered products271. Microporous scaffolds allow for both cell-
cell and cell-matrix signaling that supports the self-organization of the cells into functional tissue 
structures272,273. hPSC-derived β-cells have currently been obtained through either a 2D 
monolayer culture that is subsequently transformed into large clusters on an air-liquid interface 
or as 3D aggregates in low attachment plates or suspension cultures23–25,274. However, during 
pancreas organogenesis, islets are surrounded by a supportive extracellular matrix27,275,276. 
Mimicking the spatial cues in the pancreatic niche environment has the potential to augment the 
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in vitro hPSC differentiation toward functional β-cells. 
Herein, we investigated microporous polymer scaffolds as an in vitro platform for the efficient 
differentiation of hPSC-derived pancreatic progenitor cells to insulin-producing glucose-
responsive β-cells. Our scaffolds were formed from synthetic polymeric materials, with the walls 
supporting the assembly of pancreatic progenitors into β-cell clusters. The pore size was 
investigated for the ability to form clusters of distinct sizes. The cell structures within the pores of 
the scaffold were analyzed by histology and gene expression. The influence of ECM-coated 
scaffolds on β-cell maturation was evaluated as well to investigate the role of the matrix in cellular 
assembly and differentiation. Finally, we assessed the maturation and function of these cells 
through glucose stimulated insulin secretion assays. These studies provide insight on cell-cell 
and cell-matrix interactions that influence the differentiation of hPSCs to β-cells on microporous 
scaffolds, which may ultimately provide a platform for biomanufacturing the cells as a therapy for 
diabetes.  
3.3 Materials and Methods 
3.3.1 Microporous scaffold fabrication 
Two types of scaffolds were used poly(lactide-co-glycolide) (PLG) scaffolds and polyethylene 
glycol (PEG) scaffolds. Microporous scaffolds were fabricated as previously described277,278. 
Briefly, PLG microporous scaffolds were fabricated by compression molding PLG microspheres 
(75:25 mole ratio D,L-lactide to glycolide) and micron-sized salt crystals in a 1:30 ratio of PLG 
microspheres to salt. The mixture was humidified in an incubator for 7 min and then thoroughly 
mixed again. Scaffolds were compression molded with 77.5 mg of polymer–salt mixture into 
cylinders 5 mm in diameter by 2 mm in height using a 5 mm KBr die (International Crystal 
Laboratories, Garfield, NJ) at 1500 psi for 45s. Molded constructs were gas foamed in 800 psi 
carbon dioxide for 16 h in a pressure vessel. The vessel was depressurized at a controlled rate 
for 30 min. On the day of cell seeding, scaffolds were leached in water for 1.5 h, changing the 
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water once after 1 h. Scaffolds were disinfected by submersion in 70% ethanol for 30 seconds 
and rinsed multiple times with phosphate buffer solution (PBS).  
For the PEG hydrogels, PEG-maleimide (4-arm, molecular weight 20kDA, 20% wt/wt) polymer 
was dissolved in a HEPES buffer solution, mixed with NaCl crystals and a photoinitiator (Irgacure-
2959) then cast into a PDMS mold (diameter: 5mm, thickness 2mm). The solution is irradiated 
with UV light to photo-crosslink the PEG-maleimide and then washed to remove the sodium 
chloride and unreacted photoinitiator. The pore size of the scaffolds can be readily controlled 
through the dimensions of the porogen, and we propose to investigate scaffold pore sizes using 
porogens of 63 to 108 µm, 108 to 225 µm, 225 to 450 µm, and 500 to 600 µm.  
3.3.2 Differentiation of hPSCs and scaffold seeding 
The H1 hESC line used for these studies was obtained from the WiCell Research Institute 
(Madison, WI). Pluripotent cells were maintained on Matrigel (BD Biosciences, San Jose, CA) in 
mTeSR1 medium (STEMCELL Technologies, Vancouver, Canada). When ∼80% confluent (~3-
4 days after plating), cells were passaged using Gentle Cell Disassociation Reagent (STEMCELL 
Technologies). The differentiation of pluripotent hPSCs (Stage 0) to pancreatic progenitor cells 
(Stage IV) were performed as described 256. 
To initiate scaffold culture differentiations, Stage IV pancreatic progenitor cells were single-
cell dispersed using TrypLE Express (Life Technologies) and then seeded on scaffolds at 
concentrations ranging from 12.5-125 million cells/cm3. Prior to cell seeding, scaffolds were 
washed in cell media solution then briefly dried on sterile gauze to improve the absorption of the 
cell solution into the scaffold. Cells were distributed across both faces of the scaffold and then 
incubated for 10min to allow cell solution to be further absorbed into the scaffold before 
differentiation media was added. The differentiation towards insulin-producing glucose-
responsive β-cells (Stages V-VI) on scaffolds required 1-2 weeks based on the established 
protocol 256. A traditional hPSC suspension culture was differentiated per the described protocol 
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to provide an internal control 256. Briefly, undifferentiated hPSCs were initially seeded at 1.0 million 
cells/mL in ultra-low attachment 6 well plates (Corning, VWR), placed on an Orbi-Shaker 
(Benchmark), and set at rotation rate of 95 rpm in a 37°C incubator, 5% CO2, and 100% humidity. 
Cells were cultured for 48 hr in mTeSR1 and then cultured in the differentiation media. Human 
islets were acquired from Cell Trans Inc. for comparison. 
3.3.3 Protein adsorption to scaffolds 
For coating scaffolds with ECM proteins, scaffolds were fabricated and then disinfected in 
70% ethanol and dried again before being placed into individual wells of a 24-well tissue culture 
dish. Proteins were then coated per manufacturer’s recommendations to be consistent with our 
previous report that demonstrated enhancement in islet function following transplantation on ECM 
protein-modified scaffolds279,280. Collagen IV (25µL at 1mg/mL; Sigma), laminin-332 (25µL at 
1mg/mL, formerly termed laminin-5 and hereafter referred to as “laminin”; Sigma), 25µL of 
Matrigel (Corning, Cat#: 354277) or PBS were added to the scaffold. The scaffolds were then 
incubated at 37°C for 1 h, followed by the addition of 25 μL of the same component to each 
scaffold. Scaffolds were then incubated with 95% humidity at 37°C overnight to facilitate protein 
adsorption to the scaffold surface. Prior to cell seeding, control and ECM-coated scaffolds were 
washed in cell culture media. 
3.3.4 Cell viability 
The viability of cells on the scaffolds was qualitatively assessed using a Live/Dead® 
viability/cytotoxicity kit (Life Technologies). Cells were stained with a solution consisting of 5 µL 
of 4 mM acetomethoxy derivate of calcein (calcein-AM) and 20 µL of 2 mM ethidium homodimer‐
1 (EthD‐1) in 10mL of sterile PBS. Cells cultured on microporous scaffolds were incubated at 
37°C and 5% CO2 in the live/dead solution for 30 min, followed by a wash in PBS and then the 
viability was assessed using a fluorescent microscope (Olympus, Center Valley, PA, United 
States). 
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3.3.5 qRT-PCR Analysis 
For gene expression analysis, cell-laden scaffolds were mechanically homogenized in Trizol® 
reagent (Life Technologies), and RNA was isolated using Direct-zol™ RNA MiniPrep Plus (Zymo   
Research Corporation, Orange, CA, USA) according to the manufacturer's instructions. RNA 
concentration was determined using a NanoDrop spectrophotometer. The iScript™ Reverse 
Transcription Supermix was used to transcribe RNA into cDNA. Universal RT microRNA PCR 
assays were performed using SYBR Green MasterMix Universal RT (Exiqon), according to the 
manufacturer’s instructions. The amplification profile was assessed using a LightCycler® 480 
(Roche, Germany). Gene expression was quantified using the ΔΔCt method and fold change was 
calculated using the formula 2-ΔΔCt. Values for the genes of interest were normalized to the 
housekeeping gene (GAPDH) followed by normalization to marker expression in pluripotent 
hPSCs. Primers used for qPCR analysis are listed in Table 3.1. 
gene  primer sequence (5' to 3') 
PDX1 forward CCTTTCCCATGGATGAAGTC 
PDX1 reverse CGTCCGCTTGTTCTCCTC 
Nkx6.1 forward GGGGATGACAGAGAGTCAGG 
Nkx6.1 reverse CGAGTCCTGCTTCTTCTTGG 
MafA forward GAGAGCGAGAAGTGCCAACT 
MafA reverse TTCTCCTTGTACAGGTCCCG 
Insulin forward TTCTACACACCCAAGACCCG 
Insulin reverse CAATGCCACGCTTCTGC 
Glucagon  forward TGCTCTCTCTTCACCTGCTCT 
Glucagon  reverse AGCTGCCTTGTACCAGCATT 
ECAD forward TTGACGCCGAGAGCTACAC 
ECAD reverse GACCGGTGCAATCTTCAAA 
PCSK1 forward CTCTGGCTGCTGGCATCT 
PCSK1 reverse CGGGTCATACTCAGAGGTCC 
 
3.3.6 Immunostaining 
Table 3.1  Primers of Pancreatic Differentiation Markers Used for qRT-PCR 
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Immunostaining of in vitro cell differentiation was performed on end-stage β-cell clusters. 
Scaffold cultures were cryopreserved in isopentane and cooled on dry ice, while suspension 
clusters were fixed with 4% paraformaldehyde (Electron Microscopy Sciences; Hatfield, PA, 
United States) then embedded within OCT embedding medium (Tissue-Tek, Sakura Finetech, 
Torrance, CA) and cryosectioned to 14 µm sections. Scaffold tissue sections and cells 
differentiated in suspension cultures were fixed with 4% paraformaldehyde for 30 min, blocked 
and permeabilized for 30-min with staining buffer (5% donkey serum, Jackson Immunoresearch; 
017-000-121) and 0.1% Triton-X 100 (Acros Organics; 327371000 in PBS), stained overnight with 
primary antibodies at 4 °C, stained for 4 hr with secondary antibodies at 4 °C, and treated with 
mounting solution DAPI Fluoromount-G (SouthernBiotech; 0100-20). Digital images were 
acquired with a MicroFire digital camera (Optronics, Goleta, CA) connected to an Olympus BX-
41 fluorescence microscope (Olympus, Center Valley, PA, United States). Image quantification 
was conducted with MATLAB software using an object-based colocalization analysis. DAPI+ cells 
were identified per total area of the sectioned tissue and quantified by applying Otsu’s 
thresholding method, the watershed transform, and individual cluster thresholding. Then, each 
cell’s colocalization with immunofluorescent markers was quantified. For confocal imaging, whole 
tissue samples were fixed in 4% paraformaldehyde then stained with primary and secondary 
antibodies as described above. The labeled samples were then cleared in Murray’s clear solution 
for optical clearing for 45 min before being imaged via confocal microscopy (Nikon A1Si laser 
scanning confocal microscope, Nikon Instruments Inc, Tokyo, Japan). 
Primary antibody solutions were made in staining buffer with the following antibodies at a 
1:250 dilution: guinea pig-anti-Insulin (Dako, A05654), mouse-anti-ECAD (Novus Biologicals; 
7H12), rabbit-anti-Collagen IV (Thermo Fisher, PA128534), rabbit-anti-Laminin (Thermo Fisher, 
PA516287), rabbit-anti-Fibronectin (Abcam, AB23750). Secondary antibody solutions were made 
in staining buffer with the following antibodies at 1:500 dilution: anti-guinea pig-alexa fluor 488 
40 
 
(Life Technologies; A11073), anti-mouse-alexa fluor 555 (Life Technologies, A31570), anti-rabbit-
alexa fluor 555 (Life Technologies, A31572). 
3.3.7 Static Glucose-Stimulated Insulin Secretion Assay 
For GSIS testing, scaffold cultures and suspension clusters were first washed twice with KRB 
buffer (125 mM NaCl, 3 mM KCl, 1.2 mM CaCl2 1.2 mM MgSO4, 1 mM NaH2PO4, 22 mM NaHCO3, 
10 mM HEPES (Gibco; 15630-080), and 0.1% BSA), exposed to a basal level of glucose (2.8 
mM) in a 24 well plate for 30 minutes, then transferred to a second, fresh basal glucose solution 
and incubated for an hour. Samples from this basal glucose solution were retained. The cells 
were then washed in fresh basal level glucose for 10 minutes and next exposed to a high-level 
glucose concentration (28 mM) for an hour. Samples from the retained second basal glucose 
solution and high-level glucose solution were collected to measure insulin levels using a Human 
Insulin ELISA kit (Mercodia Inc. 10-1113-01). The cells were single cell dispersed by TrypLE 
treatment, counted in a hemacytometer, and viable cell counts were used to normalize insulin 
secretion. 
3.3.8 Statistics  
All statistical analyses were conducted using Prism graphing and data analysis software 
(GraphPad Software, Inc., La Jolla, CA, United States). Statistical differences were determined 
using non-parametric testing; an unpaired two-tailed Student t test or one-way ANOVA with 
Dunnett test for multiple comparisons. Values were reported as the mean ± SEM. n indicates the 
total number of biological replicates. 
3.4 Results 
3.4.1 Cluster formation of hPSC-derived pancreatic progenitors within scaffold pores 
Two commonly used biomaterials, PLG and PEG, were investigated for the in vitro scaffold 
culture of pancreatic progenitors to β-cells. These two materials provided a similar microporous 
structure (Fig 3.1A) with distinct material properties that can distinguish the role of structure 
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relative to the role of the material. We first evaluated cluster formation within the microporous 
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(A) SEM image of empty porous PLG scaffold shows highly porous structure with 250-425 µm pores. 
Microscope images of PEG scaffold culture (B) and suspension culture (C) display formed β-cell clusters. 
(D) Confocal imaging shows cell localization within a PEG scaffold pore at 12.5x106 cells/cm3 and (E) 
multiple scaffold pores at 125x106 cells/cm3. Cells were stained 2wks after seeding onto a PEG scaffold 
(F-H) and PLG scaffold (I-K) and examined using a live/dead assay to demonstrate minimal cell death 
during culture. Confocal imaging shows cell clusters distributed within a 2mm thick PEG scaffold pore at 
0.5mm depth (L), 1mm depth (M) and 1.5mm depth (N). 
 
Figure 3.1 In vitro culturing of hPSC-derived pancreatic progenitors on microporous scaffolds 
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scaffold cultures (Fig 3.1B) compared to the traditional suspension culture (Fig 3.1C). hPSC-
derived pancreatic progenitors dissociated into single cells were initially seeded onto 
microporous scaffolds at a density of 12.5 million cells/cm3 for culture. The use of single cells 
allows the proper infiltration of cells into the pores of the scaffolds while providing relatively 
uninhibited access of media to the cells. Through confocal microscopy, we found that this 
seeding density was not sufficient for cluster formation to occur as cells were localized to the 
surface of the pores (Fig 3.1D). Increasing the seeding density 10-fold to 125 million cells/cm3 
resulted in the cells assembling into 3D clusters within one day after seeding (Fig 3.1E), which 
resembles the self-organization that occurs in suspension cultures. Cell viability was 
consistently high (>90%) throughout the 14‐day experiment for both PEG and PLG scaffold 
conditions (Fig 3.1F-K). These observations indicated that the assembly of cells into clusters 
could be supported within the micropores yet was dependent on the cell density. This high cell 
seeding density resulted in a uniform distribution of cells and clusters throughout the scaffold 
(Fig 3.1L-N). At densities greater than 125 million cells/cm3, cells began to clump on the 
surface.  
3.4.2 Maturation of β-cell clusters within scaffolds 
We next investigated the feasibility of generating β-cell clusters in microporous scaffolds 
by measuring the expression of β-cell marker genes, which were compared with cells generated 
in suspension culture and human islets. Using qRT-PCR analysis, we found cells cultured within 
PEG and PLG scaffolds had an increased expression level of the endocrine hormone marker 
gene for insulin relative to Stage IV pancreatic progenitors. Additionally, β-cell maturation markers 
(MafA, G6PC2, and PCSK1) had expression levels on scaffold cultures that were at least 
comparable to suspension culture controls if not significantly increased. On average, the 
suspension culture produced clusters around 234 ± 63 µm in diameter (n=48 individual clusters). 
We used the tunable design of the scaffold pores to assess how varying the cluster size would 
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influence maturation within the scaffold. A correlation between scaffold pore sizes and the 
expression of key β-cell markers was observed with larger pore sizes promoting higher 
expression levels. For PEG scaffolds, pore sizes in the range of 250-425 µm had increased 
expression of pancreatic transcription factors (PDX1 and Nkx6.1) compared to suspension and 
scaffolds with pore size smaller than 250 µm (Fig 3.2A). The expression of Nkx6.1 was lower 
than human islets for both suspension and scaffold conditions suggesting the cells have not 
 
Gene expression of pancreatic endocrine hormones, β-cell-associated transcriptional factors, and β-cell 
function-related proteins in hPSC-derived Stg 4 pancreatic progenitors and Stg 6 β-cells cultured on (A) 
PEG and (B) PLG microporous scaffolds with varying pore sizes. (*P≤0.05, **P≤0.01, ***P≤0.001 for each 
condition versus human islets using one-way ANOVA with Dunnett test for multiple comparisons, n = 6-7 
biological replicates for all genes). Error bars represent the standard error of mean (SEM). 
 
A 
 
B 
 
Figure 3.2 Augmenting scaffold pore sizes enhances pancreatic progenitor differentiation 
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fully matured. However, the expression of insulin had a significant increase on scaffolds with 
pore sizes of 250-425 µm compared to suspension clusters and the other scaffold conditions. 
This trend between scaffold pore size and cell development was observed in the expression of 
β-cell maturation markers as well. Scaffolds with a pore size of 250-425 µm resulted in the 
highest expression of the insulin gene transcription factor, MafA, with the 500-600 µm pore 
size scaffolds exhibiting the second highest expression out of the in vitro conditions. The 
maturation marker proprotein convertase 1 (PCSK1) is one of the key enzymes associated 
with insulin processing and showed expression levels to be higher in scaffold cultures with 250-
425 µm pore sizes compared to the scaffolds with smaller pore sizes as well as suspension 
clusters.  
hPSC-derived pancreatic progenitors cultured on PLG scaffolds similarly demonstrated the 
development of β-cells with maturation showing a correlation with pore size (Fig 3.2B). Insulin 
expression for PLG scaffold cultures with 250-425 µm pore sizes was significantly increased 
relative to the pancreatic progenitors. The expression of pancreatic β-cell transcription factor 
PDX1 and Nkx6.1 in all four PLG scaffold conditions were lower than human islets but 
comparable to suspension clusters. While this suggests maturation could be improved, PLG 
scaffolds with 250-425 µm pore sizes showed increased expression in the key maturation 
marker, G6PC2, relative to pancreatic progenitors and suspension clusters. Overall, cells 
cultured in PEG and PLG microporous scaffolds generally showed increased expression levels 
of β-cell maturation markers. While the maturation was still not comparable to human islets, 
this deficit relative to islets is to be expected as, per the protocol used, in vivo transplantation 
is necessary to reach full maturation. This analysis revealed that pancreatic progenitors 
differentiated to β-cells in the PLG and PEG microporous scaffold show, at a minimum, 
comparable gene expression levels to the traditional suspension culture. Our observations also 
identified a relationship between scaffold pore size and β-cell maturation with 250-425 µm pore 
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size showing more significant improvements in β-cell development than in suspension culture. 
Since this pore size measurement was based on the salt porogen size used during fabrication, 
we also performed measurements after the scaffolds had been exposed to media. Using 
imaging analysis, we determined the pore size distribution for PLG and PEG scaffold cultures 
fabricated with 250-425 µm salt porogens were 371 ± 33 µm (n=30 individual pores) and 468 
± 62 µm (n=32 individual pores), respectively, after 24 hours in cell media. The pore size for 
wet PLG scaffolds remained within the estimated range while wet PEG gels had an average 
pore size distribution slightly above the range, likely due to swelling. Overall, based on these 
findings, the following studies focused on scaffolds with a relative pore size of 250-425 µm. 
3.4.3 Cell-cell communication in microporous scaffold cultures during β-cell maturation 
Next, we investigated cell-cell interactions within the scaffold culture that drive maturation in 
the pancreatic niche environment. The cell surface adhesion protein epithelial cadherin (ECAD) 
plays a critical role in the development of islets and intra-islet communication and is implicated in 
efficient insulin secretion from β-cells281–283. Thus, we assessed the presence of ECAD through 
qRT-PCR analysis in both scaffold cultures and suspension clusters. ECAD gene expression 
 
(A)  The effect of scaffold cultures versus suspension control on ECAD in maturing β-cells was determined 
by quantitative RT-PCR. ECAD gene expression levels of cells cultured in suspension or on PEG and PLG 
microporous scaffolds (*P≤0.05 compared to suspension using one-way ANOVA with Dunnett test for 
multiple comparisons, n = 4 biological replicates). Error bars represent the SEM. Immunofluorescent 
staining of suspension cluster (B) and PLG scaffold culture (C) for insulin (green), ECAD (red) and DAPI 
(blue).  
Figure 3.3 Scaffold culture influences E-cadherin interactions in β-cell clusters 
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levels were increased in cells cultured in PLG microporous scaffolds compared to suspension 
clusters (3 ± 1 vs 0.57 ± 0.03, n=4, P<0.05). (Fig 3.3A). PEG scaffold cultures showed 
comparable levels of ECAD expression relative to suspension clusters (2.8 ± 0.9 vs 0.57 ± 0.03, 
n=3-4).  Cell-cell interactions were further investigated through immunostaining where E-cadherin 
was shown to be localized in small regions in the interior of the suspension clusters with increased 
co-expression with insulin-positive cells around the exterior of the clusters (Fig 3.3B). 
Alternatively, in PLG scaffold cultures, ECAD was distributed throughout the interior of the clusters 
and with co-expressed insulin-positive cells (Fig 3.3C). Imaging analysis of DAPI+ cells 
expressing ECAD per the total area confirmed PLG scaffold cultures significantly increased 
protein expression of ECAD compared to suspension (42 ± 5% vs 21 ± 4% of total cell population, 
n=4; P<0.01). Our data suggests that microporous scaffold cultures, particularly PLG, promote 
cell-cell interactions that can play a role in driving β-cell maturation.  
3.4.4 hPSC-derived β-cell glucose-responsive in vitro function within microporous scaffolds  
The function of these β-cell clusters in scaffolds was next examined by their ability to secrete 
insulin in a glucose-responsive manner through a GSIS assay. Scaffold cultures and suspension 
clusters at the end of the six-stage differentiation were exposed to 2.8 mM and 28 mM glucose 
solutions, respectively. At the low glucose concentration, the cells in suspension or on scaffolds 
secreted similar quantities of insulin (Fig 3.4A). At the high glucose concentration, we observed 
an increase in insulin secretion per cell from both the PLG and PEG scaffold cultures, averaging 
0.8 ± 0.2 and 0.7 ± 0.1 μIU/103 cells, respectively. Whereas the suspension clusters in a high 
glucose solution secreted low amounts of insulin, 0.3 ± 0.1 μIU/103 cells, and were not glucose 
responsive. hPSC-derived β-cells cultured on the PLG scaffold had the highest insulin secretion 
index, with a threefold increase compared to the suspension culture control (1.3 ± 0.2 vs 
0.43 ± 0.06, n=3, P<0.01) (Fig 3.4B). PEG scaffold cultures also showed higher insulin secretion 
compared to the suspension control (1.11 ± 0.09, n=3, P<0.05) yet lower insulin secretion than 
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PLG. It is important to note that while the β-cells on scaffold cultures demonstrate a capacity for 
glucose-stimulated insulin secretion, the magnitude of response suggests these cells may not be 
the same as fully mature functional β-cells. Since the PLG scaffold demonstrated increased ECAD 
expression, had a higher degree of function, and is better for protein adsorption compared to PEG 
284,285, subsequent studies employed this material for further investigation of the matrix 
environment supporting β-cell maturation.  
3.4.5 ECM deposition by hPSC-derived β-cell clusters 
We subsequently assessed the ECM within the cultured cells, as ECM basement membrane 
proteins are a critical component of the pancreatic environment supporting islets. Since cells 
cultured on PLG scaffolds showed signs of β-like development and function, we used 
immunofluorescence analysis to investigate if the cells were establishing a matrix similar to the 
pancreas within the scaffold. The presence of insulin-positive cells within the clusters were first 
evaluated to confirm the pancreatic progenitors were developing into β-like cells. We observed 
an increase in insulin-expression of DAPI+ cells in PLG scaffold cultures (Fig 3.5A-C) compared 
(A) Human insulin secretion from PLG and PEG scaffold cultures and suspension clusters in response to 
low and high glucose concentrations under static conditions (scaffold cultures: n = 4 biological replicates, 
suspension: n = 5 biological replicates). (B) The stimulation index was calculated as the ratio of insulin 
release in high to low glucose concentrations (*P≤0.05, **P≤0.01 compared to suspension, n=3-4 biological 
replicates).  Error bars represent the SEM. 
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Figure 3.4 Efficient generation of glucose-responsive β-Cells from human pancreatic progenitors 
differentiated on microporous scaffold cultures 
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to suspension cultures (Fig 3.5D-F) (53 ± 2% vs 44 ± 3%, n=4, P≤0.05). Our results also showed 
ECM proteins commonly found in the extracellular matrix surrounding islets, i.e. collagen IV, 
laminin and fibronectin, were present in both suspension and scaffold cultures. Imaging analysis 
 
(A-F) Matrix composition surrounding β-cells is shown by representative immunofluorescent staining of 
PLG scaffold culture (A-C) and suspension cluster (D-F) for insulin (green), ECM protein (collagen IV, 
laminin, or fibronectin) (red) and DAPI (blue). (G) Immuno-histological analysis was performed using the 
percentage of DAPI+ cells expressing insulin, ECM proteins and cells colocalized with insulin and ECM 
proteins in suspension (gray) and PLG microporous scaffolds (black) (*P≤0.05 compared to suspension, 
n = 4 biological replicates) with error bars representing SEM.  
 
Figure 3.5 Scaffold cultures permit hPSC-derived β-cell-secreted ECM deposition 
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confirmed that the percentage of DAPI+ cells localized to ECM protein expression in the PLG 
scaffold cultures was comparable to suspension (collagen IV: 44 ± 4% vs 43 ± 4%; n=4; laminin: 
42 ± 6% vs 31 ± 3%, n=4; fibronectin: 41 ± 5% vs 35 ± 5%, n=4) (Fig 3.5G). ECM protein was 
uniformly distributed across the cell cluster in both conditions as well. Thus, relative to suspension 
cultures, the scaffold provides a similar supportive matrix for β-cell clusters that consists of ECM 
proteins commonly found in the pancreas tissue.  
3.4.6 β-cell maturation on ECM-modified microporous scaffolds 
The presence of ECM protein deposition on the naked scaffold motivated studies in which 
ECM proteins commonly found in the pancreas were deposited on the scaffold prior to cell seeding 
as a means to further enhance maturation. Using qRT-PCR analysis, we investigated pancreatic 
progenitor maturation to β-cells on PLG scaffolds coated with either collagen IV, laminin or 
Matrigel. Naked microporous scaffolds and scaffolds coated with ECM proteins showed 
comparable levels of expression for endocrine transcription factors (PDX1 and Nkx6.1) (Fig 
3.6A). However, only naked scaffolds and Matrigel coated scaffolds exhibited an increase in 
insulin expression relative to pancreatic progenitors. Evaluating cell maturation on the scaffolds 
also showed that, relative to pancreatic progenitors, only the naked scaffold cultures enhanced 
the expression of PCSK1. An analysis of the expression of pancreatic-related ECM genes 
demonstrated that the expression of COL4A1 gene, coding for collagen type IV, in naked scaffolds 
as well as scaffolds coated with collagen IV and laminin was comparable to human islets. 
However, a decrease of COL4A1 gene expression was observed in suspension cultures and 
scaffolds coated with Matrigel (Fig 3.6B). Laminin production, indicated by LamA5 gene, was 
observed to be comparable to human islets across all culture conditions. Finally, we assessed 
cell maturation through glucose-responsive function. At the low glucose concentration, the cells 
on ECM-coated scaffolds and naked scaffolds secreted similar quantities of insulin (Fig 3.6C).  
However, for the high glucose concentration, we observed insulin secretion per cell increase for 
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only the laminin-coated, collagen IV-coated and naked scaffold cultures, averaging 0.6 ± 0.2, 0.6 
± 0.2 and 0.8 ± 0.2 μIU/103 cells, respectively. Interestingly, insulin secretion per cell on scaffolds 
coated with Matrigel (0.5 ± 0.2 μIU/103 cells) failed to respond to the individual glucose challenges. 
Using the stimulation index, we observed scaffold cultures pre-coated with ECM proteins did not 
have a significant improvement in β-cell function compared to naked scaffolds (0.63 ± 0.03 for 
PLG with Matrigel, 1.2 ± 0.2 for PLG with laminin, 1.0 ± 0.2 for PLG with collagen IV compared to 
1.3 ± 0.2 for PLG, n=3) (Fig 3.6D). These findings indicate the initial introduction of ECM prior to 
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Pancreatic gene expression profile of pancreatic progenitor cells cultured on ECM-coated microporous 
PLG scaffolds (*P≤0.05, **P≤0.005 versus pancreatic progenitors using one-way ANOVA with Dunnett 
test for multiple comparisons, n = 4 biological replicates for all genes). (A)  Gene expression for 
ColIVA1 and LamA5 of Stg6 β-cells. (*P≤0.05 compared to human islets using student t-test 
comparisons, n = 4 biological replicates for all genes) (B) Human insulin secretion in response to low 
and high glucose concentrations from PLG scaffold cultures coated with either Matrigel (Mat), laminin 
(Lam) or collagen IV (Col IV) under static conditions and compared to a non-coated PLG scaffold as 
a control (n = 3 biological replicates) (C) The stimulation index was calculated as the ratio of insulin 
release in high to low glucose concentrations (D) Error bars represent the SEM.  
Figure 3.6 Effects of ECM-modified scaffold cultures on pancreatic progenitor differentiation 
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cell seeding on the scaffold does not substantially improve maturation at the end of the scaffold 
culture, which could be potentially due to deposition of cell-secreted matrix proteins throughout 
the culture.  
3.5 Discussion 
Our findings demonstrate that microporous scaffolds formed from synthetic materials can 
serve as a supportive matrix to promote the differentiation of hPSC-derived pancreatic progenitors 
toward insulin-producing glucose-responsive β-cells in vitro. Synthetic materials were used for 
these studies as they provide flexibility in synthesis and modification, have been widely applied 
for islet transplantation 286–288 and are generally easy to manufacture for large scale production. 
The scaffolds were designed to have a high porosity, a fully interconnected geometry, structural 
integrity, and a defined three-dimensional shape. Additionally, the microporous structure allows 
the 3D organization of cells into β-cell clusters, provides a high surface area-to-volume ratio for 
polymer–cell interactions, and allows nutrients to diffuse into the scaffold to support the growth of 
the seeded cells. 
hPSC-derived β-cells cultured on the scaffold showed significantly increased gene 
expression levels of pancreatic endocrine hormones, insulin and glucagon, relative to 
pancreatic progenitors. Furthermore, the gene expression of β-cell maturation markers (MAFA, 
PCSK1, and G6PC2) were increased on the scaffold compared to the suspension clusters. 
Immunohistochemical stains showed that the percentage of Ins+ cells in the PLG scaffold culture 
was increased compared to suspension cultures, suggesting that the scaffold cultures may have 
a higher efficiency at generating β-cells during differentiation. β-cell maturation was further 
investigated through glucose-responsive functional tests that demonstrated cells cultured on the 
scaffold had higher insulin secretion than suspension clusters. Our suspension control had gene 
expression that was comparable to the initial report by Rezania in 2014256. Unlike adult islets, this 
initial report indicates that suspension cultured cells do not secrete insulin in response to high 
concentrations of glucose either under static or perifusion conditions256, consistent with our 
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results. While we demonstrate scaffold-based cultures can influence maturation down a β-cell 
lineage that can drive glucose stimulated insulin secretion, the insulin index ratio of scaffold 
cultures does not resemble the function of human islets, 3.2 ± 0.1, on average24,25. Future studies 
can further assess if the scaffold cultures are equipped to properly sense glucose and confirm if 
this factor is limiting insulin secretion at high glucose concentrations. The application of more 
recent protocols255,289 to scaffold-based culture also offers the opportunity to further enhance 
glucose stimulated responses. 
Despite their similar biomaterial design, the microporous PLG and PEG scaffolds also 
exhibited a few differences in how they influenced cell differentiation. Relative to suspension 
clusters, PEG scaffold cultures showed a more significant increase in the gene expression of β-
cell maturation markers than PLG scaffolds. On the other hand, when investigating cell-cell 
interactions, only ECAD gene expression from PLG scaffold cultures showed a significant 
increase relative to the suspension cultures. This difference could have played a role in the higher 
insulin secretion observed in PLG scaffolds versus PEG scaffold cultures. Additionally, PLG 
scaffolds are a degradable material, unlike PEG, which could play a role in improved function as 
these scaffolds may allow for remodeling of the local environment. Both PEG and PLG are 
amenable to our fundamental objective – supporting β-cell maturation in a 3D environment– yet 
PLG and PEG have some differences. These variances may be due to their different mechanical 
and physical properties (i.e. hydrophobicity and protein adhesion) that could influence cell-cell 
and cell-matrix interactions. With this evidence of phenotypic differences between PLG and PEG 
scaffold cultures, these studies support future studies that investigate the mechanisms by which 
the distinct materials are directing the cellular responses.  
In this study, we also show microporous scaffolds provide an environment conducive to 
controlling the size of the structures that could be essential for maturation. The size of 
transplanted islets has been previously reported to impact insulin secretion and viability 290–292. 
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Small islet clusters can exhibit low amounts of insulin secretion, which has been attributed to 
limited cell-cell contact, while excessively large clusters are considered to have limitations from 
nutrient availability 293. Based on these results with islets, the influence of pore size, which would 
determine the hPSC-derived β-cell cluster size, was investigated. Our results suggest that 
clusters forming in pores with diameters greater than 250 µm maximized maturation toward β-
cells. These results may reflect a contribution from the surface area to maturation. In addition, a 
scaffold with larger pores could have a greater interconnected porosity, thus, aiding diffusion of 
growth media as well as enabling a more uniform distribution of seeded cells into the scaffold. 
The seeding density, in combination with the pore size, was also shown to be critical for promoting 
cell-cell interactions. At low seeding densities, the cells were observed to primarily attach to the 
walls of the pores. However, increasing the cell density increasingly favored cluster formation and 
cell-cell interactions within the pore. Expression of E-cadherin was increased within scaffold 
culture relative to suspension culture, and E-cadherin staining was observed primarily between 
cells within the pores and not at the material surface. E-cadherin is a key player in maturation as 
studies have shown that E-cadherin immune-neutralization reduces both basal and glucose-
stimulated insulin secretion 294. Collectively, the microporous scaffold can be employed to control 
the formation of clusters, and to favor cell-cell interactions that are influential in maturation.  
Protocols generally rely on hPSCs to spontaneously cluster in suspension resulting in the 
clusters varying in size 295–297, though efforts have started to focus on establishing a mechanism 
for controlling the size of the end-stage β-cell clusters due to the influence on long-term viability 
and the secretion of sufficient insulin 255,289. While physical manipulation and shear have largely 
been employed to provide control of cluster size, the pores of the scaffold can provide direct 
control on cluster size, which may be advantageous for manufacturing. For large scale cell 
manufacturing in industrial or clinical settings, shear stress has been associated with challenges 
due to low cell viability and differentiation potential or abnormal morphology or gene expression 
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298–300. In our studies, the scaffold serving as a strategy to control cell cluster size could function 
in part to protect against adverse effects of shear during large scale manufacturing.  
Similar to cell-cell interactions, interactions between stem cells and the extracellular matrix 
can induce lineage-specific differentiation and support the function of differentiated cells by 
providing a composite set of chemical and structural signals301. Herein, we report that 
differentiating cells deposited ECM proteins within the scaffold, with the composition resembling 
that found in the basement membrane around islets. Furthermore, we found ECM proteins were 
homogeneously distributed throughout the scaffold culture, thus, available for interaction with β-
cells throughout the cluster. By culturing maturing β-cell clusters in microporous scaffolds versus 
suspension, cells are able to maintain a 3D morphology while interacting with a supportive matrix. 
A supportive matrix with which the clusters can interact could enhance cell maturation, as studies 
have shown ECM proteins such as collagen IV support the formation of cell structures, while also 
stimulating cell surface receptors to influence pancreatic cell processes302. Scaffold cultures also 
offer the opportunity to modify the local microenvironment surrounding the β-cell cluster that can 
be used to investigate the role of cell-matrix interactions during differentiation. Finally, suspension 
clusters will undergo manipulation during the transplantation process that could disrupt cell-cell 
and cell-matrix interactions. Whereas, for cells cultured in scaffolds, the scaffolds can maintain 
their niche that has been established within the pores, which can support the cell structures during 
transplantation.  
Matrix deposition by the cells is likely a key step in maturation, as key integrins change over 
developmental stages 303. This deposition of matrix initiates the formation of a niche, which is 
normally present in islets and influences maturation and function. Attachment of cells to ECM may 
also benefit β-cells by maintaining tissue architecture and preserving specific intercellular 
relationships within the pores. Interestingly, scaffolds coated with either collagen IV, laminin or 
Matrigel showed comparable gene expression levels of maturation markers to naked scaffolds 
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relying on cell-secreted ECM, which contained collagen IV, laminin and fibronectin. This was 
supported by the analysis of glucose-responsive insulin secretion on ECM coated scaffolds and 
naked scaffolds that showed β-cell function was similar across all conditions as well. These results 
suggest the matrix deposited by the cells on the PLG scaffold has the potential to mimic more of 
the complex niche environment during pancreatic development compared to the individual ECM 
proteins, and the ECM deposition may mask the impact of the adsorbed ECM proteins. 
3.6 Conclusion 
This research demonstrates that scaffolds have the potential to serve as a component within 
the process of manufacturing β-cells.  The scaffold design can be tuned to control cluster size, 
promote cell-cell interactions and permit ECM deposition on the scaffold to create a supportive 
niche. Similar to organoid development in three-dimensional cultures, the pancreatic progenitors 
establish a functional niche during in vitro scaffold culture. Furthermore, the scaffolds are formed 
from materials that have been used in vivo, and thus the cell-material construct could be directly 
transplanted, which would have the added advantage of maintaining the niche that has developed 
within the scaffold. Collectively, microporous scaffolds demonstrate the feasibility as a 
biomanufacturing platform to generate insulin-producing glucose-responsive β-cells. 
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Chapter 4: In Vitro Modifications to Pancreatic Progenitor Cluster 
Maturation and Seeding on Microporous Scaffold Cultures for 
Enhancing Islet Organoid Maturation  
 
4.1 Abstract 
Patients with type 1 diabetes could benefit from cell-based insulin treatments, but the 
supply of human islet tissue is limited. Recently, we developed microporous scaffold culture 
procedures that generate functional islet organoids derived from a limitless source of human 
pluripotent stem cells (hPSCs). However, obstacles still need to be overcome in order to improve 
the maturation process efficiency of the final product. One critical hurdle is to ascertain that the 
hPSC-derived β-cells function equivalently to their endogenous counterparts. Herein, our studies 
focused on modifying differentiation protocols and process techniques to better understand 
mechanisms that can enhance the functional maturation of islet organoids cultured on 
microporous scaffolds. An engineered insulin reporter helped assess the function of individual 
cells by measuring insulin storage and secretion in vitro. By modifying the timing of cell seeding 
from pancreatic progenitor to pancreatic endoderm, islet organoids showed increased amounts 
of insulin secreted per cell. In addition, cluster integrity and minimized cell manipulation during 
the differentiation was shown to be influential to the development of the islet organoids.  Finally, 
we evaluated seeding scaffolds with dense clusters instead of a single suspension. We found that 
dissociating clusters to seed as single cells on scaffolds can hinder islet organoid maturation. 
Together, these in vitro modifications to the scaffold culture differentiation process provide rational 
guidelines towards recapitulating the complexity of mammalian organogenesis to generate cells 
that more closely resemble mature human islets.  
  
57 
 
4.2 Introduction 
Over the past few decades, the process of differentiating human pluripotent stem cells 
(hPSCs) down specific cell lineages has shown significant improvements, though some 
limitations have been observed with organoid formation on traditional culture systems. These 
breakthroughs have allowed the differentiation of various hPSC populations into somatic cell 
derivatives in vitro23,25,304. However, studying tissue patterning and organ morphogenesis in vitro 
has been hindered by the lack of appropriate culture systems that would allow the cell-cell and 
cell-matrix interactions needed for organoid formation305. Organoids are 3D cell culture systems 
that mimic some of the structural and functional characteristics of an organ. In order to produce 
these appropriate 3D culture systems, the field has turned to engineered biomaterials that can 
spatially enable cellular interactions that are needed for organ formation67. Many organoid 
cultures are grown without any spatial constraints in ill-defined 3D matrices, which allow only 
limited tunability and reproducibility306,307. By contrast, the biochemical and biophysical 
properties of engineered matrices can be tuned to support the development and maturation of 
organoid cultures that could transform drug development and research for diseases, like 
diabetes. 
Islet organoids are being developed as treatment for Type 1 diabetes (T1D), which is a 
metabolic syndrome characterized by elevated blood glucose levels that result from reductions 
in insulin production or action. To date, insulin-expressing cells can be generated from hPSCs in 
vitro to provide a therapeutic source however the difficulty of controlling the fate and 
development of these cells in the body poses a challenge to diabetes treatment. Recently, islet 
organoids consisting of pancreatic α, β, and δ cells were able to be generated in Matrigel-
collagen scaffolds but neither material is Food and Drug Administration–approved for clinical 
applications308. Synthetic polymer scaffolds provide flexibility in synthesis and modification, have 
been widely applied for islet transplantation278,280,309,310 and are clinically-translatable. The 
scaffolds can be designed to have a high porosity, a fully interconnected geometry, structural 
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integrity, and a defined three-dimensional shape. Our prior studies demonstrated the ability to 
direct pancreatic differentiation of hPSCs on microporous scaffolds in order to generate 
functional early-stage islet organoids 311. However, while we demonstrated scaffold-based 
cultures can enhance maturation, we remained unable to obtain functional human pancreatic – 
particularly insulin-producing – cells performing on par with native islets. The application of more 
recent protocols25,312 to scaffold-based culture offers the opportunity to further enhance glucose 
stimulated responses. In addition, it has been shown that only a subset of pancreatic progenitor 
cells, marked by Pdx1+ and Nkx6.1+ expressing cells, may be competent to generate mature, 
insulin-expressing cells313. This suggests the need for tools that can help further investigate 
mechanisms that influence the production of a heterogenous population of mature and 
immature cells within the derived pancreatic clusters. 
In this chapter, we present the application of improved culture systems for islet organoid 
formation, as well as the engineering of the hPSCs for monitoring the maturation and function of 
islet organoids non-invasively. This investigation will help identify subtle differences that exist at 
the transcriptomic and protein expression levels that can affect β-cell survival/proliferation and 
insulin release. Prior studies assessed heterogenous function in islets using human proinsulin 
with C-peptide-bearing superfolder green fluorescent protein (sfGFP-Cpep) expressed in 
transgenic mice314. By a moderate decrease in fluorescence intensity, the insulin reporter was 
used to reveal a rapid dispossession of insulin in only a small subset of the islet population in 
the mouse pancreas when challenged by glucose. This technology for assessing functional 
heterogeneity between individual cells can be applied towards our studies in order to help 
identify environmental influences that control the commitment of pancreatic progenitor cells 
towards a final functional fate. Thus, we developed an insulin reporter that provides 
unprecedented insight into cellular interactions that drive the maturation process within a 3D 
matrix, and can also assess dynamic insulin secretion by individual cells.  
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We then use this reporter cell line to characterize the environmental influences that 
affect hPSC differentiating into islet organoids, specifically insulin-producing β-cells. The 
derivation of functional islet organoids cultured on synthetic microporous scaffolds can provide a 
tool to molecularly dissect islet organoid development. This technology may also enable 
therapeutic advances by supporting the generation of a high-quality source of cells for 
regenerative medicine. 
4.3 Materials and Methods 
4.3.1 Microporous scaffold fabrication 
Poly(lactide-co-glycolide) (PLG) microporous scaffolds were fabricated as previously 
described277. Briefly, PLG microporous scaffolds were fabricated by compression molding PLG 
microspheres (75:25 mole ratio D,L-lactide to glycolide) and 500 to 600 µm micron-sized salt 
crystals in a 1:30 ratio of PLG microspheres to salt. The mixture was humidified in an incubator 
for 7 min and then thoroughly mixed again. Scaffolds were compression molded with 77.5 mg of 
polymer–salt mixture into cylinders 5 mm in diameter by 2 mm in height using a 5 mm KBr die 
(International Crystal Laboratories, Garfield, NJ) at 1500 psi for 45s. Molded constructs were 
gas foamed in 800 psi carbon dioxide for 16 h in a pressure vessel. The vessel was 
depressurized at a controlled rate for 30 min. On the day of cell seeding, scaffolds were leached 
in water for 1.5 h, changing the water once after 1 h. Scaffolds were disinfected by submersion 
in 70% ethanol for 30 seconds and rinsed multiple times with phosphate buffer solution (PBS).  
4.3.2 Culture of undifferentiated cells 
All cell culture work was performed with the HUES8 hESC line, generously provided by 
Dr. Douglas Melton (Harvard University) and has been previously published on24,25, and H1 
hESC line obtained from the WiCell Research Institute (Madison, WI). Undifferentiated hPSC 
lines were cultured using mTeSR1 (StemCell Technologies; 05850) in 30-mL spinner flasks 
(REPROCELL; ABBWVS10A or ABBWVS03A) on a stirrer plate (Chemglass) spinning at 60 
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rpm in a humidified 5% CO2 37°C incubator. Cells were passaged every 3–4 days by single-cell 
dispersion using TrypLE Express (Life Technologies). 
4.3.3 Differentiation of hPSCs and scaffold seeding 
hPSC differentiations were performed in 30-mL spinner flasks on a stirrer plate set at 60 
RPM in a humidified incubator set at 5% CO2 and 37 °C. hPSCs were differentiated to SC-β 
cells using the protocol previously described25. Briefly, undifferentiated cells were single-cell 
dispersed and seeded at 6 × 105 cells/mL in a 30-mL spinner flask. Cells were cultured for 72 hr 
in mTeSR1 and then cultured in the differentiation media for 6 stages. To initiate scaffold culture 
differentiations, Stg5 pancreatic endoderm clusters were seeded either as single cells or dense 
clusters on scaffolds at 125 million cells/cm3  then further differentiated according to the 
protocol2. Prior to cluster seeding, scaffolds were washed in cell media solution then briefly 
dried on sterile gauze to improve the absorption of the cell solution into the scaffold. Clusters 
were distributed across both faces of the scaffold and then incubated for 10min to allow cell 
solution to be further absorbed into the scaffold before differentiation media was added. 
Traditional hPSC suspension culture was differentiated per the described protocol to provide an 
internal control25.  
4.3.4 Designing sfGFP-Cpep fluorescent insulin reporter hPSC line  
Briefly, HEK293FT cells were co-transfected using lentiviral packaging vectors (pMDL-
GagPol, pRSV-Rev, pIVS-VSV-G, with a sfGFP-Cpep construct314,315 using Lipofectamine 2000 
(Life Technologies, Grand Island, NY,) for 48 h. The sfGFP-Cpep construct (i.e., with the 
Superfolder-GFP cDNA316 ligated into the XhoI site of the human C-peptide coding sequence315) 
driven by the upstream 2.2-kb rat Ins1 promoter included a phosphoglycerol kinase (PGK)-
promoter-mCherry selection marker. Using PEG-it (System Biosciences, Mountain View, CA), 
supernatant was concentrated for 24 h. Then it was precipitated using ultracentrifugation, 
resuspended in PBS and stored at −80 °C until use. Through viral transfection and FACS 
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sorting, clones can be identified in which the vector was correctly integrated into the cell line. 
The sfGFP-Cpep cell line was then expanded into a subclonal population and characterized. 
4.3.5 qRT-PCR analysis 
Gene expression analysis on fixed, sorted cells was obtained by first centrifugation of 
the cell pellet at 60 g for 1min at 4°C. The supernatant was discarded. Total RNA was isolated 
from the pellet using the RecoverAll Total Nucleic Acid Isolation kit (Ambion), starting at the 
protease digestion stage of manufacturer recommended protocol. The following modification to 
the isolation procedure was made: instead of incubating cells in digestion buffer for 15 minutes 
at 50°C and 15 minutes at 80°C, we carried out the incubation for 1 hour at 50°C. RNA 
concentration was determined using a NanoDrop spectrophotometer. The iScript™ Reverse 
Transcription Supermix was used to transcribe RNA into cDNA. Universal RT microRNA PCR 
assays were performed using SYBR Green MasterMix Universal RT (Exiqon), according to the  
Table 4.1 Primers used for qPCR analysis 
gene primer sequence (5' to 3') 
PDX1 forward CCTTTCCCATGGATGAAGTC 
PDX1 reverse CGTCCGCTTGTTCTCCTC 
Nkx6.1 forward GGGGATGACAGAGAGTCAGG 
Nkx6.1 reverse CGAGTCCTGCTTCTTCTTGG 
MafA forward GAGAGCGAGAAGTGCCAACT 
MafA reverse TTCTCCTTGTACAGGTCCCG 
Insulin forward TTCTACACACCCAAGACCCG 
Insulin reverse CAATGCCACGCTTCTGC 
Glucagon  forward TGCTCTCTCTTCACCTGCTCT 
Glucagon  reverse AGCTGCCTTGTACCAGCATT 
ECAD forward TTGACGCCGAGAGCTACAC 
ECAD reverse GACCGGTGCAATCTTCAAA 
PCSK1 forward CTCTGGCTGCTGGCATCT 
PCSK1 reverse CGGGTCATACTCAGAGGTCC 
NEUROD1 forward GCCCCAGGGTTATGAGACTAT 
NEUROD1 reverse ATCAGCCCACTCTCGCTGTA 
NGN3 forward CTATTCTTTTGCGCCGGTAG 
NGN3 reverse CTTCGTCTTCCGAGGCTCT 
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manufacturer’s instructions. The amplification profile was assessed using a LightCycler® 480 
(Roche, Germany). Gene expression was quantified using the ΔΔCt method and fold change 
was calculated using the formula 2-ΔΔCt. Values for the genes of interest were normalized to the 
housekeeping gene (GAPDH) followed by normalization to marker expression in hPSCs.  
4.3.6 Static glucose-stimulated insulin secretion 
This assay was performed in KRB buffer consisting of 128 mM NaCl, 5 mM KCl, 2.7 mM 
CaCl2 1.2 mM MgSO4, 1 mM Na2HPO4, 1.2 mM KH2PO4, 5 mM NaHCO3, 10 mM HEPES 
(Gibco; 15630-080), and 0.1% BSA. After preincubating the cells at 2 mM glucose, clusters 
were incubated for 1 hr at 2 mM glucose followed by 1 hr at 20 mM glucose. Insulin in the 
supernatant from these 1 hr incubations was quantified with a Human Insulin ELISA (ALPCO; 
80-INSHU-E10.1). Viable cell numbers were determined using a hemocytometer. For monitoring 
dynamic function, cells containing the sfGFP-Cpep construct or control cells (no construct) in 
basal culture media were imaged on a Leica DM IRB fluorescence microscope to establish the 
baseline insulin levels. Subsequently, the sfGFP-Cpep cells or control cells will be treated with 
saline or culture media containing 20 mM glucose for 1 hour, and then imaged again. The time 
series images were presented as a stack of multiple images which were analyzed as a 
hyperstack using ImageJ/Fiji software, version 1.8317. They were first corrected for translational 
movement using the StackReg feature, and then a thresholded-base mask was used defining 
the insulin-positive area superimposed on the scaffold culture area. Then this area was 
analyzed with Regions of Interest (ROI) for each entire islet cluster, and a fluorescence intensity 
profile was generated using the data. Flow-thru was also collected for insulin quantification.  
4.3.7 Flow Cytometry 
Clusters were single-cell dispersed with Trypsin, fixed with 4% paraformaldehyde for 30 
min at 4 °C, blocked and permeabilized with staining buffer for 30 min at 4 °C, incubated with 
primary antibodies in staining buffer overnight at 4 °C, incubated with secondary antibodies in 
staining buffer for 2 hr at 4 °C, resuspended in staining buffer, and analyzed. Scaffold cultures 
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were washed in ice-cold RPMI media, then minced and digested in 10 mL of 1mg/ml Type II 
collagenase (Sigma-Aldrich Inc., St. Louis, MO, USA) at 37°C, 30 minutes with vigorous 
shaking. Tissue homogenate was then strained through a 100μm filter and washed in PBS. 
Samples were then fixed, stained with antibodies and analyzed using a LSR Fortessa flow 
cytometer (Becton, Dickinson & Co., Franklin Lakes, New Jersey, USA). Compensation and 
data analysis were completed using FlowJo software (FlowJo, LLC, Becton, Dickinson & Co., 
Franklin Lakes, NJ, USA). All antibodies were used at 1:300 dilution except where noted. The 
antibodies used were: rat-anti-C-peptide (DSHB; GN-ID4-S), mouse-anti -nkx6.1 (1:100; DSHB, 
F55A12-S), goat-anti-pdx1(R&D Systems; AF2419), anti-mouse-alexa fluor 647 (Invitrogen; 
a31571), anti-goat-alexa fluor 405 (Abcam; ab175664), anti-rat-alexa fluor 405 (Abcam; 
ab175671), 
4.3.8 Animals 
Male NSG mice (Jackson Laboratories, Bar Harbor, ME, United States) between 8 and 
10 weeks of age received an intraperitoneal injection of 130 mg/kg streptozotocin 4–7 days prior 
to transplant. (Sigma-Aldrich, St. Louis, MO). Each day leading up to surgery, blood glucose 
levels were measured using the tail vein prick technique (Accu-chek/Roche, Basel, 
Switzerland), and body weight was recorded. The criteria to include a mouse in the study was 
the following: glucose readings above 350 mg/dL on 2 consecutive days leading up to transplant 
surgeries, and no more than a 20% reduction in weight since streptozotocin injection. Following 
surgery, glucose and body weight for each mouse were measured three times per week. All 
studies involving mice were approved by the University of Michigan Animal Care and Use 
Committee. 
4.3.9 Transplantation studies 
Cell-laden scaffolds were implanted as previously described318. Briefly, mice were 
anesthetized with 2% isoflurane until loss of consciousness was confirmed by pinch reflex test. 
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The abdominal area was shaved and sterilized with betadine and ethanol. An approximate 5 
mm incision was made in the peritoneal wall, in the middle of the abdominal region, and the 
epididymal fat pads (EFP) were located and unwrapped outside of the abdominal wall. Scaffolds 
were wrapped within the epididymal fat pad, then placed back into the peritoneal cavity. The 
incision was then closed in 2-layers using absorbable suture. Mice were given a dose of 0.005 
mg/gram body weight Rimadyl carprofen (Zoetis, Florham Park, NJ, United States) and allowed 
free access to food and water postoperatively. After 30 days, blood serum was collected to 
quantify circulating human C-peptide levels. Mice were fasted 5 h before blood collection. Thirty 
minutes prior to blood collection, mice received an intraperitoneal injection of 2 g/kg glucose in 
the form of 20% glucose. Approximately 200 μL of blood was collected from the saphenous vein 
during the period between 30 and 60 min post glucose stimulation. Serum was collected from 
whole blood by 20 min of coagulation followed by centrifuging at 2000g for 20 min. Isolated 
serum was analyzed for human C-peptide levels using the manufacturer’s provided ELISA 
protocol (AbCam, Cambridge, MA, United States).Mice were euthanized between 30-50 days 
post-transplant for post-analysis. 
4.3.10 Statistics  
All statistical analyses were conducted using Prism graphing and data analysis software 
(GraphPad Software, Inc., La Jolla, CA, United States). Statistical differences were determined 
using non-parametric testing; an unpaired two-tailed Student t test or one-way ANOVA with 
Dunnett test for multiple comparisons. Values were reported as the mean ± standard error of 
mean (SEM). n indicates the total number of biological replicates. 
4.4 Results  
4.4.1 Transplantation of islet organoid scaffold cultures for in vivo maturation 
We previously detailed an approach generating islet organoids on microporous PLG 
scaffolds that produced hPSC-derived β cells capable of undergoing glucose-stimulated insulin 
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secretion (GSIS) in static incubations. We sought to further assess the maturation of islet 
organoids cultured on scaffolds by testing their capacity to function in vivo. The transplantation 
process consisted of transplanting the islet organoids in the epidydimal fat pad of 
immunocompromised mice that had been chemically induced to be diabetic with streptozotocin 
(STZ). The implantation process involved minimal manipulation on the islet organoids as they 
were already supported by the biomaterial scaffold for delivery. After transplantation in the 
diabetic mice, we evaluated function by assessing fasting blood glucose levels over 50 days 
(Fig 4.1A). Human C-peptide in the blood was detected after 30 days, 0.58 ± 0.16 ng/mL, 
however after 50 days it was no longer detectable. (Fig 4.1B). We observed that, after 50 days, 
the grafts did not demonstrate a systemic effect on glucose metabolism. qRT-PCR analysis was 
conducted on cells after 30 days and 50 days post implantation to characterize islet organoid in 
vivo maturation. We found, after 30 days, transplanted cells showed increased gene expression 
levels of the endocrine hormone marker gene for insulin relative to the in vitro control. (Fig 
4.1C). Additionally, expression of a key β-cell maturation marker, MafA, increased relative to the 
in vitro scaffold culture control. MAFA (a basic leucine zipper transcription factor) is expressed 
in adult β-cells and is thought to be critical in establishing β-cell function in adult islets319–322. 
After 50 days, however, we no longer observed an increase in the expression of β-cell function 
in the transplanted cells relative to the in vitro control.  
These results suggest the maturing scaffold cultures were able to secrete insulin in vivo 
up to 30 days but not at a therapeutic dose capable of restoring euglycemia in diabetic mice. 
Further in vitro maturation could enhance the development of the islet organoids in vivo. The 
current differentiation protocol generated scaffold cultures with an in vitro glucose-responsive 
insulin secretion index ratio of 1.3 ± 0.2, which is significantly lower than human islets, 3.2 ± 0.1, 
on average24,25. Thus, we sought to utilize a protocol described in Velazco-Cruz et al. (2019), 
referred to here as the Velazco-Cruz protocol, and, with modifications to either the protocol or 
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our process techniques, better understand how to enhance islet organoid maturation on 
microporous scaffolds. 
 
4.4.2 Characterization of islet organoid maturation on scaffolds using fluorescent insulin reporter 
We first assessed if seeding scaffolds with cells resembling a more mature stage 5 
pancreatic endoderm rather than stage 4 pancreatic progenitors could better utilize the scaffold 
microenvironment and, thus, enhance functional maturation. The Velazco-Cruz protocol 
(A) Blood glucose measurements of mice transplanted with PLG scaffold cultures over 50 days (n=3). (B) 
Human C-peptide levels from individual mice are shown on a box and whisker plot. (C) Gene expression 
of pancreatic endocrine hormones, β-cell-associated transcriptional factors, and β-cell function-related 
proteins in hPSC-derived insulin-producing clusters prior to transplantation (stage 6), 30 days after 
transplantation and 50 days after transplantation. (*P≤0.05, **P≤0.01 compared to pre-transplantation 
control using one-way ANOVA with Dunnett test for multiple comparisons, n = 3 biological replicates for 
all genes). Error bars represent the standard error of mean (SEM). 
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Figure 4.1 In vivo function and maturation of hPSC-derived insulin-producing clusters on scaffold 
cultures 
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incorporates 3D cultures that were shown to help maintain cluster integrity and enhance 
progenitor development25. The six-stage protocol also involves a dissociation step where 
pancreatic progenitor clusters are reaggregated to help generate almost pure populations of 
endocrine cells containing β-like cells that secrete high levels of insulin and express β cell 
markers. However, we did not perform this dissociation step as we found reaggregating clusters 
to be a challenging process. This could be attributed to the amount of manipulation required to 
dissociate the clusters into single cells. Flow analysis was conducted to characterize the 
development of pancreatic endoderm cells prior to seeding on scaffolds. hPSCS were induced 
into pancreatic progenitors with approximately 29.9 ± 3.1% PDX1+Nkx6.1+ cells and, 
subsequently, pancreatic endoderm with an increased PDX1+Nkx6.1+ population, 36.1 ± 1.1% 
cells, and 22.3 ± 2.0% C-pep+Nkx6.1+ cells (Fig. 4.2A). Thus, the protocol showed an increase 
in C-peptide+ cell populations, a protein produced by the insulin gene, in addition to β-cell 
markers, PDX1+ and NKX6-1+, as the cells differentiated. Pancreatic endoderm cells were then 
dissociated into single cells and seeded on porous PLG scaffolds. Clusters formed within the 
first 24 hours and were then cultured for 10-14 days in order to generate functional, insulin-
producing clusters. Notably, analysis of protein expression in cells cultured on scaffolds 
revealed an increase in pancreatic transcription factors, PDX1 and Nkx6.1, relative to the 
pancreatic progenitor control (Fig. 4.2B). Additionally, we observed increased expression of 
endocrine hormone marker genes, insulin and glucagon. Maturation markers commonly used to 
indicate insulin processing were assessed and showed MafA expression in cells cultured on 
scaffolds increased compared to progenitor controls.  
 A sfGFP-Cpep construct323,324 was then used to investigate the differentiation efficiency, 
heterogeneity in maturation and reproducibility of this approach. The construct includes a 
phosphoglycerol kinase (PGK)-promoter-mCherry marker for selection through FACS. This 
construct was transduced into the H1 line using a lentivirus, sorted and a subclonal population 
was then generated. Flow analysis of insulin-producing cells cultured on scaffolds confirmed the 
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GFP marker could be used as a reporter for C-peptide since the percentage of GFP+ cells was 
comparable to the percentage of C-peptide+ cells within the total  cell population (Fig. 4.2C). Gene 
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expression analysis of transduced cells and non-transduced cells demonstrated that the viral 
transduction did not affect the ability for hPSCs to differentiate down the pancreatic lineage (data 
not shown). Live imaging shows insulin content within sfGFP-Cpep cells as they differentiated 
towards a pancreatic lineage (Fig. 4.2D). After stage 5, we observed GFP+ cells uniformly 
distributed within the clusters and an increase in GFP+ cells as pancreatic progenitors underwent 
maturation in both suspension and on scaffold cultures.  
 The functional maturation of these insulin-producing clusters in scaffolds was examined 
by their ability to secrete insulin in a glucose-responsive manner through GSIS. Scaffold 
cultures generated using the protocol detailed in either the Velazco-Cruz protocol or Rezania et  
al. 2014, referred to here as the Rezania protocol, were exposed to 2 mM and 20 mM glucose 
solutions. We found the insulin index ratio for the scaffold cultures, 1.2 ± 0.3, was similar to both 
the suspension, 1.5 ± 0.4, (Fig. 4.2E) and the prior scaffold cultures generated using the 
Rezania protocol311. At the low glucose concentration, the cells generated on scaffolds with the 
Velazco-Cruz protocol secreted increased quantities of insulin relative to cells generated with 
the Rezania protocol (2.7 ± 0.2 versus .7 ± 0.1 μIU/103 cells, P≤0.05, n= 4-7) (Fig. 4.2F). At the 
high glucose concentration, we also observed an increase in insulin secretion per cell from the 
Velazco-Cruz scaffold cultures relative to the Rezania protocol (3.2 ± 0.6 and 0.8 ± 0.1 μIU/103 
cells, P≤0.05, n= 4-7). Thus, we were able to show that scaffold cultures seeded with a more 
 
(A) Representative flow cytometric dot plots of dispersed stage 4 and stage 5 clusters immunostained for 
the indicated markers. (B) Gene expression of pancreatic markers in stage 4 pancreatic progenitors and 
insulin-producing stage 6 clusters (*P≤0.05, **P≤0.01 compared to pancreatic progenitor, n = 6). (C) 
Differentiated stage 6 insulin-producing clusters derived from sfGFP-Cpep hPSC cells were analyzed by 
flow cytometry. Undifferentiated sfGFP-Cpep hPSCs were used for negative gating of sfGFP-Cpep 
expression. (D) Bright-field and fluorescent images of differentiated clusters in suspension and scaffold 
cultures are shown; scale bars, 100 μm. White arrows show scaffold matrix. (E) Human insulin secretion 
from PLG scaffold cultures generated with either the Rezania or Velazco-Cruz protocol in response to low 
and high glucose concentrations under static conditions (Rezania scaffold cultures: n = 3 biological 
replicates, Velazco-Cruz: n = 8 biological replicates). (F) The stimulation index was calculated as the ratio 
of insulin release in high to low glucose concentrations (*P≤0.05, **P≤0.01 compared to suspension, n=3-
4 biological replicates). Error bars represent the SEM.  
 
Figure 2 hPSC-derived β-cell Maturation using Velazco-Cruz protocol on PLG scaffolds with sfGFP-
Cpep reporter Representative flow cytometric dot plots of dispersed stage 4 and stage 5 clusters 
immunostained for the indicated markers (A). Gene expression of pancreatic markers in stage 4 pancreatic 
progenitors and insulin-producing stage 6 clusters (*P≤0.05, **P≤0.01 compared to pancreatic progenitor, 
n = 6) (B). Differentiated stage 6 insulin-producing clusters derived from sfGFP-Cpep hPSC cells were 
analyzed by flow cytometry. Undifferentiated hPSCs were used for negative gating of sfGFP-Cpep 
expression. (C) Bright-field and fluorescent images of differentiated clusters in suspension and scaffold 
cultures are shown; scale bars, 100 μm. White arrows show scaffold matrix. (D) Human insulin secretion 
from PLG scaffold cultures generated with either the Rezania or Velazco-Cruz protocol in response to low 
and high glucose concentrations under static conditions (Rezania scaffold cultures: n = 3 biological 
replicates, Velazco-Cruz: n = 8 biological replicates). (E) The stimulation index was calculated as the ratio 
of insulin release in high to low glucose concentrations (*P≤0.05, **P≤0.01 compared to suspension, n=3-
4 biological replicates) (F). Error bars represent the SEM.  
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and high glucose concentrations under static conditions (Rezania scaffold cultures: n = 3 biological 
replicates, Velazco-Cruz: n = 8 biological replicates). (E) The stimulation index was calculated as the ratio 
of insulin release in high to low glucose concentrations (*P≤0.05, **P≤0.01 compared to suspension, n=3-
4 biologi al r plicates) (F). Error bars repre nt the SEM.  
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progenitors and insulin-producing stage 6 clusters (*P≤0.05, **P≤0.01 compared to pancreatic progenitor, 
n = 6) (B). Differentiated stage 6 insulin-producing clusters derived from sfGFP-Cpep hPSC cells were 
analyzed by flow cytometry. Undifferentiated hPSCs were used for negative gating of sfGFP-Cpep 
expression. (C) Bright-field and fluorescent images of differentiated clusters in suspension and scaffold 
cultures are shown; scale bars, 100 μm. White arrows show scaffold matrix. (D) Human insulin secretion 
Figure 4.2 hPSC-derived β-cell maturation using Velazco-Cruz protocol on PLG scaffolds with sfGFP-
Cpep reporter 
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mature progenitor cells resembling pancreatic endoderm were able to enhance the maturation 
of the insulin-producing clusters indicated by increased MafA gene expression and enhanced 
insulin secretion per cell. However, the glucose-responsive insulin index ratio did not show a 
significant improvement, thus, we sought to modify the protocol to address the challenges with 
reaggregating clusters that could be limiting the generation of cells with enhanced glucose-
responsive function.  
 
4.4.3 Modifications to the Velazco-Cruz protocol for aggregating dissociated pancreatic 
progenitors to influence islet organoid maturation 
Reaggregating clusters after the pancreatic progenitor state has been shown to act as a 
endocrine purification process that improves cluster maturation25,312,325,326. Thus, we aimed to 
investigate if incorporating this protocol step, thereby removing non-endocrine cells, would 
influence islet organoid development and function. Since this step was challenging with 3D 
dense clusters, we utilized the 2D culture detailed in the Rezania protocol to generate stage 4 
pancreatic progenitors then transitioned the cells to a 3D culture using the Velazco-Cruz 
protocol for further maturation. This modified protocol, referred to here as the Rezania-Cruz 
protocol, leveraged some of the established processes used for traditional 2D cultures that were 
still being  developed for a 3D environment. As a result, we found dissociating pancretic 
progenitors in a 2D monolayer required less manipulation and generated higher cell viability 
compared to dissociating 3D clusters.  
Using the sfGFP-Cpep cell line, we generated pancreatic progenitor cells on a 2D plate 
and observed trace amounts of cells expressing insulin (Fig. 4.3A). However, after progenitors 
were dissociated and allowed to aggregate in suspension, we observed cluster formation and an 
increase in GFP+ cells within the clusters. Enhanced cluster maturation after the aggregation step 
was assessed by qRT-PCR analysis. Aggregated clusters showed an increase in insulin 
expression as well as the maturation marker, MafA, relative to the prior day’s progenitor cells in 
2D monolayer (Fig. 4.3B). We found clusters did not form without including Y27632, a 
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RHO/ROCK pathway inhibitor that has been found to prevent apoptosis. As a result, we added 
Y27632 throughout stage 5 to investigate if this would help maintain cluster integrity and shape 
as cells recovered from the dissociation process. By the end of stage 5, most pancreatic 
endoderm clusters expressed the fluorescent insulin reporter. However, brightfield images at 
stage 5 day 7 showed irregular shaped clusters with fluorescent cells congregated to one region 
of the cluster indicating cellular polarization (Fig. 4.3C)327. This morphology differs from the native 
human islet that consists of pancreatic cells distributed throughout the cluster328,329. Thus, we 
reduced Y27632 administration to only the day cells were transfered to suspension for 
aggegration to investigate if overexposure caused the cellular polarization to occur. As the stage 
5 differentiation continued without Y27632, the cluster size reduced from 172.1 µm ± 9.6 to 57.1 
µm ± 2.6 while the population of GFP+ cells increased throughout the clusters (Fig. 4.3D). By the 
end of stage 5, the    clusters retained their round shape, were predominately GFP+ but there was 
a significant reduction in cell density. These results indicate modifying the protocol with Y27632 
improved cell survival after manipulation on the cells but overexposure can lead to cluster 
polarization of endocrine cells, GFP+ cells, and  non-endocrine cells, GFP- cells.  
 Stage 5 pancreatic endoderm clusters were dissociated and seeded on scaffolds or 
maintained in suspension for futher maturation. While cells continued to express the insulin 
reporter on both scaffolds and in suspension, we observed the cell density in suspension 
continued to decrease during stage 6 relative to the scaffold cultures. We then characterized the 
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Representative images of differentiated clusters in suspension during stage 5 with exposure to ROCK 
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Figure 4.3 sfGFP-Cpep reporter characterizes modified protocol for enhanced PLG scaffold culture 
function 
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maturation of islet organoids on scaffold cultures generated with the modified protocol. The 
majority of GFP+ cells expressed NKX6.1 (Fig. 4.3E). However, the fraction of cells co-
expressing C-peptide and NKX6.1, 29.3 ± 3.8%, was lower than the cell population from islet 
organoids generated using the unmodified Velazco-Cruz protocol. The static GSIS indicated 
islet organoids cultured using the modifed protocol generated an insulin secretion index, 1.7 ± 
0.6, with a heterogenous population of mature and immature cells that resulted in a wide 
variation in function (Fig. 4.3F). Thus, reaggregating clusters at the pancreatic progenitor stage 
prior to seeding scaffold cultures was able to generate functional islet organoids that resembled 
human islet function but further studies would need to be completed to improve the consistency.  
 
4.4.4 Scaffold culture process modifications reduce manipulation on clusters to augment islet 
organoid function 
Based on the influence cell manipulation had on organoid development, we modified 
how we seeded scaffolds to investigate if reducing cell processing steps would affect the 
generation of functional, mature cells. The modified process step consisted of seeding intact 
pancreatic progenitor clusters on scaffolds rather then dissociating the clusters into a single cell 
solution for seeding. In addition, cells could benefit from the supportive scaffold matrix while 
leveraging their pre-established cell-cell interactions. Pancreatic progenitor clusters were 
generated using the Velazco-Cruz protocol with a small population of cells expressing the 
insulin fluorescent reporter (Fig. 4.4A). Clusters were then transplanted on scaffolds at the 
same density as prior single cell suspensions, 125 million cells/cm3. We observed an increase in 
GFP+ cells during stage 5 in both suspension and on scaffolds. We then performed gene 
expression analysis at the end of stage 5 and found β cell genes, including insulin, NKX6.1, 
glucagon, MAFA, and PCSK1, were increased in islet organoids cultured on scaffolds compared 
to the suspension control (Fig. 4.4B). NeuroD1 and NGN3 are pancreatic endocrine markers 
that were also increased on scaffold cultures relative to suspension. In addition, E-cadherin had 
increased expression levels on scaffold cultures indicating the cell-cell interactions within 
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seeded clusters were enhanced relative to suspension clusters. 
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 Analysis of the insulin reporter during stage 6 provided dynamic insights to how the cells 
functionally matured. Representative images of sfGFP-Cpep cells on scaffolds were analyzed 
over time for fluorescent intensity where increases in intensity mean increases in insulin 
biosynthesis and decreases correlate with insulin secretion (Fig. 4.4C). We found the 
fluorescence intensity doubled between day 1 and day 3 of stage 6 then increased again by a 
quarter around day 8 before plateauing. Static GSIS analysis assessed function of PLG scaffold 
cultures seeded with 
clusters or single cells (Fig. 4.4D). PLG scaffolds seeded with clusters were comparable to 
clusters in suspension (1.1 ± 0.1 vs 1.3 ± 0.2, n=5-6), while PLG scaffolds seeded with a single 
cell suspension showed a decreased insulin index ratio, (1.0 ± 0.1 vs 1.3 ± 0.2, n=5-8, P<0.05). 
  
We evaluated cluster function further by monitoring dynamic C-Peptide secretion in 
sfGFP-Cpep clusters under a high glucose concentration. Imaging analysis showed a gradual 
10% decrease in fluorescence intensity over a 20minute stimulation period in 20mM glucose, 
which together with the GSIS data confirms the PLG scaffolds generated glucose-responsive 
insulin-secreting cells (Fig. 4.4E). Synchronous insulin release is typically observed with islets 
following in vitro glucose stimulation. As a result, we investigated this response in the islet 
organoids. Due to the integrated nature of the scaffold culture, we considered different regions 
of the islet organoid as clusters and found the clusters exhibited asynchronous responses (Fig. 
 
(A) Bright-field and fluorescent images of sfGFP-Cpep differentiated clusters in suspension and on 
scaffold cultures at stage 5 are shown; scale bars, 500 μm. (B) Gene expression of pancreatic endocrine 
and maturation markers as well as ECAD gene expression in pancreatic progenitors at the end of stage 
5 (*P≤0.05, **P≤0.01, ***P≤0.001 compared to suspension, n = 4) (C) Representative images of 
differentiated clusters on a scaffold culture during stage 6. Cell-laden area on scaffold is indicated by white 
dashed circle. Fluorescence integrated density of scaffold culture is plotted over the duration of stage 6 
and normalized to initial intensity (D) Stimulation index shows human insulin secretion from suspension 
and PLG scaffold cultures seeded with either pancreatic progenitors in single cell suspension or dense 
clusters in response to low (2mM) and high (20mM) glucose concentrations under static conditions 
(*P≤0.05 compared to suspension, n = 5-7 biological replicates). (E) Fluorescent imaging of scaffold 
cultures in response to high glucose (20mM) measured fluorescence integrated density over 20 minutes. 
Fluorescence intensity was normalized to initial intensity. (F) Different regions, or clusters, of a 
representative scaffold were assessed for changes in fluorescence integrated density over 20 minutes. 
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Figure 4.4 Effect of seeding pancreatic progenitors as dense clusters on PLG scaffold cultures 
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4.4F). We observed heterogenous functional maturation on the scaffold with some clustered 
regions, like Cluster 1 and 4, showing more than 10% loss in fluorescence intensity while other 
regions, like Cluster 2 and 3, were closer to 5% loss. These results suggest that scaffold culture 
function could be improved if there was a homogenous population of clusters that resembled the 
clusters with more insulin secretion during GSIS.  
4.5 Discussion 
Our studies demonstrate the support of the scaffold microenvironment during organoid 
maturation could be enhanced by adjusting the differentiation stage of cells seeded on scaffolds 
as well as the seeding technique. With the support of a novel fluorescent insulin reporter stem 
cell line, these findings provide mechanistic insights regarding material design and β-cell 
development during the in vitro maturation of islet organoids on scaffolds. Scaffold cultures 
seeded with a more mature progenitor cell resembling pancreatic endoderm were able to 
enhance the secretion of insulin per cell in the islet organoids. These results indicate organoid 
development could benefit from incorporating scaffold cultures near the end of the differentiation 
process rather than during early cell fate decisions. Reaggregated pancreatic endoderm cells 
cultured on scaffolds also enhanced islet organoid maturation with similar insulin secretion 
function to human islets however functional variability from this modified protocol needs to be 
further evaluated. We also found glucose-responsive functional tests showed the insulin 
secretion index of scaffolds seeded with dense clusters were comparable to the suspension 
clusters while scaffolds seeded with dissociated cells had decreased function.  
Microporous scaffold cultures provide a supportive 3D niche that promotes cell-cell and 
cell-matrix interactions to facilitate islet organoid maturation311. This organization into a tissue, 
rather than a collection of cells, facilitated transplantation as the scaffolds could be directly 
transplanted, which contrasts with the cells that are manually aggregated and then 
transplanted23,25. Thus, the scaffold-based transplantation exposed the cells to significantly less 
manipulation, particularly around the time of transplant, which can be a challenging transition for 
77 
 
cell survival under the best of conditions. However, low quantities of human C-peptide present 
in the blood demonstrated that transplanted islet organoids were functionally, mature but not 
capable of processing insulin to regulate blood glucose metabolism under in vivo conditions. 
Key characteristics of -cell function include the sensing of physiological glucose levels, the 
rapid release of stored insulin vesicles, and the immediate cessation of insulin secretion once 
glucose levels have been normalized. This complex process requires optimal coordination of 
multiple regulatory processes that exist in endogenous -cells. Thus, we transitioned 
differentiation protocols to the Velazco-Cruz protocol and evaluated mechanistic modifications 
to enhance islet organoid maturation prior to transplantation. hPSC-derived stage 5 pancreatic 
endoderm clusters generated prior to scaffold seeding showed increased PDX1+Nkx6.1+ cell 
populations, as well as, Cpep+ cell populations compared to stage 4 pancreatic progenitor cells. 
By modifying the timing of cell seeding from pancreatic progenitor to pancreatic endoderm, islet 
organoids showed increased amounts of insulin secreted per cell.  
In order for the islet organoid’s response to culture manipulations to be directly 
monitored, we engineered an insulin reporter hPSC line with the insertion of a human Pro-
insulin C-peptide-modified super folded green fluorescent protein. This tool helped establish a 
baseline for hPSC-derived β-cell function that was used to assess the impact of varying the 
differentiation protocol. In order to enhance organoid function demonstrated by the insulin 
secretion index, protocol modifications were made to incorporate a 2D monolayer of pancreatic 
progenitors that required less cell manipulation to dissociate cells. After pancreatic progenitors 
were dissociated and allowed to aggregate in suspension, we observed cluster formation and 
an increase in GFP+ cells within the clusters. The increasing density of GFP+ cells in the overall 
cell population could be the result of the non-endocrine cells being removed during the 
reaggregation step. While cells continued to express the insulin reporter on both scaffolds and 
in suspension throughout stage 6, we observed the cell density in the suspension culture 
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continued to decrease relative to the scaffold cultures. Cell maintainence on the scaffolds is 
likely attributed to the supportive matrix consisting of a cell-secreted ECM niche. While the 
modified Rezania-Cruz protocol facilitated cluster formation by incoporating a less harsh 
dissocation process on a 2D monolayer, the scaffold culture differentiation led to a 
heterogenous population of mature and immature cells. This was demonstrated by GSIS and 
suggests that the aggregation step could generate cells more akin to neonatal islets that are still 
on the path to full maturation. 
Since modifying the protocol to support cluster integrity showed improvement in function, 
we evaluated a less manipulative process step for seeding scaffold cultures. Gene expression 
of scaffold cultures seeded with dense clusters rather than dissociated cells demonstrated 
scaffold cultures enhanced maturation during pancreatic endoderm development relative to 
suspension clusters. While the maturation markers used were helpful in establishing function, 
further assessment of the scaffold cultures with a more expansive group of glucose sensing 
markers can provide more insight on limited insulin secretion quantities at high glucose 
concentrations. For any given scaffold, the initial seeding influences cell density, retention, and 
spatial distribution within the scaffold, which eventually will affect the function of the construct330. 
A single cell suspension allows for easy infiltration and uniform distribution throughout a porous 
scaffold. However, seeding scaffolds with a single cell suspension requires dissociating cell-cell 
and cell-matrix bonds within differentiated clusters, thus a harsh manipulation process is used 
that could impair the cell’s development. Modifying this process to seed intact clusters on 
scaffolds reduces the strain put on cells as they differentiate to insulin-producing organoids. As 
a result, the modified seeding technique led to islet organoids with increased insulin secretion 
indexes. Though, while scaffold cultures seeded with clusters demonstrated glucose-responsive 
function, the insulin index ratio was relatively low compared to human islets. This functional 
response could be attributed to one of the challenges with seeding clusters on scaffolds, which 
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is that infiltration rates can be very low, resulting in poor loading, and non-uniform distribution of 
cells within the scaffolds. This is due in part to the hydrophobicity of the polymer material and, in 
some degree, to the plugging of the porous scaffold by cells trapped at the outer surface of the 
construct. Since the scaffold has tunable properties, a future study can increase the scaffold 
pore size to identify if cluster infiltration could be inhibiting organoid maturation. 
Developing an insulin reporter allowed us to carry out non-invasive assessments of 
maturation heterogeneity between clusters rather than relying on traditional methods that either 
assess an entire cell population or require the study to end. The sfGFP-Cpep containing cells 
provided for easy and dynamic quantification of insulin secretion to assess the effect of culture 
modifications on islet organoid’s ability to process insulin. We found the fluorescence intensity of 
islet organoids cultured on scaffolds doubled between day 1 and day 3 of stage 6 then 
increased again by a quarter around day 8. These observations align with prior studies showing 
that cells are considered mature once they reach stage 6 day 9 of this protocol25. 
Immunofluorescence imaging during GSIS showed GFP-positive cells in islet organoids 
exhibited varying decreases in intensity, indicative of a heterogenous response of organoids 
throughout the scaffold. This observation was corroborated by ELISA testing that showed islet 
organoids secreted insulin under glucose-challenged environments, but the insulin secretion 
index ratio was not comparable to human islets. This loss in intensity shown by the islet 
organoids resembles the 10% loss shown by islets in prior studies323. The kinetics of the release 
of sfGFP-Cpep from isolated islets appear identical however individual clusters on the scaffold 
culture show the response between clusters is not identical. Future studies can then take this 
information and further characterize these scaffold cluster regions using RNA-seq analysis to 
help identify β-cell heterogeneity and how the microenvironment influences development. 
The sfGFP insulin reporter tool could enhance our understanding of beta-cell maturation 
by faithfully representing normal trafficking, processing, insulin storage, and secretion. Because 
sfGFP-Cpep is a parallel marker of endogenously stored insulin, we can exploit survival surgery 
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using epifluorescence imaging of the pancreatic surface in vivo to estimate insulin content in the 
pancreatic tail region similar to our in vitro studies. In vivo, fluorescence imaging of the implant 
would allow visual assessment of islet organoid insulin content within the transplant site. This 
could help demonstrate if euglycemia is not reached in a diabetic model as a result of only a 
small population of maturing cells are efficiently secreting insulin or a large population are 
secreting trace amounts of insulin. As a result, future studies of these maturing pancreatic 
progenitors in vivo will lead to invaluable insights about the function of the scaffold culture and 
help determine the heterogeneity of cell populations after transplantation. Continuous, long-term 
observation —over several differentiation stages — could also help provide the temporal 
information to help further decode the function of the organoid responses for insulin storage and 
release within individual clusters. Taken together, these studies provide insight into the activity 
of islet organoids, as well as individual hPSC-derived β-cells, as they develop through 
maturation on microporous scaffolds before and after transplantation. In addition, we prove the 
feasibility of evaluating insulin content and secretion, key β-cell indicators, as the islet organoids 
differentiate under varying scaffold conditions. Once we can consistently demonstrate that stem 
cell-derived -cells are the true equivalent of the endogenous -cells, then transplantation into 
human diabetic patients can become a reality.  
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Chapter 5: Human Lung Organoids Develop into Adult Airway-Like 
Structures Directed by Physico-Chemical Biomaterial Properties 
 
5.1 Abstract 
Tissues derived from human pluripotent stem cells (hPSCs) often represent early stages 
of fetal development, but mature at the molecular and structural level when transplanted into 
immunocompromised mice. human lung organoids (HLOs) transplantation has been further 
enhanced with biomaterial scaffolds, where HLOs had improved tissue structure and cellular 
differentiation. Here, our goal was to define the physico-chemical biomaterial properties that 
maximally enhanced transplant efficiency, including features such as the polymer type, 
degradation, and pore interconnectivity of the scaffolds. We found that transplantation of HLOs 
on microporous scaffolds formed from poly(ethylene glycol) (PEG) hydrogel scaffolds inhibit 
growth and maturation, and the transplanted HLOs possessed mostly immature lung progenitors. 
On the other hand, HLOs transplanted on poly(lactide-co-glycolide) (PLG) scaffolds or 
polycaprolactone (PCL) led to tube-like structures that resembled both the structure and cellular 
diversity of an adult airway. Our data suggests that scaffold pore interconnectivity and polymer 
degradation contributed to the maturation, and we found that the size of the airway structures and 
the total size of the transplanted tissue was influenced by the material degradation rate. 
Collectively, these biomaterial platforms provide a set of tools to promote maturation of the tissues 
and to control the size and structure of the organoids.  
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5.2 Introduction 
 
Human lung organoid models facilitate the study of cell fate decisions during development 
and for modeling diseases such as cystic fibrosis and goblet cell metaplasia, and infections such 
as respiratory syncytial virus32,331–337. We have previously demonstrated that human pluripotent 
stem cell (hPSC)-derived human lung organoids (HLOs) possess a complex tissue structure in 
vitro, which includes both the epithelium and supporting tissue (cartilage, smooth muscle, 
fibroblasts) 32,195,331–337.  
Notably, in vitro HLO cultures reflect the fetal airway, with adult airway-like structures 
generated only after in vivo transplantation195. Maturation following in vivo transplantation of HLOs 
reflects observations with numerous other organoid and hPSC-based systems32,338–341,. While 
many other studies have shown successful transplantation of hPSC-derived tissues under the 
kidney capsule or other vascular sites within the murine host, HLOs required the assistance of a 
PLG microporous polymer scaffold to support engraftment and vascularization following 
transplant into the epididymal fat pad of immunocompromised mice. After 8 weeks, the 
transplanted HLO (tHLO) had airway-like structures that resembled native adult airways including 
proper cellular organization, epithelial cellular ratios and airway cell types. Airway-like structures 
were also surrounded by smooth muscle and possessed cartilage, as would be the case in the 
human airways195. However, these previous studies did not identify the polymer scaffolds design 
parameters that conferred an engraftment and growth advantage for HLOs.   
In this report, we investigated the physico-chemical properties of microporous scaffolds that 
support HLO maturation into airway structures. Polymers have different degradation rates and 
may have distinct interactions with the host, so microporous scaffold support of transplanted HLO 
were tested using diverse materials including poly(lactide-co-glycolide) (PLG), polycaprolactone 
(PCL), and poly(ethylene glycol) (PEG). The interconnected pore size was varied, as well, through 
the initial scaffold fabrication and also through the degradation rate of the polymers. For these 
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material platforms, we investigated airway maturation, immune response, as well as overall 
explant and airway size. Identifying the biomaterial design parameters that influence airway 
maturation and structure will enable the development of platforms that can direct the structure to 
better model airway homeostasis and disease environments.  
5.3 Materials and Methods 
5.3.1 Maintenance of hESCs, generation of HLOs, and seeding on scaffolds 
H1 human embryonic stem cell (hESC) line (NIH registry #0043) and H9 (NIH registry 
#0062) was obtained from the WiCell Research Institute. H1 hESC line was used to derive all 
HLOs for these experiments except for Fig 5.2 where H9 hESC and H9 GFP hESC lines were 
used to derive HLOs. H9 GFP hESC line was generated by infecting H9 hESCs with pLenti PGK 
GFP Puro virus generated from the plasmid purchased from AddGene (Cat#: 19070)342. H9 GFP 
hESC clonal line was generated by puromycin selection flow cytometry analysis sorting (FACS) 
for GFP high expressing cells. All hESC lines were approved by the University of Michigan Human 
Pluripotent Stem Cell Research Oversight Committee. hESCs were maintained as previously 
described34. HLOs were derived as previously described32. Foregut spheroids, which grow into 
HLOs, were seeded on scaffolds as previously described 195. 
5.3.2 Scaffold fabrication 
75:25 PLG scaffolds were fabricated as previously described195,343. 85:15 (Resomer® RG 858 S, 
Poly(D,L-lactide-co-glycolide), Sigma, Cat#: 739979-1G) and 50:50 PLG (Resomer® RG 505, 
Poly(D,L-lactide-co-glycolide) ester terminated, MW: 54,000-69,000, Sigma,Cat#: 739960) were 
fabricated the same as 75:25 PLG scaffolds. 20% (w/v) 4-arm PEG maleimide, 20,000MW 
(JenChem, Cat#: A7029-1) hydrogels were fabricated as previously described278. PCL scaffolds 
were fabricated as previously described344. Large interconnected PCL were commercially bought 
(National Institute of Standards and Technology, Cat#:8394).  
5.3.3 Scaffold transplantation 
84 
 
Scaffolds were implanted as previously described195. Briefly, mice were anesthetized and prepped 
as for omental transplants. The epididymal fat pads of male 7–10 week old NOD-scid IL2Rgnull 
(NSG) were exposed using a lower midline incision. Scaffolds were then placed along the 
epididymal blood vessels and covered with epididymal fat. An intraperitoneal flush of Zosyn (100 
mg/kg; Pfizer Inc.) was administered after which the incision was closed in 2-layers using 
absorbable suture. Mice were euthanized between 1-8 weeks post-transplant. 
5.3.4 Immunohistochemistry, hematoxylin and eosin stain (H&E), and imaging 
Immunostaining and H&E were carried out as previously described345. Antibody information and 
dilutions can be found in Table 5.1. All images and videos were taken on a Nikon A1 confocal 
microscope or the Zeiss Axio Observer.Z1.  
Table 5.1: Primary and secondary antibody information 
Primary Antibody Source Catalog # Dilution Clone 
Chicken anti-GFP Aves Lab GFP-1020 1:500 polyclonal 
Mouse anti-Acetylated 
Tubulin (ACTTUB) 
Sigma-Aldrich T7451 1:1000 6-11B-1 
Mouse anti-E-
Cadherin (ECAD) 
BD Transduction 
Laboratories  
610181 1:500 
36/E-
Cadherin 
Mouse anti- Human 
Mitochondria 
(huMITO) 
Millipore MAB1273 1:500 113-1 
Mouse anti-PLUNC R&D Systems MAP1897 1:200 monoclonal 
Rabbit anti-
Cytokeratin5 (CK5) 
Abcam ab53121 1:500 polyclonal 
Rabbit anti-NKX2.1 Abcam ab76013 1:200 EP1584Y 
Rabbit anti-P63 
Santa Cruz 
Biotechnology 
sc-8344 1:200 H-129 
Secondary Antibody Source Catalog # Dilution  
Donkey anti-chicken 
488 
Jackson Immuno 703-545-155 1:500  
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Donkey anti-mouse 
488 
Jackson Immuno 715-545-150 1:500  
Donkey anti-mouse 
647 
Jackson Immuno 415-605-350 1:500  
Donkey anti-mouse 
Cy3 
Jackson Immuno 715-165-150 1:500  
Donkey anti-rabbit 488 Jackson Immuno 711-545-152 1:500  
Donkey anti-rabbit 
Cy3 
Jackson Immuno 711-165-102 1:500  
5.3.5 Flow Cytometry  
Cell disassociation and flow cytometry was previously described344. Antibodies used are as follow: 
Fluor® 700 anti-CD45 (1:125, clone 30-F11, Biolegend), V500 anti-CD11b (1:100, clone M1/70, 
BD Biosciences), FITC anti-Ly6C (1:100, clone HK.14, Biolegend), PE-Cy7 anti-F4/80 (1:80, 
clone BM8, Biolegend), APC anti-CD11c (1:80, clone N418, Biolegend), and Pacific Blue™ anti- 
Ly-6G/Ly-6C (Gr-1) (1:70, clone RB6-8C5, Biolegend). 
5.3.6 Quantification 
Airway diameters were measured using ImageJ software. The longest and shortest diameter was 
measured per airway structure and then averaged together. Explant size was measured using a 
ruler by placing the longest side of the tHLO on the ruler. Ki67+ cells and ECAD+, Ki67+ cells were 
quantified using a program developed in lab by Kevin Rychel, previously described277.  
5.3.7 Experimental replicates and statistics 
All experiments were done on at least three (n=3) independent biological samples for each 
experiment. All error bars represented SEM while the long bar represented the average. 
Statistical differences were assessed with Prism software using unpaired t-test. 
5.4 Results 
5.4.1 PLG, PEG and PCL have varying extents of HLO derived airway maturation  
Microporous scaffolds with similar architectures and formed from either 75:25 
(lactide:glycolide) PLG or 20% (w/v) 4-arm PEG-maleimide microporous scaffold were tested for   
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their ability to support transplantation of foregut spheroids. Both scaffolds had pores ranging in 
size from 225 µm to 450µm, and were cylinder shaped with a diameter of 5mm diameter and a 
thickness of 2mm. PLG is a degradable, hydrophobic polyester that will adsorb proteins while 
PEG scaffolds are non-degradable hydrogels and were formed with or without the adhesion 
peptide RGD. PLG and PEG scaffolds were seeded with foregut spheroids and cultured for 7 
days in vitro, during which time the foregut spheroids grew to fill the pores (Fig 5.1A). Scaffolds 
were then transplanted into the epididymal fat pad of NSG mice. This highly vascularized implant 
site346 is accessible by a minimally invasive surgery, has a large surface area347 and the presence 
of pro-angiogenesis cytokines348, which has supported the use of this site for transplantation. After 
8 weeks, tissue was found within and around the PLG scaffold, and histological examination 
revealed that the tHLO tissue contained airway-like structures. The majority of the PLG scaffold 
should be degraded by this time point349,350 and, accordingly, the material was not detected in 
histological sections (Fig 5.1C). 
Growth of the transplanted PLG scaffolds contrasted with the PEG-seeded scaffolds. 8 weeks 
after transplantation, PEG scaffolds appeared intact and the spheroids remained within the pores 
independent of whether the scaffold was modified with RGD (Fig 5.1B). We hypothesized that 
the individual HLOs would grow together on the surface of the PEG scaffold and form airway-like 
structures. However, the transplanted spheroids remained within the separate pores. We 
investigated the possibility that smaller airways formed within the pores of the PEG scaffold;  
 
(A) Approximately 50 foregut spheroids were seeded onto PLG and PEG with or without RGD. 
Wholemount images were taken after 1 week in culture. (B) Scaffolds were transplanted into the 
epididymal fat pad of immunocompromised mice and retrieved 8 weeks later. The PLG tHLO grew up to 
2.5cm while the tissue remained within the PEG scaffolds with or without RGD. (C) The histology of the 
PLG and PCL tHLOs had organized pseudostratified epithelium resembling native airway epithelium 
(shown by black arrows). The PEG tHLOs showed intact scaffold (shown by orange arrows) and both the 
PEG and the tissue within the pores of the PCL had no organized epithelium but remained as clusters of 
cells (shown by blue arrows). (D) Some of the clusters of cells within the PEG scaffold were lung marker 
NKX2.1+ and human mitochondria (huMITO)+. Scale bars for A-B:1mm, C:200µm, and D:100µm. 
 
Figure 1 HLOs seeded on PLG, PEG, and PCL scaffolds affects airway structure formation. A) 
Approximately 50 foregut spheroids were seeded onto PLG and PEG with or without RGD. Wholemount 
images were taken after 1 week in culture. B) Scaffolds were transplanted into the epididymal fat pad of 
immunocompromised mice and retrieved 8 weeks later. The PLG tHLO grew up to 2.5cm while the tissue 
remained within the PEG scaffolds with or without RGD. C) The histology of the PLG and PCL tHLOs had 
organized pseudostratified epithelium resembling native airway epithelium (shown by black arrows). The 
PEG tHLOs showed intact scaffold (shown by orange arrows) and both the PEG and the tissue within the 
pores of the PCL had no organized epithelium but remained as clusters of cells (shown by blue arrows). 
D) Some of the clusters of cells within the PEG scaffold were lung marker NKX2.1+ and human 
mitochondria (huMITO)+. Scale bars for A-B:1mm, C:200µm, and D:100µm. 
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Figure 5.1 HLOs seeded on PLG, PEG, and PCL scaffolds affects airway structure formation. 
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however, the PEG hydrogels only had clusters of cells within the pores and did not possess tissue 
resembling airway structures (Fig 5.1C). The tissue within the PEG pores was derived from both 
spheroids and host (murine) cells, as we observed cells expressing the human-specific 
mitochondria marker (huMITO) along with huMITO-negative cells. huMITO+ cells co-expressed 
NKX2.1, an early lung epithelial–specific transcription factor351,352, yet no mature cell types or 
airway-like structures were observed in the PEG explants (Fig 5.1D). In comparison, the 
organized airway structures observed in the PLG explants expressed the lung marker NKX2.1 
and were huMITO+. Further characterization of the lung tissue was previously described in Dye 
et al.195. 
We next tested the ability of PCL scaffolds to support transplantation and lung organoid growth 
in vivo. Both PLG and PCL are polyester polymers that degrade predominantly by simple 
hydrolysis of the ester bond into acidic monomers. However, due to its higher molecular weight 
and higher hydrophobicity, PCL has a slower degradation rate than PLG353,354. PCL scaffolds were 
seeded with spheroids and transplanted for 8 weeks. Similar to the PEG, PCL scaffolds were still 
intact after 8 weeks in vivo (Fig 5.1C). No organized epithelial structures were observed within 
the pores of the PCL grafts but the scaffolds had clusters of cells similar to what is observed in 
the PEG transplants (Fig 5.1C). On the other hand, there were airway-like structures that formed 
on the outside of the scaffolds where tHLOs had expanded. Collectively, these results suggest 
that the polyester polymers (PLG, PCL) supported the spheroid engraftment and development of 
airway structures after 8 weeks, but that failure of the scaffold to degrade prevented the growth 
and development of spheroids into airway-like structures.  
5.4.2 Initial immune response at microporous scaffolds may contribute to HLO responses 
The initial immune response within the microporous scaffolds was investigated as a potential 
mechanism underlying the differential maturation on the various materials. Note that these studies 
were performed within NSG mice that lack an adaptive immune system in order to prevent 
rejection, yet these mice retain innate immune cells that respond to transplantation of the 
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construct. Lung organoids were transplanted and collected after 1 week in vivo, with analysis of 
the innate immune response. PEG tHLOs had a significantly greater percentage of leukocytes 
(CD45+) than PLG and PCL tHLOs (Fig 5.2A), which indicates greater cell recruitment from the  
 
host tissue. From the CD45+ population, the PEG tHLOs had significantly higher percent of 
CD11b+GR1+Ly6c- cells, often referred to as myeloid derived suppressor cells, and significantly 
less CD11c+F4-80- (dendritic) cells and Ly6c+F4-80- (monocyte) cells compared to PLG and PCL 
tHLOs (Fig 5.2B). No differences were observed between the PLG and PCL scaffolds. While the 
immune cell population at the graft may not fully recapitulate the immune-response of biomaterials 
in an immunocompetent environment, these data suggest that the immune response could be a 
contributing factor to the inhibition of HLO maturation in PEG scaffolds relative to PLG and PCL 
scaffolds. 
5.4.3 HLO fusion during formation of airway-like structures 
We subsequently investigated the contribution of HLO interaction in adjacent pores to the 
formation of airway structures, which was motivated by the observations of airway structures 
Foregut spheroids were cultured on scaffolds for 1 week in vitro, transplanted into the mouse epididymal 
fat pad, and then retrieved after 1 week to observe the innate immune response. (A) The PEG tHLOs had 
39% CD45+ Leukocytes (n=6) compared to 17% CD45+ cells in PLG tHLOs (n=7) and 19% CD45+ cells 
in PCL tHLOs (n=7) P≤0.005 (B) PEG, PCL and PLG and similar percent of macrophages (CD11b+F4-
80+). PEG tHLOs had significantly higher MDSCs (CD11b+GR1+Ly6c-) compared to PLG and PCL tHLOs, 
*P≤0.05. In contrast, PEG tHLO had significantly lower dendritic cells (CD11c+F4-80-) and monocytes 
(Ly6c+F480-) *P≤0.05. All error bars represent SEM. 
Figure 5.2 The innate immune profile for PEG, PLG, and PCL tHLOs. 
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forming on the surface of slow degrading PCL scaffolds, but not within the pores. In order to 
(A) GFP H9 hESC line and H9 hESC derived HLOs were seeded onto 75:25 PLG and PCL scaffolds. 
Wholemount images of the scaffolds cultured for 1 week in vitro had GFP+ HLOs next to a pore of GFP- 
HLOs indicated by the red arrow head in both PLG and PCL conditions. (B) After transplanted for four 
weeks, the GFP+ cells were mixing with the GFP- cells and both expressed early lung marker NKX2.1 
(red). No organized epithelial structures were observed for either scaffold. (C) After transplanted for 8 
weeks, airway structures formed and were comprised of GFP+ and GFP- cells in both PLG and PCL tHLOs. 
The airway structures expressed NKX2.1 (red). The fused GFP+ and GFP- HLOs in both PLG and PCL 
had multiciliated cells labelled by acetylated tubulin (ACTTUB, white) and basal cell marker P63 (red). 
Scale bars for A-B: 200µm, B-C: 100µm, and C: 50µm, 10µm. 
Figure 5.3 HLOs fuse together to form airway structures 
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analyze the fusion of multiple organoids into an airway structure, scaffolds were seeded with 
HLOs constitutively expressing GFP (GFP+) and GFP- HLOs. Following culture of HLOs in PLG 
and PCL scaffolds for 1 week in vitro, we observed pores seeded with GFP+ HLOs that were 
adjacent to pores containing GFP- HLOs (Fig 5.3A). Scaffold were transplanted and retrieved 
after 4 and 8 weeks in vivo. After 4 weeks in vivo, airway structures were not present, yet there 
were populations expressing the lung marker NKX2.1 that were either GFP+ or GFP- indicating 
both HLO populations survived and successfully generated lung progenitors (Fig 5.3B). After 8 
weeks, airway structures were observed in PLG and on the outside of PCL tHLOs, and these 
structures contained airway-like structures that possessed multiciliated cells (ACTTUB+) and 
basal cells (P63+). These airway structures had both GFP+ and GFP- cells both in PCL and PLG 
tHLOs (Fig 5.3C), indicating that the airway structures form by the HLOs fusing from adjacent 
pores in both the surface pores of PCL and in the degrading pores of the PLG tHLOs.  
5.4.4 Scaffold degradation affects the HLO derived airway size 
We next investigated the contribution of polymer degradation to the number of airway-like 
structures with the hypothesis that faster degradation would permit more HLOs fusing in 
adjacent pores, thus, support larger airway-like structures. Previously, the 75:25 PLG scaffolds 
were used to transplant HLOs and were thoroughly characterized in Dye et al. 2016195. Yet, now 
with the use of multiple types of polymers with varying degrees of degradation, we quantified the 
impact on airway diameter size. We first investigated polymers with faster and slower 
degradation rates than 75:25 PLG. The airway diameters in the PCL tHLOs trended towards 
being slightly smaller (276 µm) compared to 75:25 PLG tHLOs (333 µm, Fig 5.4A). We also 
transplanted HLOs onto 85:15 PLG polymer which degrades at a rate intermediate of that 
between 75:25 PLG and PCL355. The 85:15 PLG tHLOs had significantly smaller airway 
diameter (224µm, p=0.049) than the 75:25 PLG (Fig 5.4A, C). In addition, the 85:15 PLG tHLO 
had a similar phenotype to the PCL tHLO, with the airway-like structures present adjacent to the 
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scaffold and the tissue within the pores remaining as cell clusters (Fig 5.4A, C). We then 
fabricated a faster degrading polymer scaffold consisting of 50:50 PLG to further investigate 
whether degradation could support larger airway-like structures355. The 50:50 PLG tHLOs 
trended towards larger airways (414µm) relative to the 75:25 PLG (Fig 5.4A, C), though the 
(A) The average measurement was taken of the longest and shortest diameter for each cross section of 
an airway structure in a 8wk tHLO. The 85:15 PLG tHLOs (224µm) had the significantly shorter diameter 
compared to the 75:25 control PLG (333µm) *P≤0.05. The 50:50 PLG tHLO had the longest diameter at 
415µm. The PCL control and large interconnected PCL tHLOs had similar diameter at 277µm and 299µm 
respectively compared to the 85:15 PLG tHLO (224µm). All error bars represent SEM. (B-C) Histology 
sections of PLG (75:25), large interconnected PCL, 85:15 PLG and 50:50 PLG represent the quantified 
sections. Scale bars (B) 200µm and (C) 400µm.   
Figure 5.4 The degradation rate of the scaffold affected airway diameter. 
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difference was not significant. Collectively, the size of the airway structures was influenced by 
the degradation rate of the scaffold, with slower degrading polymers leading to smaller airway-
like structures.  
We next tested the hypothesis that an increase in the size of pore interconnections could 
increase HLO fusion while creating larger airway structure, as HLO fusion may be limited for slow 
degrading materials that led to smaller airway structures. We obtained PCL scaffolds constructed 
by 3D printing rods of PCL in a cross-hatch pattern within a 5mm wide, 2mm tall cylinder (same 
dimensions as the scaffold used in earlier experiments), which has large pore connections 
(300µm) relative to the PCL scaffolds described previously, which range from 10 – 100 µm344. In 
testing the large interconnected porous scaffolds, the size of the airway structures was similar 
between PCL scaffolds with varying pore interconnectivity (Fig 5.4A, B). These results suggest 
that while fusion of cells can be aided by adjacent pores and degradation to contribute to the 
formation of airway structures, pore interconnectivity does not seem to directly determine the size 
of airway-like structures. 
5.4.5 Controlling the tHLO explant size 
After 8 weeks, we found the size of the explant was a function of the polymer type and design. 
The size of the explant for HLOs transplanted on PLG scaffolds reached diameters up to 2.5 cm, 
which is five times the original scaffold diameter (5 mm). Relative to 75:25 PLG tHLOs, the other 
tHLO conditions had a significant reduction in explant size. The explant sizes in fast degrading 
50:50 PLG, slow degrading 85:15, and large interconnected PCL scaffolds were 0.81 cm, 0.53 
cm, and 0.65 cm respectively. The PCL tHLO explant size was significantly smaller than 75:25 
PLG tHLOs, with the PCL explants having diameters in the range of 0.5 to 0.6 cm (Fig 5.5A). 
However, the 50:50 PLG tHLOs were significantly larger than the 85:15 PLG tHLO. All together, 
these data suggested that both the slow and fast degrading PLG caused a reduction in explant 
size, but the size reduction was more significant in the slow degrading polymers, 85:15 PLG and 
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PCL. Both the PCL control and PCL large interconnected pores were similar in size (Fig 5.5A). 
Thus, the size of pore interconnections does not appear to significantly impact the explant size. 
Proliferation within the explant was subsequently investigated as a contributing factor to the 
explant size. A significant two-fold change in proliferation (Ki67+cells) in 75:25 PLG tHLO (19.5%) 
was observed relative to PCL tHLO (8.7%) (Fig 5.5B-C). During native lung development, both 
the branching airway epithelium and surrounding mesenchyme contain proliferating cells345,356.  
ECAD+ was used to differentiate between the mesenchyme and epithelium structures. The 
increase in proliferation in PLG tHLOs was observed in both the clusters of epithelial cells marked 
(A) Overall, the 75:25 PLG had the largest explant size (1.18cm, n=6) after an 8wk transplant compared 
to both fast (50:50 PLG, n=5) and slow degrading (85:15 and PCL, n=5) *P≤0.05. The fast degrading 
50:50 PLG tHLO was significantly larger than the 85:15 PLG tHLO explant *P≤0.005. (B) Ki67+ cells (red) 
were present within the epithelial airway structures labelled with ECAD (green) and the surrounding tissue 
both in PCL and 75:15 PLG. (C) 75:25 PLG (19.6% ± 1.8%) had significantly more Ki67+ cells than PCL 
(8.7% ± 1.8%). D) The 75:25 PLG had significantly more Ki67+ cells in the ECAD+ and ECAD- areas 
(ECAD+: 6.7 ± 0.9, ECAD-: 13.8% 1.7) compared to PCL tHLO (ECAD+: 3.009 ± 1.0, ECAD-: 6.4% 1.1). 
Both for PCL and PLG tHLOs there was significantly more Ki67+ cells in the surrounding tissue (ECAD-) 
compared to the organized epithelium (ECAD+). **P≤0.005, *P≤0.05 All error bars represent SEM. 
 
Figure 5.5 The degradation rate of the scaffold affected explant size of tHLO. 
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by E-Cadherin (ECAD+) within airway-like structures, and the surrounding tissue (ECAD-). 
Interestingly, both in PLG and PCL tHLOs, proliferation was significantly greater in the tissue 
adjacent to the scaffold relative to the ECAD+ airway-like structures (Fig 5.5D).  
5.5 Discussion 
In this report, we have demonstrated that the type of material and degradation of the 
microporous scaffold can affect lung airway formation, airway size, and explant size derived 
from transplanted HLOs (Table 5.2). Previously, 75:25 PLG microporous scaffolds were used to  
Scaffold 
Material 
Pore 
Size 
Interconnected 
Pore Size 
Degradation 
Rate 
Spheroid 
Engraftment 
(Fig.1) 
Airway 
Diameter 
Size 
(Fig.4) 
Tissue 
Explant 
Size 
(Fig.5) 
PLG 75:25 
250-
425µm 
10-100µm Fast 
Throughout 
Scaffold 
333µm 1.18cm 
PLG 85:15 
250-
425µm 
10-100µm Medium 
Throughout 
Scaffold 
224µm 0.53cm 
PLG 50:50 
250-
425µm 
10-100µm Very Fast 
Throughout 
Scaffold 
415µm 0.81cm 
PEG 
250-
425µm 
10-100µm N/A 
Within the 
Pores 
No 
Airway 
Formation 
N/A 
PEG-RGD 
250-
425µm 
10-100µm N/A 
Within the 
Pores 
No 
Airway 
Formation 
N/A 
PCL 
250-
425µm 
10-100µm Slow 
Within the 
Pores 
277µm 0.65cm 
Large 
Interconnected 
PCL 
300µm 300µm Slow 
Within the 
Pores 
299µm 0.5cm 
transplant HLOs into the epididymal fat pad195. Since no maturation occurred when HLOs were  
placed into the kidney capsule or sewn in the omentum of an immunocompromised mouse, we 
hypothesized that the tHLOs needed a surface to grow and expand on in order to mature in airway 
structures. We then tested this hypothesis and found that the HLOs did not require the support of 
Table 5.2: Physico-chemical properties of microporous scaffolds that support HLO 
maturation into airway structures 
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the pores to form airway-like structures, but instead needed specific material properties to allow 
for the development of airway structures. More specifically, the degradation of the material 
affected airway size and overall explant size of the tHLO. 
As the airway structures formed, the individual HLOs fused together to form these structures 
evident by the GFP+ and GFP- HLOs forming into one airway. Interestingly, the buds forming 
together occurred when the scaffold held its shape (PCL) or degraded (75:25 PLG) over the 8 
weeks in vivo. Thus, the degradation was not necessary for the HLOs to fuse together to form the  
airway structures; however, there were no structures within the pores of the scaffolds that held 
the scaffold structure during the 8 weeks (PCL and 85:15 PLG). The fusion of the HLOs took 
place either on the surface of the PCL scaffold or as the PLG scaffold degraded. After 
incorporating a larger interconnected porous design to the PCL scaffold, we observed airway 
formation within the scaffold. Collectively, the HLOs could only form airway structures if they 
had the space to fuse and expand together into epithelial tubes. This need of expansion aligns 
with airway formation during lung development where the airways start as one epithelial bud 
that continually bifurcates and expands into the surrounding mesenchyme to ultimately form a 
network of airways357,358. 
The degradation of the material contributed to multiple properties of the organoids: airway 
size and overall explant size. Deriving variations in airway size will allow the study of airway 
diseases such as COPD and asthma in both large and small airway models359. An airway 
ranging in size from 200-350µm represents a 5th generation airway in a native human lung while 
the 4th generation ranges from 400-600µm360. Here by changing the degradation we were able 
to represent two types of airways, 4th and 5th generation size that are observed in the native 
adult lung. The data with PLG and PCL indicated that the airway size was maximal for 75:25 
PLG, with slightly smaller structures for 50:50 PLG and 85:15 PLG, suggesting that degradation 
plays a role and that maximal size occurs at an intermediate rate of degradation. One 
mechanism by which degradation can influence airway size is through the fusion of organoids 
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from adjacent pores. Polymer degradation would influence fusion by increasing the size of the 
interconnections between pores over time, which would allow for greater connectivity. Polymer 
degradation would also function to remove the polymer as a substrate for organoid 
development, which may also influence proliferation and maturation. Collectively, these results 
are consistent with the general idea that the polymer degradation should be matched with the 
rate of tissue formation.  
Multiple scaffolds maintained the ability to form mature airway structures, which did not form 
without the presence of a material, yet the explant size was a function of the scaffold properties. 
PCL scaffolds allowed for the formation of structures at the surface of the material, yet not within 
the pores of the scaffold. The increased size resulted from an increase of proliferation from the 
supporting tissue including the mesenchyme with a lesser extent increase of proliferation from 
the organized epithelium. However, the increased size of the explant did not influence the size 
of the airway-like structures that formed. The scaffold properties influenced the proliferation of 
the progenitor cells, that subsequently influenced the overall size of the explant. A more 
controlled growth of the organoid would allow for longer studies to be performed, since the 
explant growth will not impede the mouse health. For instance, future studies could use HLOs 
generated from patient specific hPSCs lines that have Cystic Fibrosis (CF). Patients with CF 
have mutations in Cystic Fibrosis Transmembrane conductance Regulator (CFTR), which 
causes excess of mucus within the airways which leads to chronic infection and inflammation of 
the lung epithelium361. With this model, HLOs could be generated from CF patient specific hPCS 
and studied in the tHLO model that provides a human airway model. Since the explant size is 
smaller, longer studies can be conducted in order to understand the short and long-term effects 
of CF on the airway epithelium and surrounding tissue including smooth muscle, cartilage and 
vasculature.  
Microporous scaffolds composed of PEG did not support maturation over the 8 weeks and 
the HLOs remained as NKX2.1 progenitors. HLOs were seeded onto PEG hydrogels with and 
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without modification with RGD, a fibronectin binding peptide, in order to investigate if ECM 
signaling may be a signal directing maturation. The presence of RGD peptide did not impact 
maturation, suggesting that either adhesion is not a limiting factor in HLO maturation or that the 
RGD is insufficient to trigger the necessary signaling cascades. The innate immune response, 
which is active in immunocompromised mice, differed significantly between PEG versus PLG 
and PCL. The increase in immune cell recruitment in PEG scaffolds could be due in part to 
hydrogel swelling, which creates a larger volume that can contain more immune cells. This 
difference in scaffold environments could be a contributing factor that influenced HLOs 
maturation since it is known that the immune system affects hPSCs and tissue regeneration 
including adult stem cells362–364. 
Overall, HLO maturation was supported by multiple microporous scaffolds that resulted from 
fusion of organoid clusters in adjacent pores. Our studies show the physico-chemical properties 
of the scaffold can be manipulated to influence the properties of explant, such as the number 
and size of airways structures and the size of the explant. The biomaterials, thus, provide a tool 
that may be capable of directing tissue formation from organoids for the purpose of modeling 
normal development, and also for modeling disease states. Specific to airways, controlling 
airway and total explant size will allow for new models for airway diseases such as asthma, 
COPD, and CF with the potential to perform long-term studies.   
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Chapter 6: Regulation of Adipose Tissue Inflammation and Systemic 
Metabolism in Murine Obesity by Interleukin-4-Expressing Polymer 
Implants 
 
6.1 Abstract 
Dysfunctional adipose tissue, including defects in inflammation and cellular metabolism, 
plays a central role in the pathogenesis of obesity-related metabolic disease, including type 2 
diabetes. Targeting adipose tissue in obesity using biopolymer implants is a novel approach 
towards developing therapy for metabolic disease. In this report, we study effects of porous 
poly(lactide-co-glycolide) (PLG) implants coated with interleukin 4 (IL-4)-expressing lentivirus 
into epididymal adipose tissue of mice fed high-fat diet (HFD) on local adipose tissue 
inflammation and systemic metabolism, using flow cytometry, immunohistochemistry, qRT-PCR, 
and in vivo systemic metabolic phenotyping. We also studied early and established murine 
obesity, modeled by 2-week and 10-week HFD respectively. PLG implants carrying an IL-4-
expressing lentiviral vector transplanted into the epididymal fat pad of mice induced subtle 
effects on adipose tissue inflammation and adipogenesis that included increased CD3+CD4+ T-
cell frequency, increased CD206 gene expression, and increased adipocyte hypertrophy, along 
with reduced fasting blood glucose levels. These effects were observed in early obesity but 
were not maintained in established obesity. These results show that local delivery of cytokine-
expressing biopolymer implants to adipose tissue influences tissue inflammation and systemic 
metabolism over short time periods. Further study will be required to show more dramatic and 
durable metabolic effects, but these data demonstrate that modified polymer implants 
transplanted into adipose tissue have the potential to modulate local tissue and systemic 
inflammation and metabolism. 
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6.2 Introduction 
Dysfunctional adipose tissue plays a central role in the pathogenesis of obesity-related 
metabolic disease, including type 2 diabetes. As adipose tissue mass expands beyond a critical 
point, its nutrient storage capacity is overwhelmed, causing adipocyte metabolic dysfunction and 
impaired nutrient buffering capacity, leading to systemic nutrient overflow, toxicity in multiple 
tissues, and metabolic disease. These processes are exacerbated by an inflammatory response 
directed towards dead and dying adipocytes, potentiating adipose tissue failure. Selective “repair” 
of adipose tissue metabolic dysfunction and inflammation improves systemic metabolism in 
murine obesity365, supporting adipose tissue as a target for therapy. Nonetheless, effective 
adipose tissue-based therapeutics remain elusive.  
Efforts to date directed towards adipose tissue-based therapy include transplant of intact 
subcutaneous adipose tissue (SAT) into mice, as well as delivery of adipocytes in artificial 
matrices. Transplant of intact SAT into the visceral cavity of obese mice improves systemic insulin 
resistance366–368, but such a strategy is likely not feasible in humans. Engineered adipose tissues 
using adipocytes or preadipocytes embedded in hydrogels to date are confined to preclinical 
models369, and suffer from limitations inherent to cell-based therapy, including limited in vivo cell 
viability and infectious/alloreactive complications associated with non-autologous cell sources. 
Cell-free therapeutic vectors delivered from artificial polymers eliminate many of these problems. 
Biomaterial implants have been widely used for engineering the adipose tissue because they are 
biodegradable, easily fabricated, and capable of delivering molecules for localized release to 
modulate the microenvironment 370–373. We previously reported local IL-33 delivery from porous 
poly(lactide-co-glycolide) (PLG) implants attenuates graft-destructive T cell infiltration of adipose 
tissue in an islet transplant model374. Our goal in this study was to extend these results into a 
murine model of obesity and test the utility of PLG implants engineered to deliver lentiviral vectors 
expressing the human cytokine interleukin 4 (IL-4) in modulating local adipose tissue inflammation 
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and systemic metabolism. We hypothesized that implantation of IL-4-implants into adipose tissue 
of mice would attenuate tissue inflammation and systemic insulin resistance. 
6.3 Materials and Methods 
6.3.1 Synthetic polymer implant fabrication 
6.3.2 Animals 
Animal experiments were approved by University of Michigan Institutional Animal Care 
and Use Committee consistent with AAALAC regulations and NIH Guidelines for Care and Use 
of Animals. Eight-week old male C57Bl/6 mice (The Jackson Laboratory, Bar Harbor, ME, USA) 
were divided into three experimental arms: sham operation, empty implant, and IL-4-implant, 
and were transplanted into the epididymal fat pads as previously described278. Briefly, mice 
were anesthetized with 2% isoflurane, the abdomen was shaved and sterilized, and epididymal 
fat pads were delivered through a midline abdominal incision. One implant was wrapped in each 
epididymal fat pad, then placed back into the peritoneal cavity and the midline incision closed 
with suture (Fig 6.1A). For sham surgery, a midline abdominal incision made, epididymal fat 
pads were delivered through the incision, then placed back into the peritoneal cavity and the 
midline incision closed with suture. One week after surgery, mice were placed on a 60% high fat 
diet (HFD, Research Diets Inc., New Brunswick, NJ, USA, Cat#D12492). Two time-points were 
studied: 2 weeks HFD and 10 weeks HFD, to model early obesity/initiation and established 
obesity respectively. Body weights were measured weekly. At the end of each feeding protocol, 
glucose tolerance testing (GTT) was performed as described376. Briefly, after a 6 hour fast, mice 
received an intraperitoneal injection of 2g/kg of D‐glucose, using a 250 mg/ml D‐glucose 
solution in sterile PBS. Blood glucose levels collected by tail vein nick were measured at 
baseline (before injection, time 0), 15,30, 60, 90, and 120 min after the glucose injection, using 
a Precision Xtra glucometer (Abbott Laboratories, Inc., Bedford, MA, USA). After GTT, animals 
were euthanized and tissues collected (epididymal fat pad, subcutaneous inguinal/flank fat pad, 
and liver) (Fig 6.1B). 
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6.3.3 Adipocyte sizing  
Adipocyte area (µm2) was measured using fixed hematoxylin/eosin-stained tissue 
sections imaged on an Olympus IX-81 fluorescent microscope using Texas Red channel (595-
605nM). Images were captured as multiple TIFF-gray-scale images and analyzed with ImageJ 
software. Adipocyte area was measured in 200-500 cells from multiple slides per specimen and 
averaged for each tissue sample. 
6.3.4 Quantitative real-time polymerase chain reaction (qRT-PCR) 
Tissue samples were mechanically homogenized in Trizol® reagent (Life Technologies, 
Grand Island, NY, USA), RNA isolated using Direct-zol™ RNA MiniPrep Plus (Zymo Research 
Corp., Irvine, CA, USA), and concentration determined using a NanoDrop ND-1000 
spectrophotometer (Nanodrop Technologies Inc., Wilmington, DE, USA). iScript™ Reverse 
Transcription Supermix was used to transcribe RNA into cDNA. Universal qRT-PCR assays 
were performed using SYBR Green MasterMix Universal RT (Exiqon Inc., Woburn, MA, USA) 
and gene target-specific primers (Table 6.1). Amplification profile was assessed using a 
LightCycler® 480 (Roche Inc., Indianapolis, IN, USA). Gene expression was normalized to 
ribosomal 18S housekeeping gene expression and fold change calculated using the 2-ΔΔCt 
method(Livak and Schmittgen 2001).  
6.3.5 Flow cytometry 
eWAT fat pads were washed in ice-cold RPMI media, then minced and digested in 10 
mL of 1mg/ml Type II collagenase (Sigma-Aldrich Inc., St. Louis, MO, USA) at 37°C, 30 minutes 
with vigorous shaking. Tissue homogenate was then strained through a 100μm filter, washed in 
RPMI media, centrifuged, and the resultant stromal vascular cell fraction pellets isolated and 
incubated with 0.5mL of 0.1M ammonium chloride buffer for 5 minutes at room temperature to 
lyse red blood cells and then washed with PBS. In preparation for staining, cells were 
resuspended in RPMI and incubated in Fc block (anti-CD16/32), (Invitrogen Inc., Carlsbad, CA, 
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USA, Cat#14-0161) for 5 minutes on ice prior to staining for 30 minutes. Samples were then 
fixed, stained with antibodies (Table 6.2) and analyzed using a LSR Fortessa flow cytometer 
(Becton, Dickinson & Co., Franklin Lakes, New Jersey, USA). Compensation and data analysis 
were completed using FlowJo software (FlowJo, LLC, Becton, Dickinson & Co., Franklin Lakes, 
NJ, USA). Isotype antibodies were used to establish gating.  
6.3.6 Statistics 
  All statistical analyses were conducted using GraphPad Prism graphing and data 
analysis software (GraphPad Software, Inc., La Jolla, CA, USA). Groups were compared using 
a one-way ANOVA with Tukey's multiple comparison test. Values were reported as the mean ± 
SEM. Each experimental arm (sham, empty implant, hIL-4 implant) included 8 mice. 
6.4 Results 
6.4.1 Implants loaded with hIL-4-expressing lentiviral vectors induce local hIL-4 expression in 
adipose tissue in early obesity 
We studied transplantation of implants into visceral eWAT based on prior data 
demonstrating the visceral cavity to be a preferred site for influencing systemic metabolism in 
obesity382–384. Local transgene expression of hIL-4 in murine eWAT was quantified using qRT-
PCR. At 2 weeks, hIL-4 gene expression in eWAT of hIL-4-implants in mice was significantly 
increased relative to sham and empty implant mice at 2 weeks (24.4±6.9 versus 1.0±0.6, and 
1.7±0.7, P≤0.0.05, respectively), but not 10 weeks (1.9±0.9 versus 1.0±0.2, and 1.8±1.1, 
respectively) (Fig 6.1C). These data demonstrate that lentivirus-modified implants effect 
adipose tissue transgene expression for at least 2 weeks.  
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(A) Synthetic polymer implants into eWAT fat pads. (B) Study design timeline; BG: fasting blood glucose; 
GTT: intraperitoneal glucose tolerance test. (C) Expression of hIL-4 in murine adipose tissue measured 
by qRT-PCR at 2 and 10 weeks after implants were transplanted; ordinate: fold difference in transcript 
level relative to sham mice; *P≤0.05 relative to the sham, ψ P≤0.05 relative to mice receiving empty 
implants 
 
 
Figure 1: Transfection of adipose tissue with hIL-4-PLG implants (A) Synthetic polymer implants into 
eWAT fat pads. (B) Study design timeline; BG: fasting blood glucose; GTT: intraperitoneal glucose 
tolerance test. (C) Expression of hIL-4 in murine adipose tissue measured by qRT-PCR at 2 and 10 weeks 
after implants were transplanted; ordinate: fold difference in transcript level relative to sham mice; *P≤0.05 
relative to the sham, ψ P≤0.05 relative to mice receiving empty implants 
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Figure 6.1 Transfection of adipose tissue with hIL-4-PLG implants 
Figure 6.2 Transfection of adipose tissue with hIL-4-PLG implants 
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We next investigated the effect of adipose tissue delivery of implants on systemic 
glucose metabolism in obesity. HFD induced obesity in mice consistent with numerous 
published data, with no difference in body weights between experimental arms (Fig 6.2A). 
sWAT and liver weights after 2 weeks HFD were similar between experimental arms, but eWAT 
weight was decreased in mice receiving empty implants relative to sham and hIL-4-implant arms 
(Fig 6.2A). No difference in tissue weights were observed after 10 weeks HFD (data not 
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shown). At 2 weeks HFD, hIL-4-implants caused a significant decrease in fasting blood glucose 
levels compared to sham and empty implant mice (Fig 6.2B); no difference in GTT results were 
observed between experimental arms at 2 weeks or 10 weeks (Fig 6.2C, D). These results 
indicate that hIL-4-implants transplanted into eWAT induce subtle but measurable improvement 
in systemic glucose metabolism in early but not in established obesity. 
6.4.3 Implants induce hIL-4-dependent and hIL-4-independent effects on adipose tissue T-cell 
and macrophage infiltration in early obesity 
Given the link between adipose tissue inflammation and metabolism, we next studied the 
effects of implants on local adipose tissue inflammation. Flow cytometry analysis revealed no 
difference between sham, empty implant, and hIL-4-implant mice in the frequency of leukocytes 
(CD45+ cells) in eWAT at 2 or 10 weeks (Fig 6.3A, B). At 2 weeks, hIL-4-implant mice showed 
an increase in CD4+CD3+ T-cell frequency relative to empty implants and sham mice, but no 
such difference in T cell frequency was observed at 10 weeks (Fig 6.3C, D). No difference in 
the frequency of total adipose tissue macrophages (ATM, CD45+CD64+ cells) was observed 
between all three experimental arms at 2 weeks or 10 weeks (Fig 6.3E, F). Mice receiving 
empty implants manifested an increase in CD45+CD64+CD206+ and 
CD45+CD64+CD206+CD11c+ macrophage subpopulations at 2 weeks relative to sham arm and 
hIL-4-implant mice, differences that disappeared at 10 weeks (Fig 6.3G, H). qRT-PCR analysis 
of eWAT revealed increased CD206 expression at 2 weeks in hIL-4-implant and empty implant 
mice relative to sham mice, along with an increase in TNFA expression in empty implant mice 
relative to sham mice, differences that disappeared at 10 weeks (Fig 6.4). Together these data 
suggest that hIL-4-implants induce increased infiltration of T cells and M2-like ATM in adipose 
(A) Total body weights of mice over course of 10-week study; tissue weights at 2 weeks. (B) Fasting blood 
glucose levels for sham, empty implant, and hIL-4 implants; *P<0.05 comparing sham and hIL-4-implant 
arms, using one-way ANOVA with Tukey's multiple comparison test. (C) Glucose tolerance tests (GTT) 2 
and 10 weeks after implant; *P≤0.05 comparing sham and hIL-4-implant arms (D) Area under the curves 
(AUC) for GTT; *P≤0.05 compared to sham arm 
 
 
Figure 2: hIL-4-PLG implants regulate systemic glucose metabolism (A) Total body weights of mice 
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ANOVA with Tukey's multiple comparison test. (C) Glucose tolerance tests (GTT) 2 and 10 weeks after 
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Figure 6.4 hIL-4-PLG implants regulate systemic glucose metabolism 
 
Figure 6.5 hIL-4-PLG implants regulate systemic glucose metabolism 
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tissue in early but not established obesity. 
 
A. 
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(A) Flow cytometry gating strategy. (B) Flow cytometry analysis of CD45+ leukocytes, CD3+CD4+ T cells, 
CD64+CD11c- ATM, CD64+ CD11c-CD206+ ATM and CD64+CD11c-CD206+CD11c+ ATM in adipose tissue after 
2 weeks and 10 weeks from mice receiving IL-4 coated implants, empty implants, or sham 
 
B. 
Figure 6.7 hIL-4-implants regulate adipose tissue inflammation 
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Inflammation-related gene expression assessed by qRT-PCR in eWAT; ordinates: fold differences in 
transcript levels relative to sham arm as referent =1; mean fold differences relative to sham +/- SEM: 
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*P≤0.05, **P≤0.01 compared to sham  
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Figure 6.10 Implants influence obesity-related inflammation in adipose tissue  
 
Figure 6.11 Implants influence obesity-related inflammation in adipose tissue  
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6.4.4 IL-4-implants induce adipocyte hypertrophy and metabolic gene expression in adipose 
tissue in early obesity 
We next studied the effects of implants on adipose tissue hypertrophy and metabolic 
gene expression. Histological analysis of adipocyte size in eWAT at 2 weeks HFD revealed 
larger adipocytes in hIL-4-implant treated mice relative to sham and empty implant mice 
(959.6±40.4µm2 versus 788.6±27.2µm2, P≤0.01, and 828.4±42.0µm2, P≤0.05, respectively); no 
differences in adipocyte size were observed between experimental arms at 10 weeks HFD (Fig 
6.5A-C). qRT-PCR analysis of a panel of metabolic genes demonstrated increased GLUT-1 
expression in eWAT from empty implant and hIL-4-implant mice relative to sham mice at 2 but 
not 10 weeks, and decreased ATGL and FASN expression in hIL-4-implant mice relative to 
sham mice at 2 but not 10 weeks (Fig 6.5D). Together these data demonstrate that hIL-4-
implants induce adipocyte hypertrophy and alterations in metabolic gene expression in early but 
not established obesity. 
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6.5 Discussion 
Mechanisms underlying adipose tissue inflammation in obesity are not well-defined, but 
increased M1-like ATM, along with alterations in T-cells, have been implicated385,386. Multiple 
cytokines regulate macrophage and T-cell mediated inflammation. We studied implants loaded 
with hIL-4-expressing lentivirus, given prior data demonstrating that the delivery of this construct 
in the spinal cord led to long-term sustained expression377. IL-4 has also been shown to induce 
Th2 and regulatory T cells and an M2 phenotype in macrophages in multiple model 
systems387,388, changes that would be expected to attenuate the adipose tissue inflammatory 
response associated with obesity. We demonstrate that PLG implants carrying an hIL-4-
expressing lentiviral vector regulated adipose tissue inflammation, adipocyte hypertrophy, and 
systemic insulin resistance in early murine obesity induced by 2 weeks HFD, but that these 
effects are not maintained in established obesity at 10 weeks HFD.  
Prior data by our group demonstrate that similar biomaterial implant-based delivery of 
lentiviral vectors into murine eWAT in model systems studying gene delivery leads to transgene 
expression primarily in macrophages, and that turnover of these cells limits the duration of 
transgene expression389. Similarities of these prior models with our experimental design in this 
manuscript suggest that ATM are the likely target of IL-4 lentivirus transduction in the present 
model, and that the transient effects of hIL-4 implants on adipose tissue and systemic 
metabolism in this obesity model are likely the result turnover of ATM beyond the 2-week time-
point. In addition, hIL-4 transgene expression was sustained for 12 weeks when delivered in the 
spinal cord but we did not observe this similar effect when delivered in the eWAT390. This 
suggests the site of lentiviral delivery can affect sustainability and that the transient effect 
(A) Representative H&E stained images of eWAT adipocytes at 2 and 10-weeks; scale bar: 100 µm. (B-C) 
Mean adipocyte area in eWAT; *P≤0.05 comparing empty implant and hIL-4-implant arms; **P≤0.01 
comparing hIL-4 arm to sham arm (D) Metabolic gene expression assessed by qRT-PCR in eWAT; 
ordinates: fold differences in transcript levels relative to sham arm as referent =1; mean fold differences 
relative to sham +/- SEM: ATGL: hIL4: 0.46 +/- 0.15; Empty: 1.21 +/- 0.59; FASN: hIL4: 0.27 +/- 0.09; Empty: 
0.57 +/- 0.29; GLUT-1: hIL4: 6.62 +/- 1.61; Empty: 11.45 +/- 3.12; *P≤0.05, **P≤0.01 compared to sham 
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ordinates: fold differences in transcript levels relative to sham arm as referent =1; mean fold differences 
relative to sham +/- SEM: ATGL: hIL4: 0.46 +/- 0.15; Empty: 1.21 +/- 0.59; FASN: hIL4: 0.27 +/- 0.09; Empty: 
0.57 +/- 0.29; GLUT-1: hIL4: 6.62 +/- 1.61; Empty: 11.45 +/- 3.12; *P≤0.05, **P≤0.01 compared to sham 
 
 
Figure 5: PLG implants regulate adipocyte hypertrophy and metabolic gene expression (A) 
Representative H&E stained images of eWAT adipocytes at 2 and 10-weeks; scale bar: 100 µm. (B-C) 
Mean adipocyte area in eWAT; *P≤0.05 comparing empty implant and hIL-4-implant arms; **P≤0.01 
Figure 6.13 PLG implants regulate adipocyte hypertrophy and metabolic gene expression 
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observed could be partly attributed to the eWAT environment, like inflammation associated with 
HFD.  
We demonstrate increased adipose tissue CD3+CD4+ T-cells in response to hIL-4 
implant transplantation. Prior data by our group demonstrates that the localized delivery of IL-33 
from our implants in the eWAT induces a Treg response391. Our qRT-PCR results do not 
demonstrate increased Treg markers in adipose tissue with implants (genes), but nonetheless, 
subtle alterations in Treg frequency is consistent with an improvement in system glucose 
metabolism. We also observed subtle changes in ATM phenotype consistent with an M2 shift, a 
finding consistent with the known effects of IL-4 on macrophage phenotype in multiple 
systems387,388, as well as established effects of IL-4 and M2 ATM on metabolism in 
obesity386,392,393. 
Adipocyte hypertrophy is an adaptive response in early obesity, increasing adipocyte 
nutrient storage capacity to prevent overflow of lipids into the systemic circulation. hIL-4 implant 
implantation was associated with increased adipocyte hypertrophy in early obesity, consistent 
with this concept. hIL-4 implants also induced decreased expression of ATGL and FASN, genes 
that regulate the rate limiting steps of adipocyte lipolysis and fatty acid synthesis respectively. 
While increased lipolysis might be expected to decrease adipocyte hypertrophy, it is possible 
that differences in magnitude of induction of ATGL and FASN activities in response to implants 
may tip the balance of adipocyte cellular metabolism towards hypertrophy. Further studies will 
be necessary to define the specific effects of implants on adipocyte cellular metabolism in vivo. 
Interestingly, increased GLUT1 expression was observed in eWAT in mice treated with both 
empty implants and hIL-4-implant, suggesting that implants induce some changes in tissue 
function independent of their biocargos. Notably, a single previous report by Hendley et al. 
studied the effect of implantation of empty (no cytokine vector) PLG implants into eWAT fat 
pads on metabolism in murine obesity, and confirmed effects on metabolism independent of 
cytokine cargo, including increased GLUT1 expression394. These investigators observed 
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improved glucose tolerance after 2 weeks of animals receiving implants by a glucose tolerance 
test, but no improvement in fasting blood glucose levels as we observed in response to hIL-4-
implants. In their study, mice received twice the implant dose (4 per mouse), and underwent 
implant transplantation one week after HFD initiation, compared to our study, in which implants 
were transplanted one week prior to HFD initiation. These investigators did not test implants 
loaded with cytokine vector, nor did they study inflammation or longer HFD time-points. These 
differences may account for the fact that in our study, we saw no effect of empty implants on 
glucose homeostasis; our data suggest that lower implant doses may require concomitant 
cytokine delivery to achieve measurable effects on glucose homeostasis.  
 We demonstrate that PLG implants loaded with hIL-4-expressing lentivirus vectors 
implanted into eWAT effect modest improvement in systemic glucose homeostasis along with 
subtle changes in adipose tissue leukocyte infiltration and adipose tissue metabolism in early 
murine obesity, but that these effects disappear in late obesity. More detailed studies of this 
model will be necessary to elucidate the precise effects of implants on adipose tissue 
macrophage and T-cell subpopulations, and determine if refinement of implant dosing and 
biocargo will have more durable effects on systemic metabolism. Nonetheless, this report 
demonstrates promise for synthetic polymer implants as a therapeutic tool for obesity. 
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Gene  Primer Sequence (5'-3') 
Human IL-4 forward ACATTGTCACTGCAAATCGACACC 
 reverse TGTCTGTTACGGTCAACTCGGTGC 
FASN forward AGCGGCCATTTCCATTGCCC 
 reverse CCATGCCCAGAGGGTGGTTG 
PPAR γ forward TGTGGGGATAAAGCATCAGGC 
 reverse CCGGCAGTTAAGATCACACCTAT 
ATGL forward CTGAGAATCACCATTCCCACATC 
 reverse CACAGCATGTAAGGGGGAGA 
C/EBP‐α forward GTTAGCCATGTGGTAGGAGACA 
 reverse CCCAGCCGTTAGTGAAGAGT 
C/EBP-β  forward CAAGCTGAGCGACGAGTACA 
 reverse AGCTGCTCCACCTTCTTCTG 
C/EBP-δ forward CCTGGAGGGTTTGTGTTTTCTG 
 reverse CCCCAAAGCTATGTGCCTTTC 
18S forward GCAATTATTCCCCATGAACG 
 reverse GGCCTCACTAAACCATCCAA 
CD28 forward TGGCTTGCTAGTGACAGTGG 
 reverse CATTGGTGGCCCAGTAGAGG 
IL-10 forward ATGCAGGACTTTAAGGGTTACTTGGGTT 
 reverse ATTCGGAGAGAGAGGTACAAACGAGGTTT 
CD206 forward TCTTTGCCTTTCCCAGTCTCC 
 reverse TGACACCCAGCGGAATTTC 
MCP-1 forward GCCAACTCTCACTGAAGCCA 
 reverse TGCTGCTGGTGATCCTCTTG 
TGF-β forward ACCGCAACAACGCCATCTAT 
 reverse GTAACGCCAGGAATTGTTGC 
Ym1 forward GATCTCAATATACACAGTGC 
 reverse GAGCTTAGCCAAAGCTGAC 
TNF-α forward TTGACCTCAGCGCTGAGTTG 
 reverse CCTGTAGCCCACGTCGTAG 
GATA-3 forward GAAGGCATCCAGACCCGAAAC 
 reverse ACCCATGGCGGTGACCATGC 
Arg1 forward GAACACGGCAGTGGCTTTAAC 
 reverse TGCTTAGCTCTGTCTGCTTTGC 
Mouse IL-4 forward TCGGCATTTTGAACGAGGTC 
 reverse GAAAAGCCCGAAAGAGTCTC 
Pref-1 forward GACCCACCCTGTGACCCC 
 reverse CAGGCAGCTCGTGCACCCC 
STAT-3 forward ACCCAACAGCCGCCGTAG 
 reverse CAGACTGGTTGTTTCCATTCAGAT 
STAT-6 forward TGAGGTGGGGACCAGCCGG 
 reverse GTGACCAGGACACACAGCGG 
GLUT-1 forward GCCCCCAGAAGGTTATTGA 
 reverse CGTGGTGAGTGTGGTGGA 
IGF-1 forward AAAGCAGCCCCGCTCTATCC 
 reverse CTTCTGAGTCTTGGGCATGTCA 
Table 6.1: qRT-PCR Primers 
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Target Channel Clone Vendor Catalog # 
CD45  eFluor 450 30-F11 Invitrogen, eBioscience, Carlsbad, CA, 
USA 
48-0451 
CD64  PE X54-4/7.1 BD Biosciences, (Franklin Lakes, NJ, 
USA 
558455 
CD11c  APC-eFluor 780 N418 Invitrogen, eBioscience, Carlsbad, CA, 
USA 
47-0114 
CD206  Brilliant Violet 
605 
C068C2 Biolegend Inc., San Diego, CA, USA 141721 
CD4  APC GK1.5 Invitrogen, eBioscience, Carlsbad, CA, 
USA  
17-0041 
CD3  PerCP-Cy5.5 145-2C11 Invitrogen, eBioscience, Carlsbad, CA, 
USA 
45-0031 
Rat IgG2a K 
Isotype 
Control 
PerCP-Cy5.5 eBR2a Invitrogen, eBioscience, Carlsbad, CA, 
USA 
45-4321-80 
Rat IgG2b 
kappa Isotype 
Control 
PE eB149/10H5 Invitrogen, eBioscience, (Carlsbad, CA, 
USA 
12-4031-82 
Rat IgG2b 
kappa Isotype 
Control 
eFluor 450 eB149/10H5 Invitrogen, eBioscience, Carlsbad, CA, 
USA 
48-4031-82 
Rat IgG2b 
kappa Isotype 
Control 
APC-eFluor 780 eB149/10H5 Invitrogen, eBioscience, Carlsbad, CA, 
USA 
47-4031-82 
Rat IgG2a 
kappa Isotype 
Control 
Brilliant Violet 
605 
RTK2758 Biolegend Inc., San Diego, CA, USA 400539 
Rat IgG2a 
kappa Isotype 
Control 
APC eBR2a Invitrogen, eBioscience, Carlsbad, CA, 
USA 
17-4321-81 
Table 6.2: Flow Cytometry Antibodies 
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Chapter 7: Conclusions and Future Perspectives on Bioengineering 
Strategies to Advance Organoid-Based Therapies 
 
7.1 Summary and significance of findings 
Recent advances in three-dimensional cultures have led to the generation of human 
organoids, which comprise of tissue structure and cellular organization similar to the native 
organ, while possessing the specified cell types32,34,49,52,266,267. Organoids provide an excellent 
platform for drug screening and may hold great potential for organ replacement therapies395–397. 
Currently, their major strength comes as a discovery tool to better understand human 
development and disease. While three-dimensional culture techniques have proved 
groundbreaking for generating components of the intestine, brain, liver, stomach, and the 
eye32,34,49,52,266,267, these approaches have not been applied to the development of functional 
islets. Traditionally, hPSC-derived cells have been cultured as 3D aggregates on low 
attachment plates or in suspension cultures23,274,398. Yet, during organogenesis the progenitors 
congregate into structures that are surrounded by a supportive extracellular matrix27–29.As a 
result, the field has turned to biomaterials that can spatially enable cell-cell and cell-matrix 
interactions that are needed for organ formation. However, many organoid cultures utilize 
reconstituted extracellular matrices, like Matrigel, as scaffolds, which are often poorly chemically 
defined, not translatable and allow only limited tunability. Thus, synthetic microporous scaffolds 
were evaluated for organoid cultures as a tunable, 3D culture environment that is more 
physiologically representative of the architecture of the native environment compared to 
traditional culture systems.  
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This dissertation focuses on developing scaffold technologies that can serve as a 
supportive matrix to promote in vitro development and function of islet organoids (Chapter 3 and 
4), in vivo maturation of lung organoids (Chapter 5) as well as regulate the in vivo immune 
response to support cell transplantation (Chapter 6). The underlying concept is that cellular 
behavior can be guided by manipulating environmental signals. Adequately controlling the 
formation of complex tissues remains a challenge partly due to a lack of effective strategies that 
can drive a complex array of biological signals in a spatially and temporally controlled manner. 
Thus, this work sought out to design effective biomanufacturing scaffold platforms for organoid 
transplantation that could overcome these challenges and provide a promising cell-replacement 
strategy for the treatment of diseases. 
 In Chapter 3, a microporous polymer scaffold was used in a novel way to support the 
differentiation of hPSC-derived pancreatic progenitor cells into 3D insulin-producing clusters. 
Our studies showed scaffolds provide a means to control the cell-cell interactions and can 
provide matrix-based signals that enable more consistent and efficient maturation of hPSC-
derived β-cells. Two different synthetic scaffold materials, PEG and PLG, were utilized for these 
studies as they provide flexibility in synthesis and modification, have been widely applied for 
islet transplantation286–288 and are generally easy to manufacture for large scale production. The 
microporous structure provided a high surface area-to-volume ratio for polymer–cell interactions 
and allowed nutrients to diffuse into the scaffold, which facilitated the 3D development of cell 
clusters. The scaffold also provided a strategy to control cell cluster size that could protect 
against adverse effects of shear during clinical manufacturing.  
 Characterization of β-cell development within the scaffolds revealed a correlation with 
maturation and the scaffold pore size. Clusters forming in pores with diameters greater than 250 
µm generated cells with increased expression of insulin and β-cell maturation markers. This 
relationship may be contributed to larger pores having a greater interconnected porosity, thus, 
aiding diffusion of growth media as well as enabling a more uniform distribution of seeded cells. 
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In addition, unlike suspension clusters, the clusters in scaffolds are in close proximity that reflect 
how islets are organized within the native pancreas and could lead to an increase in cell-cell 
interactions. E-cadherin gene and protein expression analysis confirmed scaffold cultures 
enhance cell-cell interactions relative to suspension cultures. Collectively, we show the 
microporous scaffold controls the formation of clusters and promotes cell-cell interactions that 
are influential in maturation.  
These studies also examined cell-matrix interactions by coating scaffolds with individual 
ECM components in isolation, as well as, Matrigel, a mixture of ECM proteins, to establish a 
matrix representative of the native islet extracellular microenvironment. The relationship 
between cells and their ECM is highly dynamic and reciprocal. The results of this work 
demonstrated that cell-secreted ECM deposited on the empty scaffold surface provided a niche 
environment comparable to the ECM-coated scaffolds. This indicates that natural proteins do 
not need to be introduced on the scaffold prior to cell seeding in order to promote the assembly 
and function of insulin-producing clusters in vitro. More importantly, the matrix deposited by the 
cells on the PLG scaffold has the potential to mimic more of the dynamic, complex niche 
environment during pancreatic development compared to the coated ECM proteins that may 
mask the impact of the adsorbed ECM proteins. β-cell function was demonstrated through 
glucose-responsive functional tests that showed cells cultured on both PEG and PLG scaffolds 
had higher insulin secretion than suspension clusters. Collectively, the scaffold design including 
pore size, biomaterial, and ECM coating was shown to generate functional islet organoids that 
reflected the native islet architecture and environment. Thus, both scaffold materials are 
considered amenable to our fundamental objective – supporting β-cell maturation in a 3D 
environment.  
The application of more recent protocols255,289 to scaffold-based cultures offered the 
opportunity to further enhance glucose stimulated responses in islet organoids and characterize 
mechanisms that could improve in vitro maturation on the microporous scaffold. Chapter 4 
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demonstrated that the support of the scaffold microenvironment during organoid maturation 
could be enhanced by adjusting the differentiation stage of cells seeded on scaffolds as well as 
the seeding technique. PLG was used for these investigative scaffold culture studies as it 
generated islet organoids with higher insulin secretion function relative to PEG and was a  well-
established model for islet transplantation studies279,310,399. hPSCs were differentiated using a 
new protocol described in Velazco-Cruz et al. (2019) to improve cluster maturation compared to 
the prior protocol described in Rezania et al (2014). By changing protocols, the culture system 
transitioned to a 3D environment with cell clusters in suspension versus a 2D monolayer prior to 
scaffold seeding. Scaffold cultures were then seeded with more mature progenitor cells 
resembling stage 5 pancreatic endoderm and showed enhanced secretion of insulin per cell 
compared to scaffolds seeded with stage 4 pancreatic progenitors. These results indicate 
incorporating cells on scaffolds after they have made their early cell fate decisions in the 
differentiation process could generate more functional organoids.  
Prior studies showed how cell-cell and cell-matrix interactions established during the 
differentiation process played a crucial role during cell development, thus the influence of cell 
manipulation on organoid maturation was evaluated. hPSCs were cultured on a 2D monolayer 
that requires less daily manipulation compared to 3D cultures and differentiated to stage 4 
pancreatic progenitors then reaggregated in suspension. This reaggregation step on 
differentiated cells has been shown to increase the percentage of endocrine cells in the culture 
but also requires established cell interactions to be manipulated. GSIS functional testing of 
scaffold cultures seeded with cells from reaggregated clusters showed this modified protocol 
could generate islet organoids with insulin secretion comparable to human islets. However, the 
modified protocol also generated immature clusters thus the functional variability from this 
modified protocol needs to be further evaluated. A process step for seeding scaffold cultures 
was also modified by seeding scaffolds with dense clusters rather than a single cell suspension 
of dissociated clusters. Relative to suspension clusters, scaffold cultures seeded with dense 
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clusters showed enhanced expression of β-cell maturation markers after the pancreatic 
endoderm stage. In addition, scaffolds seeded with dense clusters showed an insulin secretion 
index that was comparable to the suspension clusters while scaffolds seeded with dissociated 
cells had decreased function. As a result, less manipulation on pancreatic endoderm clusters 
combined with maintaining cell-cell contacts and providing ECM signals should be considered in 
order to improve islet organoid function. 
Furthermore, a novel fluorescent insulin reporter stem cell line was developed to give 
mechanistic insight regarding material design and cell development throughout the in vitro 
differentiation. This engineered hPSC line with the insertion of a superfolder green fluorescent 
protein in the C-peptide (sfGFP-Cpep) coding sequence helped assess the function of individual 
clusters by measuring dynamic insulin storage and secretion. Developing an insulin reporter 
allowed us to carry out non-invasive assessments of maturation during these studies as well as 
assess heterogeneity in function between clusters rather than relying on traditional methods that 
either assess an entire cell population or require the study to end. Immunofluorescence imaging 
of islet organoids in a high glucose solution showed GFP-positive cells in islet organoids 
exhibited a functional decrease in sfGFP-Cpep (insulin) but varied in intensity, indicative of a 
heterogenous functional response. This observation was corroborated by ELISA testing that 
showed islet organoids secreted insulin under glucose-challenged environments, but the insulin 
secretion index ratio was not comparable to human islets. Incorporating this reporter cell line 
laid the foundation for using cells to report on the activity of transcription factors (TFs) 
associated with pancreatic development or β-cell maturation, or the expression of key proteins 
indicative of function (e.g., insulin) over the course of differentiation. The ability of a reporter to 
provide a non-invasive, real-time measurement both in vitro and in vivo enables quantification of 
the activity for key TFs or promoters throughout the entire maturation process, which can be 
connected to the material design.  
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While the polymer scaffold provided a useful model to assess how the ECM influences in 
vitro organoid development, the islet organoids generated would be characterized as early-
stage organoids since they still lacked structural and functional similarities to the endogenous 
counterpart. Similarly, in vitro human lung organoid (HLO) cultures only reflect the fetal airway, 
with adult airway-like structures generated only after in vivo transplantation195. Prior studies 
showed HLO transplantation was further enhanced with biomaterial scaffolds, where HLOs had 
improved tissue structure and cellular differentiation after being transplanted for 8 weeks. 
Chapter 5 focused on identifying the polymer scaffolds design parameters that directed 
engraftment and in vivo maturation for HLOs, which could then be applied to promote islet 
organoid in vivo development as well. 
In order to evaluate the role of polymer material on in vivo organoid development, PLG. 
PEG and PCL scaffolds were generated for organoid cultures. In contrast to PLG scaffolds, 
transplantation of HLOs on microporous PEG hydrogel scaffolds led to inhibited growth and 
maturation with transplanted HLOs remaining as immature NKX2.1+ lung progenitors. The 
presence of RGD, a fibronectin binding peptide, bound to the PEG gel did not impact maturation 
either, suggesting that either adhesion is not a limiting factor in HLO maturation or that the RGD 
is insufficient to trigger the necessary signaling cascades. On the other hand, HLOs 
transplanted on PCL led to tube-like structures that resembled both the structure and cellular 
diversity of an adult airway. Similar to PLG, PCL scaffolds allowed for the formation of structures 
at the surface of the material, yet, more similar to PEG, tissue formation did not occur within the 
pores of the scaffold. Each polymer has a different degradation rate with PLG degrading in 2-4 
months, PCL degrading over a year and PEG being non-degradable400. These variations in 
organoid growth suggest that polymer degradation contributed to the maturation, and that the 
size of the airway structures and the total size of the transplanted tissue was influenced by the 
material degradation rate. Histological staining showed the increased explant size resulted from 
an increase of proliferation from the supporting tissue including the mesenchyme with a lesser 
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extent increase of proliferation from the organized epithelium. Thus, scaffold properties were 
shown to have influenced the proliferation of the progenitor cells, which subsequently influenced 
the overall size of the explant. 
Airway structure formation was evaluated using GFP+ and GFP- HLOs to better 
characterize organoid growth within the scaffolds after transplantation. As the airway structures 
formed, the individual HLOs fused together to form these structures evident by the GFP+ and 
GFP- HLOs forming into one airway. Surprisingly, the buds were able to form together when the 
scaffold held its shape (PCL) or degraded (75:25 PLG) over the 8 weeks in vivo. Thus, the 
degradation was not necessary for the HLOs to fuse together; however, the HLOs could only 
form airway structures if they had the space to fuse and expand together into epithelial tubes. 
Additional studies focused on testing the hypothesis that maximal airway size occurs at an 
intermediate rate of degradation. Evaluating PLG scaffolds of varying degradation rates 
confirmed this theory by showing that the airway size was maximal for 75:25 PLG control, with 
slightly smaller structures for the faster degrading 50:50 PLG and slower degrading 85:15 PLG. 
One mechanism by which degradation can influence airway size is by increasing the size of the 
interconnections between pores over time. This would allow for greater fusion of organoids from 
adjacent pores. Overall, these results are consistent with the general idea that the polymer 
degradation should be matched with the rate of tissue formation. Our studies show the physico-
chemical properties of the scaffold can be manipulated to influence the properties of explant, 
such as the number and size of airways structures and the size of the explant. Controlling 
airway and total explant size will allow for new models for airway diseases such as asthma, 
COPD, and CF with the potential to perform long-term studies. Collectively, these biomaterial 
platforms were shown to provide a set of tools to promote maturation of the tissues and to 
control the size and structure of the organoids. 
Despite the potential shown here for organoid cultures on microporous scaffolds, 
immune tolerance remains a major challenge due to the abundance of foreign antigens 
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recognized by the host immune system and the arduous task of regulating the natural immune 
response to attack foreign tissues or cells. Using scaffold technologies to develop and 
transplant organoids, however, allows existing immunosuppressive therapies, or emerging 
tolerance therapies, to be incorporated into the scaffold to prevent tissue rejection. Towards this 
goal, Chapter 6 investigates a method for immunomodulatory cytokine delivery from scaffold 
implants that can be used to modulate a specific set of immune cells for tolerance induction.  
PLG microporous implants were loaded with human IL-4 (hIL-4)-expressing lentivirus to 
induce Th2 and regulatory T cells as well as an M2 phenotype in macrophages in order to 
attenuate the adipose tissue inflammatory response. Implants were then transplanted in the 
epididymal fat pad of immunocompetent mice who were given a high fat diet (HFD) to challenge 
the inflammatory environment. Despite the sustained expression shown in prior studies that 
used a similar approach to deliver lentivirus in the spinal cord390, viral delivery of hIL-4 in the 
epididymal fat pad resulted in short-term, localized transgene expression. Prior data suggested 
that adipose tissue macrophages (ATM) are the likely target of hIL-4 lentivirus transduction in 
the present model389. Consequently, the transient effects of hIL-4 implants on adipose tissue 
and systemic metabolism in this obesity model are likely the result of turnover of ATM beyond 
the 2-week time-point. We also observed subtle changes in the ATM phenotype consistent with 
an M2 shift, a finding consistent with the known effects of IL-4 on macrophage phenotype in 
multiple systems387,388. 
PLG implants loaded with hIL-4-expressing lentivirus vectors implanted into eWAT 
induced a modest improvement in systemic glucose homeostasis, but these effects disappeared 
in late obesity. The short-term effect on glucose metabolism is likely attributed to the transient 
viral expression in the local environment. Analyzing the immune response in the fat pad at the 
2-week transplant time-point revealed there was an increased CD3+CD4+ T-cell population in 
adipose tissue in response to hIL-4 implant transplantation. hIL-4 implants also induced 
decreased expression of ATGL and FASN, genes that regulate the rate limiting steps of 
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adipocyte lipolysis and fatty acid synthesis, respectively. hIL-4 implant transplantation was 
associated with increased adipocyte hypertrophy in early obesity, consistent with these results. 
Interestingly, increased GLUT1 expression was observed in fat pads in mice treated with both 
empty implants and hIL-4-implant, suggesting that implants induce some changes in tissue 
function independent of their biocargos. More detailed studies of this model will be necessary to 
elucidate the precise effects of implants on adipose tissue macrophage and T-cell 
subpopulations and determine if refinement of implant dosing and biocargo will have more 
durable effects on systemic metabolism. In summary, PLG implants carrying an hIL-4-
expressing lentiviral vector regulated adipose tissue inflammation, adipocyte hypertrophy, and 
systemic insulin resistance in early murine obesity induced by 2 weeks HFD, but these effects 
were not maintained in established obesity at 10 weeks HFD. These studies demonstrate how a 
gene delivery system might be used in conjunction with organoid transplantation to create an 
area of localized immunosuppression that would protect regenerated tissue from immune attack 
while decreasing or eliminating the requirement for systemic immunosuppression. 
The Shea lab is performing groundbreaking research at the interface of biomaterials, 
tissue engineering, and developmental biology using synthetic microporous scaffolds, and the 
studies presented in this dissertation advance these technologies with the end goal of translation 
from bench to clinic. Taken together, this dissertation introduces a novel biomanufacturing 
platform as an alternative to the traditional suspension culture to improve the development and 
efficacy of cell-based therapies. These conclusions establish the groundwork for understanding 
the influential role of the ECM and relevant factors that are necessary to enhance the function of 
transplanted organoids. In order to further characterize the critical components in the extracellular 
microenvironment that regulate these effects, additional studies should be carried out, which are 
described in the next section. 
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7.2 Future directions 
There are several key questions that need to be examined in order for further progress to 
be made toward the ultimate goal of using synthetic microporous scaffolds for organ 
transplantation in humans. This section will highlight some recommended new directions for 
continuing the work detailed in this thesis.  
7.2.1 Measure metabolic maturation of mitochondria in islet organoids to characterize function 
The process of generating hPSC-derived insulin-expressing cells is well established 
however little is known about their bioenergetic requirements or how closely their energy 
metabolism is governed by the constraints of the genetic developmental program. The transition 
from a pluripotent stem cell through progressive stages of differentiation probably involves 
dynamic changes in the energy demand for cellular processes, depending on the needs of the 
individual cell types. ATP generation in aerobic cells is divided between two main pathways: 
anaerobic glycolysis and mitochondrial oxidative phosphorylation. On the basis of changing 
energy demands, and the need to limit the production of mitochondrial reactive oxygen species, 
it might be expected that the relative contribution of these two pathways would change during 
differentiation.  
Characterizing mitochondrial metabolism as hPSCs differentiate down the pancreatic 
lineage could elucidate key characteristics that indicate whether the islet organoids will be mature 
or immature. Assessing mitochondrial respiratory function in islet organoids generated under 
various scaffold conditions as well as in suspension could provide a more complex understanding 
of maturation as well. Studies have shown that human islets show increased oxygen consumption 
rate (OCR) upon stimulation with high glucose. The capacity for maturing organoids to raise OCR 
as efficiently as human islets in response to glucose could be another assessment that the 
organoids are metabolically mature and effectively engage mitochondrial oxidative 
phosphorylation for glucose oxidation. In addition, the analysis of individual clusters within the 
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maturing pancreatic progenitors in vitro could provide metabolic markers that will identify 
pathways or factors that will enhance homogenous maturation. 
Some studies suggest that the mitochondrial population increases as a universal 
phenomenon from the initiation of hPSC differentiation regardless of the differentiation lineage 
401. On the other hand, several energy-consuming processes might be diminished during the early 
transition to a differentiated state, and it might not be accompanied by a mitochondrial 
expansion402–405. Changes in metabolic regulation in vitro might reflect the typical energy 
requirements of these cell types in vivo and, thus, be guided by genetic developmental programs. 
Future studies should follow the genetic regulators of energy metabolism in tandem with the 
bioenergetics to clarify the different forces driving mitochondrial function. 
7.2.2 Targeted genome editing for iPSC-derived organoids 
Future studies may enable iPSCs to culture islet organoids. iPSCs derived from patient’s 
adult cells can undergo CRISPR genome editing to correct a disease-related mutation and then 
undergo transplantation as functional organ-like units used to advance tissue repair and 
functionality. Monogenic diabetes occurs at a young age due to mutations in a single gene, 
leading to impaired function of the pancreatic β-cells. A particular genetic modification (e.g. 
knockout, knockin) can be generated in a well-differentiating, healthy hPSC line or a candidate 
mutation can be corrected in patient-derived hiPSCs. A proof-of-concept use of genome editing 
in the organoid field was recently demonstrated406. Effective genome editing of human stem cells 
in primary intestinal organoids using CRISPR/Cas9 was proven. Then, using CRISPR-Cas9-
mediated HDR, intestinal organoids from two patients with cystic fibrosis were genome edited to 
fix the mutation, the primary cause of the disease. It was shown that the genome-edited intestinal 
organoid systems expressed the corrected CFTR allele, which subsequently resulted in fully 
functional proteins in these organoids. This study demonstrates how genome editing of iPSC-
derived organoids could be a potential gene therapy strategy, with limited risks to off-target tissue 
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mutagenesis. It is important to keep in mind, however, some of the challenges that come with 
translating iPSCs to the clinic. In order for this technology to be successful, we will need to address 
the cost of manufacturing personalized medicine that meets the regulatory demands of the FDA 
as well as ensure patient safety.  
7.2.3 In vivo imaging of β-cell function in sfGFP-Cpep islet organoids to measure glucose-
mediated heterogeneity  
While the cellular components required for GSIS are well established, the key signaling 
pathways that regulate β cell metabolism and insulin secretion in vivo remain poorly understood. 
Analysis of insulin content, or insulin secretion, in real time is difficult for transplanted cells, thus, 
it is tough to determine when euglycemia is not achieved due to a limited group of highly-
responsive insulin-secreting cells or alternatively a large group of minimally-responsive cells. 
Using the sfGFP-Cpep reporter would address some of these challenges in understanding what 
factors in the in vivo milieu are critical to promoting and maintaining functional maturation.  
In vivo imaging of Ca2+activity in a recent study revealed heterogeneity of β-cell functional 
development in vivo occurred as two waves propagating from the islet mantle to the core, 
coordinated by islet vascularization407. This asynchronous behavior was also observed in mice 
with pancreatic sfGFP-Cpep cells where a small subset of islets showed rapid dispossession of 
a major fraction of their stored sfGFP-Cpep (insulin) content, whereas most islets exhibited no 
demonstrable loss of sfGFP-Cpep (insulin)314. These studies strongly suggest that there are “first 
responder” islets to an in vivo glycemic challenge, which cannot be replicated by islets in vitro. 
This heterogenous response observed in the pancreas could be a major regulator of glucose 
metabolism but not so easily replicated by transplanted hPSC-derived clusters that are dispersed 
across a transplant site. Alternatively, the scaffold culture presents a physical structure similar to 
the pancreas tissue that integrates clusters into connective tissue that might enhance the ability 
for clusters to function similarly to their endogenous counterpart.  Using the sfGFP-Cpep tool, we 
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have made preliminary attempts at evaluating in vivo heterogenous function in hPSC-derived 
scaffold cultures that can be further improve upon to compare to transplanted suspension clusters 
and further examine what role an asynchronous response plays in glucose metabolism. These 
studies can also help provide new insights for the optimization of the differentiation process. 
7.2.4 Designing dynamic organoid culture environments through multi-faced scaffolds 
Bioengineered scaffold matrices facilitate dynamic variation of mechanical and 
biochemical properties to guide in vitro three-dimensional culture conditions for individual cell 
types. Studies in Chapters 3, 4 and 5 demonstrate how scaffold cultures can be utilized to develop 
different organoids as a universal platform. The scaffold’s tunable features combined with the 
enabling of the organoid tissue to remodel the local environment through ECM deposition and 
material degradation allows the scaffold culture to reflect the specific niche for different organoids. 
In order to advance the capabilities shown by the synthetic scaffolds, future studies should focus 
on developing multi-faceted scaffold designs that recapitulate tissue heterogeneity in terms of 
spatial arrangement and temporal changes. New scaffold designs could incorporate 
compartmentalized regions in the biomaterial structure that are functionalized with molecular 
factors that form concentration gradients through the construct and guide organoid development 
and tissue architecture. The rate the supportive scaffold matrix degrades demonstrated a critical 
component for in vivo HLO growth. Applying new technologies to regulate degradation might allow 
this technology to be applied to a wider variety of organoid cultures. A number of scaffold designs 
could be investigated to achieve this control, such as self-assembling peptides and peptide 
amphiphiles that provide for controllable scaffold gelation, degradation, and presentation of cell 
adhesion motifs.408 Hydrogels that are created with bifunctional crosslinkers containing MMP 
degradable peptide sequences have also been shown to influence differentiations and could 
provide cells the ability to dynamically remodel their environment as they grow409. EphA, a family 
of receptor tyrosine kinases, along with their Ephrin-A ligands—both of which are localized to the 
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cell membrane—mediate cell-cell interactions between β-cells to regulate insulin secretion410. 
Inclusion of EphA/Ephrin-A fusion proteins into the scaffold may provide cells a more natural 
environment by “cloaking” the scaffold with ligands found on mature beta cells to help signal the 
islet organoids toward a more mature phenotype. Recent advances in biofabrication technologies 
approaches have also enabled the fabrication of scaffolds that aim to mimic the dynamic nature 
of the native extracellular matrix.411  
7.2.5 Expression profiling of sorted cells generated from hPSC-derived islet organoid 
development 
One of the biggest challenges in stem cell research in recent years is the development of 
differentiation protocols to efficiently generate functional, robust cells for therapeutic applications. 
In order to learn more about progenitor cells at different stages along the differentiation process 
in which they become progressively more committed to the final beta cell fate either in suspension 
or on scaffold cultures, studies can focus on identifying, isolating and characterizing stage specific 
progenitor cells. Stage specific cell types could be identified by either SRY box 17 (SOX17) or 
pancreatic and duodenal homeobox 1 (PDX1), two transcription factors which are expressed 
relatively early in pancreatic differentiation. Characterizing these time points may serve as useful 
markers for monitoring the differentiation of hPSCs under the influence of different growth factors 
at different time points. The sorting of precursors at key stages of pancreatic beta cell 
differentiation enables systematic assessment of the effect of signaling factors, small molecules 
or other compounds on growth, differentiation and survival of these progenitor cells. The 
expression profile of these populations could be assessed in order to compare the influence of 
scaffold and suspension cultures on specific precursor cell types during particular stages of the 
differentiation. Moreover, it is anticipated that the information gained through these studies will 
permit more efficient generation of populations enriched with functional beta cells derived from 
stem cells. 
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7.2.6 Engineering organoid vascularization within scaffold cultures 
Both HLO’s and islet organoids were transplanted on PLG microporous scaffolds in the 
epididymal fat pad, but only the HLO’s showed further maturation and tissue organization. While 
this could be attributed to the level of maturation of organoids prior to transplantation, future 
studies should assess if this difference in in vivo development between organoids could be 
addressed through enhanced vascularization. During organogenesis, developing tissues 
interact with a complex network of vasculature which permits not only oxygen, nutrient and 
waste exchange, but also allows for a structural template for growth. In order to test this, in vivo 
studies could consist of utilizing a pocket scaffold design that allows for an inner layer protein 
loaded PLG disk to be inserted between two scaffold culture halves and locally release VEGF 
within the implant site. An alternative method would be to culture an endothelial-derived scaffold 
culture and transplant the vascular tissue along with the islet organoid scaffold culture to 
promote vasculature support to the organoid. The mechanisms that guide the difference in how 
these two organoids mature in vivo could also be limiting other organoids thus these studies will 
provide useful observations for the field. 
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Chapter 8: Appendix 
Chapter 8.1: Microporous scaffolds support islet transplantation in non-human primate studies 
Clinical islet transplantation has the potential to become a cure for Type 1 Diabetes (T1D). 
However, a number of barriers limit the widespread application of this technology. A translatable 
supply of islets and the underlying autoimmune and immune response to the transplanted cells 
reflect two major barriers; however, a third major challenge is the isolation of a transplantable 
site for the long-term engraftment and functionality of islets. Clinically, islets are transplanted 
intrahepatically, which is associated with an instant blood mediated inflammatory response 
(IBMIR) that can damage the cells. Furthermore, the liver has numerous critical functions and 
thus little can be done to alter this transplantation site. Extrahepatic sites have been 
investigated, primarily using encapsulation approaches to protect islets from the host immune 
response. However, these approaches often lead to the exclusion of blood vessels that would 
normally revascularize the islets. The Shea lab has been working for over 10 years on islet 
transplantation on microporous scaffolds that allow for revascularization of the transplanted 
islets. The ability to revascularize the islets distinguishes this approach from encapsulation 
systems, as revascularization can provide the nutrients necessary for islet survival while also 
facilitating the sensing of blood glucose and the distribution of insulin. These microporous 
scaffolds have also been functionalized to control the local environment, which was initially 
employed to enhance the engraftment of the transplanted islets (e.g., extracellular matrix 
proteins, trophic factors). More recently, the scaffolds have also been employed to modulate the 
innate and adaptive immune responses (e.g., immune cytokines, Tregs) to delay rejection or 
promote immune tolerance, which is emerging as an essential component for any cell 
transplantation strategy. These microporous scaffolds will be studied in large animal models, 
134 
 
performed in collaboration with the Oberholzer and Lyubimov laboratories, with the aim of 
initiating clinical trials using this technology. 
 Polymer scaffolds, used for the transplantation of islets to mouse models, were scaled to 
accommodate the transplantation of islets to the omentum of non-human primates (NHP). PLG 
and PEG polymer scaffolds were scaled up to 35 mm in diameter and 2 mm in thickness (Fig 
8.1.1) using the same manufacturing techniques previously used for fabricating mouse 
scaffolds. Furthermore, standardized GMP manufacturing and sterilization protocols were 
developed for reproducible scale-up manufacturing of these scaffolds. For NHP scaffold 
transplantation studies, the scaffolds were sterilized using gamma irradiation and scaffold 
integrity was examined before and after, and scaffold polymer concentrations were optimized to 
withstand the sterilization process (Fig 8.1.2). Sterilized scaffolds tested for the presence of 
bacterial contaminants found that sterilized scaffolds were negative for aerobic and anaerobic 
bacteria, yeast, and fungi (Fig 8.1.3). Endotoxin testing was also conducted on sterilized 
scaffolds and determined no significant presence of endotoxins following sterilization (<10 EU 
endotoxin level reported for scaffolds; up to 20 EU/device are FDA thresholds for endotoxin 
levels) (Fig 8.1.4). 
 
An islet seeding device (A) was developed to maximize the islet seeding efficiency. Either 25 mm 
diameter or 35 mm diameter NHP scaffolds (B) are placed into the islet seeding reservoir and islets 
suspended in media are added to the reservoir. A vacuum is attached to the attachment to pull through 
the media to the flow-through reservoir, leaving islets seeded to the scaffold (99% islet seeding 
efficiency). Human islets seeded to a PEG hydrogel scaffold (C), where islets can be seen as white 
masses and the PEG scaffold is a translucent blue color. Human islets seeded to PEG hydrogel scaffolds 
using the islet seeding device remain viable and functional following a 24 hour incubation in media, as 
indicated by the glucose stimulated insulin secretion assay (D). 
Figure 8.1.1 Scale-up of scaffolds for NHP studies and optimizing islet seeding. 
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This was further confirmed by performing a blood panel and showing no significant increases in 
inflammatory immune cell populations after the transplant. (Table 8.1.1). An islet seeding device 
was developed (Fig 8.1.1A) for the reproducible and homogenous seeding of islets to the 
The process of irradiating scaffolds for sterility had affected their handling with seeding and transplantation. 
We thus investigated modifications to the formulation such that the scaffolds would have properties similar 
to what has been used in the past. PEG and PLG scaffolds were fabricated using varying concentrations 
of polymer and the dry weights and wet (swollen) weights were compared between non-irraditated (control) 
and gamma-irradiated scaffolds to determine which scaffold fabrication parameters were the least affected 
by gamma irradiation. 
Figure 8.1.2 Impact of Gamma Irradiation on PEG and PLG Scaffolds 
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scaffolds. Human islets seeded to PEG hydrogel scaffold (Fig 8.1.1C) using the islet seeding 
Figure 8.1.4 Bacteriology panel for sterilized PEG scaffold. 
Sterilized scaffolds tested for the presence of bacterial contaminants found that sterilized 
scaffolds were negative for aerobic and anaerobic bacteria, yeast, and fungi. 
Sterilized scaffolds tested for presence of endotoxins yielded a negative test for endotoxins (<0.298 
EU/mL endotoxin level reported for scaffolds; <0.5 EU/mL or <20 EU/device are FDA thresholds for 
endotoxin levels for devices directly or indirectly in contact with blood, respectively) 
Figure 8.1.3 Endotoxin testing of sterilized PEG scaffold. 
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device remain viable and functional following a 24 hour incubation in media, as indicated by the 
glucose stimulated insulin secretion assay (FIG 8.1.1D). Next, scaffolds without islets were 
transplanted to the bursa omentalis of a non-diabetic NHP to determine the optimal surgical 
procedure: laproscopic or open-surgery; and optimal transplant site: scaffold transplanted on top 
of bursa omentalis (Fig 8.1.5A) or scaffold transplanted to a pocket within the bursa omentalis 
(Fig 8.1.5B). Also, this transplantation of scaffolds (no islets) to the bursa omentalis of non-
immunosuppressed NHPs was used for 30-day immunoreactivity study to determine 
inflammatory response to scaffolds and immune cell profile within scaffolds. The 
immunoreactivity study demonstrated no significant presence of immune cells or inflammation 
for PEG and 
 Table 8.1.1: Comprehensive results of blood panel from a NHP 30 days following 
transplantation for the immunoreactivity study. 
 
 Table 8.1.2: Comprehensive results of blood panel from a NHP 30 days following 
transplantation for the immunoreactivity study. 
 
 Table 8.1.3: Comprehensive results of blood panel from a NHP 30 days following 
transplantation for the immunoreactivity study. 
 
 Table 8.1.4: Comprehensive results of blood panel from a NHP 30 days following 
transplantation for the immunoreactivity study. 
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A PEG hydrogel laproscopically transplanted on top of the bursa omentailis of a NHP immediately 
following transplantation.A PEG hydrogel (side-view) transplanted to a pocket within the bursa omentalis 
of a NHP, 30 days following transplantation. 
Figure 8.1.6 PEG hydrogel transplantation to the bursa omentalis of a NHP. 
An incision was made into the omentum of a NHP to create a pocket in which a scaffold was inserted (A), 
then wrapped in the omental tissue (B). Scaffold wrapped in the omentum was placed back into the peritoneal 
space (C) and can be seen transplanted to the omentum prior to suturing the NHP (white arrow, D). 
Figure 8.1.5 Scaffold transplantation to the bursa omentalis of a NHP for 30 day immunoreactivity study. 
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PLG scaffolds, compared to the omentum (control), 30 days following transplantation (Fig 8.1.6-
7). Previous clinical islet transplantation studies have demonstrated that intraportal islet 
transplantation provokes an instant blood mediated inflammatory reaction that leads to 
significant, immediate islet cell loss. Using the omentum as a transplant site with a microporous 
scaffold could reduce the need for using multiple donors to achieve long-term insulin 
independence after islet transplantation. We showed in this study that the scaffolds are 
biocompatible in the omentum and, for next steps, plan to obtain toxicology data that is 
necessary to pursue an IND through the FDA to begin clinical trials for human islet 
transplantation. UIC has extensive regulatory experience in working with the FDA and has filed 
several INDs for islet cell transplantation. UIC is currently in the process of biologic license 
application, and anticipates obtaining licensure for human, isolated cadaveric islets by June 
 
Scaffolds, transplanted without islets, and omentum were removed from NHP 30 days following 
transplantation and stained for alpha-smooth muscle actin (red), CD11b (green) CD8 (yellow), and nuclear 
counterstain with DAPI (blue). Scale bar = 200 µm. This analysis and others suggest that the material is 
well tolerated and that inflammation or fibrosis would not obviously limit engraftment or function. 
Figure 8.1.7 Immunohistochemistry Staining for Immune Markers of PLG, PEG Scaffolds and Omentum 
from Immunoreactivity Study 
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2017. Having licensure for the human islet cell product would greatly simplify future INDs in 
testing scaffolds that fall under this device category by the FDA. Transplantation of scaffolds 
seeded with purified islets (Fig 8.1.8) to non-diabetic, immunosuppressed NHPs for 30 days 
demonstrated that islets were not rejected and were still present 30 days following 
transplantation. Finally, diabetic, immunosuppressed NHPs transplanted with scaffolds, seeded 
with islets (non-therapeutic dose), determined that islets remain functional – regulating blood 
glucose levels (Fig 8.1.9A), decreasing demand for exogenous insulin administration (Fig 
1.8.9A), and producing C-peptide (Fig 8.1.9B) – up to 10 days following transplantation, and 
histology demonstrates the presence of extensive insulin staining 30 days following 
transplantation (Fig 8.1.9C). 
 
 
 
 
Islets were isolated from 4 NHP donors and purified. Islet purity was assessed using a DTZ stain (A) 
and islet viability was assessed using a live/dead stain (B). Islets were seeded to scaffolds using our 
proprietary islet seeding device 2 days following isolation and transplanted to a diabetic, 
immunosuppressed NHP. 
Figure 8.1.8 NHP islet isolation, purification, and transplantation to diabetic, immunosuppressed NHP 
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 In order to improve the therapeutic function of the transplanted islets on scaffolds, we 
increased the islet load from 40K IEQ to approx. 110K IEQ. Diabetic, immunosuppressed NHPs 
were transplanted with scaffolds seeded with an increased islet dose and we found that islets 
showed a similar result to the lower dose by regulating blood glucose levels (Fig 8.1.10), 
decreasing demand for exogenous insulin administration (Fig 8.1.10), and producing C-peptide 
(Fig 8.1.11) – up to 12 days following transplantation. IVDTT demonstrated that the transplant 
 
Blood glucose levels and decreased demand for exogenous insulin within the first 30 days following 
transplantation of a sub-therapeutic dose of islets (A), C-peptide production was also observed within the 
first 10 days following transplantation (B), and histology demonstrates the presence of extensive insulin 
staining 30 days following transplantation (insulin = green, DAPI nuclear counterstain = blue, scale bar = 
200 µm. (C)  
Figure 8.1.9 Transplantation of allogeneic islets (non-therapeutic dose) using microporous PLG polymer 
scaffolds to the omentum of NHPs. 
Figure 8.1.10 Blood Glucose Levels and Daily Insulin Administration for CN9086 Allogeneic Scaffold 
Transplant Recipient (on Immunosuppression). 
BGLs were well managed (<205 mg/dL) for the first 2 weeks post-transplant. Insulin administration 
was reduced in the immediate post-transplant period (2 weeks) from 6 units daily to 4 units daily. 
Transplant dose = approximately 34,186 IEQ/kg 
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was not able to maintain glucose homeostasis after a 15 day time point in the diabetic monkey 
(Fig 8.1.12). We investigated the immune response to the scaffolds and found no abnormalities 
A functional response was not detected at Day 14 or Day 29 post-transplant.  
Figure 8.1.11 C-Peptide Levels for CN9086 
Figure 8.1.12 Intravenous Dextrose Tolerance Test (IVDTT) to Assess Functional Response of Islets. 
The diabetic NHP recipient maintained detectable C-peptide levels until Day 8 post-transplant. Prior to 
transplant, loss of islet function was confirmed post-STZ (Day -16). Baseline Reading = Day -22  
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were noted in the CBCs or chemistries which supports the safety of the scaffold implant (Fig 
8.1.13). 
A 
B 
 
No abnormalities were noted in the CBCs or chemistries which supports the safety (non-toxicity) of 
the PLG scaffold implant. Formal toxicology studies are pending later this year.  
Figure 8.1.13 Complete Blood Counts (CBCs) (A) and Blood Chemistries (B) for CN9086 for the Pre- and 
Post-Transplant Period. 
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 Scaffolds were explanted at Day33 (Fig 8.1.14) and stained for immune cell populations 
as well as insulin-expressing cells. We found a small population of insulin-expressing cells were 
present in the scaffold after approximately 30 days and immunes cells were predominantly 
located around the perimeter of the scaffold colocalized with the remaining islets (Fig 8.1.15-
16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
 
Macroscopically, the scaffold appears vascularized at retrieval. During 
tissue removal, adhesion of the scaffold-omentum to the colon was 
observed.  
Figure 8.1.14 Seeded Scaffold Day of Transplant (A) and Explanted Scaffold 
at Day 33 (B). 
 
Insulin and glucagon positive cells were identified primarily on the perimeter of the scaffold. 
Figure 8.1.15 Immunohistochemistry of Explanted Scaffold from CN9086 at Day 33. 
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These results led us to evaluate the scaffold’s influence on islet function to determine if it was 
affecting the in vivo output. Irradiation had shown to affect the scaffold integrity earlier, thus we 
A 
 
A 
 
A 
 
A 
 
A 
 
A 
 
A 
 
A 
B 
 
B 
 
B 
 
B 
 
B 
 
B 
 
B 
 
B 
Figure 8.1.16 Immunohistochemistry shows no significant presence of immune cells or inflammation for PLG 
scaffolds  
Scaffold in omentum was stained for alpha-smooth muscle actin (red), CD11b (green) and nuclear counterstain 
with DAPI (blue) with a (A) 10x and (B) 5x objective. Immune cells are localized to the perimeter of the scaffold. 
Insulin secretion from NHP islets seeded on irradiated and non-irradiated PLG scaffolds under GSIS static 
conditions indicate a reduction in insulin secretion index (A) for islets seeded on irradiated scaffolds. (B) 
We show that the loss of function occurs at higher concentrations of glucose while both scaffolds show 
similar insulin secretion levels when exposed to low glucose. (n = 4 biological replicates, error bars 
represent the SEM.) 
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Figure 8.1.17 NHP islet function on irradiated and non-irradiated PLG scaffolds 
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seeded NHP islets on irradiated and non-irradiated scaffolds and tested insulin secretion under 
glucose-challenged environments (Fig 8.1.17). We found islets seeded on irradiated scaffolds 
had a significant decrease in insulin secretion relative to islets seeded on non-irradiated 
scaffolds. This is likely affecting our functional results and suggests that we should further 
optimize our scaffold material composition to aide either diffusion through the scaffold or islet 
viability after the scaffold is irradiated.  
In the future, upon obtaining an IND through the FDA, we anticipate to conduct a pilot 
trial with three, brittle, type I diabetic patients presenting with severe, hypoglycemic 
unawareness qualifying for islet transplantation using UIC’s immunosuppressive protocol. The 
foldable scaffold would be seeded with purified, human islets at a dose of a minimum of 5000 
IEN/kg, and then placed laparoscopically on the omentum of the recipients. Patients would 
receive the UIC protocol of immunosuppression as previously described and be monitored for 
glycemic control, insulin requirements, C-peptide, fructosamine levels and HbA1c, as well as a 
series of other metabolic markers to evaluate overall glycemic and metabolic control. At the end 
of 6 months, the patient would undergo a diagnostic laparoscopy for macroscopic inspection of 
the abdominal cavity and evaluation of the transplant site. Additionally, these investigations 
could deliver important clues on whether this transplant site and the use of scaffolds could 
provide a safe, retrievable site for future, hPSC derived ß-cell transplants into brittle, type I 
diabetic patients.  
We will continue the translation of the research studies in multiple directions. First, the 
NHP studies will continue towards the goal of eliminating the systemic immunosuppression 
through applying the immune tolerance strategies that have been demonstrated to work with the 
transplantation on microporous scaffolds, which includes ECDI-fixation of donor splenocytes or 
FasL modification of islets, both of which are currently be investigated in non-human primate 
models and have demonstrated efficacy with microporous scaffolds. Furthermore, the Shea 
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laboratory is developing nanoparticles for immune tolerance that are aimed as an off-the-shelf 
alternative to isolating and manipulating splenocytes. 
Chapter 8.2: Injectable in situ crosslinked PEG hydrogels with tunable gelation time and affinity-
controlled protein release 
8.2.1 Abstract 
The goal of this work was to develop an injectable protein delivery system for use in the 
middle ear that can provide localized release of NT-3 growth factors in a controlled and 
sustained manner. We identified a one-step mixing formulation to prepare injectable in situ 
forming PEG hydrogels crosslinked by thiol-vinyl sulfone Michael addition that provides 
convenience and flexibility for gel handling due to its tunable gelation time. PEG hydrogels 
prepared by this formulation were further demonstrated with high stability, good mechanical 
rigidity and elasticity, low cytotoxicity, long residence time and low immune responses in vivo. 
PEG hydrogels were the modified with affinity- peptides specific for NT-3 protein, which were 
selected by phage display. NT-3 loaded hydrogels provided a controlled release that was 
dependent upon the peptide affinity and the protein-to-peptide ratio. Collectively, the studies 
developed an injectable PEG hydrogel formulation that allows for affinity-controlled protein 
release. 
8.2.2 Introduction 
Hydrogels have great potential in tissue engineering and local drug delivery412–414. 
Biocompatible hydrogels have been extensively used in cardiac tissue engineering415, bone and 
cartilage repair416, as well as wound healing417. Gels have also been loaded with different 
therapeutic agents such as small drugs, growth factors, and siRNA for local drug delivery to 
various sites in the body, such as the middle and inner ear418, the vitreous body and 
subconjunctival area in the eye419, and the brain420 . Drug delivery to these target sites requires 
low tissue damage in medication administration, flexibility of the hydrogel to adapt to different 
structures in these sites, and low cytotoxicity418–420.  
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Recently, injectable hydrogels have been extensively researched due to their minimally 
invasive injection method to replace implantation surgery and their ability to match irregular 
defects in the target sites421,422. Injectable hydrogels are formed by sol-gel transition induced by 
physical (i.e. electrostatic interactions and hydrophobic interactions) or chemical (i.e. Michael 
addition and Schiff base reaction) crosslinking reactions after injection421,422. External stimuli such 
as temperature and pH are usually required to drive the gelation through non-covalent physical 
crosslinking reactions. A major concern in physically crosslinked hydrogels is their low mechanical 
stability because physical reactions that drive gel formation might be reversed over time, altering 
their morphology and properties and further causing the collapse of the gel structure421,422. In 
contrast, chemically crosslinked hydrogels formed by irreversible covalent bonds provide higher 
mechanical strength and higher stability, but the potential damage of local cells and tissues 
exposed to toxic agents such as initiators in chemical reactions worries people423. Controlling the 
speed of gel formation to provide enough time for handling and injecting is another critical issue 
in designing injectable chemically crosslinked hydrogels424. 
Easy handling and minimal invasiveness provide facility to use injectable hydrogels. 
However, the most important factor in the design and use of hydrogels for delivering therapeutic 
agents is their sustained and controlled drug release414. Burst drug release or immobilization of 
drug diffusion from hydrogels can be the result of an inappropriate ratio of mesh size to drug 
size414,422, poor bioadhesion or short residence time of hydrogels in the target sites425. Previous 
studies suggest developing hydrogels with controlled drug release involve changing the network 
structure of hydrogels by external stimuli to modify drug diffusion and designing cleavable 
chemical bonds or physical interactions between drugs and polymers to sustain drug release414.  
In this study, we introduced an injectable in situ crosslinked poly(ethylene glycol) (PEG) 
hydrogel via Michael addition between 4-arm PEG vinyl sulfone (PEG-4VS) and 4-arm PEG thiol 
(PEG-4SH)426. We found that the thiol-vinyl sulfone reaction provides a tunable gelation time at 
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different temperatures that makes it suitable for gel handling and injecting, and PEG hydrogels 
prepared by this method show high mechanical strength, superior bioadhesion, long residence 
time and good biocompatibility in vivo.  
Macromolecules show burst release in this type of injectable PEG gels. We then designed 
gels with affinity-controlled drug release by conjugating the PEG polymers with protein-targeting 
peptides in order to use their binding affinity to sustain and control protein release from hydrogels. 
NT-3 was chosen as a model protein in this study. NT-3 is a neuron growth factor that is critical 
for recovering cochlear function and regenerating inner ear ribbon synapse after hearing injury427. 
NT-3 has been reported locally delivered to round window membrane (the membrane between 
the middle ear and the inner ear) in the tympanic cavity by hydrogels, and then diffuses through 
the membrane to inner ear428. Because of the irregular structure of the cavity and the high safety 
requirement for intratympanic administration, injectable hydrogels such as thermo-sensitive 
Poloxamer 407 (Pluronic F127) have been favored to deliver drugs to inner ears and  some 
formulations have been undergoing pre-clinical or clinical evaluation428,429. Poloxamer 407 is a 
non-ionic poly(ethylene oxide)a-poly(propylene oxide)b-poly(ethylene oxide)a (PEO-PPO-PEO) 
triblock copolymer that transitions to gels above the lower critical solution temperature (LCST) 
driven by the increased hydrophobic interaction among PPO blocks430. In this study, we used 
physically crosslinked Poloxamer 407 hydrogels as a control to compare with chemically 
crosslinked PEG hydrogel to evaluate the potential of this injectable PEG hydrogel to be used as 
a protein delivery system for inner ear therapy.  
NT-3 targeting peptides were screened out from a Ph.D.TM-7 phage display peptide library 
in this study, and their affinity to NT-3 proteins was quantified by a bio-layer interferometry (BLI) 
based platform. Phage display, a well-established powerful and popular technology, has been 
extensively used in many fields, including antibody engineering431,432, ligand screening433,434, 
peptide drug discovery and manufacture435,436, disease molecular diagnostic analysis437, 
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biosensing438 and vaccine research and development439. The high capacity and abundance of 
random phage display library makes it appropriate for high-throughput screening of peptide 
ligands that specifically bind with the given targets.  
Using our protein-loaded, peptide-conjugated PEG hydrogels, we studied how the peptides’ 
affinity and the peptide-to-protein ratio affect the affinity-controlled protein release from PEG 
hydrogels. Developing injectable hydrogels, of which network morphology and properties could 
be tuned and the affinity between polymers and payloads can be modified, to control the load and 
release of therapeutic agents can consequently lead to significant therapeutic efficacy.  
8.2.3 Materials and Methods 
Materials. 4-arm PEG thiol (20 kD), 4-arm PEG vinylsulfone (20 kD) and 4-arm PEG 
Maleimide (20 kD) were purchased from JenKem Technology USA, and they all have 
pentaerythritol core structure. Poloxamer 407, FITC-dextran (40 kD) and L-cysteine were 
purchased from Sigma-Aldrich. Recombinant human NT-3 and its ELISA kit were from 
BioLegend. Thiol-functionalized peptides were synthesized by GenScript. Alexa Fluor 488 
(AF488) C5 Maleimide, CellTrace FarRed dye and Ellman’s reagent were purchased from 
ThermoFisher Scientific. All the antibodies were from Biolegend. 
Preparation of PEG Hydrogel by One-Step Mixing and Hydrogel Crosslinking 
Efficiency. 4-arm PEG thiol (PEG-4SH) and 4-arm PEG vinyl sulfone (PEG-4VS) were separately 
dissolved in PBS to prepare 30% (w/v) PEG stock solution. 30% PEG-4SH solution, 30% PEG-
4VS solution and PBS were mixed together at 1: 1: 4 or 1: 1: 2 or 1: 1: 1 ratios to prepare cargo-
free 10% or 15% or 20% (w/v) PEG hydrogel, respectively. To prepare protein-loaded, peptide-
conjugated 20% PEG hydrogels, NT-3 proteins were first mixed with thiol-functionalized targeting 
peptides at the desired ratios in 10 µl of PBS, and then mixed well with 10 µl of 30% PEG-4SH 
solution, followed by mixing with 10 µl of 30% PEG-4VS solution. The mixture was then incubated 
at 37 °C to allow gel formation.  
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Hydrogel crosslinking efficiency was identified by measuring the unreacted thiols in PEG 
hydrogels using Ellman’s reagent. Briefly, PEG-4SH solution and PEG-4VS solution were mixed 
at different SH/VS ratios, and then incubated at 37 °C to form hydrogels. 30 µl of PEG hydrogels 
were immersed in 300 µl of Ellman’s reagent solution and then incubated at room temperature on 
a shaker for 15 min. Absorbance of colored products of thiols reacting with Ellman’s reagent was 
measured at 412 nm on a plate reader (BioTex), and the amount of thiols in PEG hydrogels was 
quantified by comparison to a standard curve composed of known concentrations of L-cysteine. 
Swelling Behavior of PEG Hydrogels. 200 µl of 10% (w/v), 15% and 20% PEG hydrogels 
(~12 mm in diameter and ~4 mm in height) were dried up at 60 °C for 2 days, and then placed in 
water at room temperature. At the desired time points, hydrogels were removed from the water, 
dried the surface quickly with Kimwipe paper and then weighted. Three hydrogels were prepared 
for each polymer concentration. Swelling degree (H) was calculated by the following equation: 
𝐻 (%) =  
𝑚𝑡 − 𝑚0
𝑚0
 × 100          (1) 
Water content (W) in the hydrogel was calculated by the following equation: 
𝑊 (%) =  
𝑚𝑡 − 𝑚0
𝑚𝑡
 × 100          (2)  
where mt is the weight of the hydrogel at t time, and m0 is the weight of the dry hydrogel, and 
(mt-m0) is the water weight (Mt) at t time. Winfinite is the water content when the equilibrium is 
reached. 
Elasticity and Rheological Analysis of PEG Hydrogels. The rheological properties of 
10%, 15% and 20% PEG hydrogels were measured on a rheometer (Discovery HR-2, TA 
Instruments). The storage modulus (G′) and loss modulus (G″) were detected keeping strain at 
2% with a continuous frequency (0.1−100 rad/s) at room temperature. Hydrogels were measured 
in the air or in PBS solution. 
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Bioadhesion and Residence Time of Hydrogels.  
In vitro, bioadhesion and residence time of PEG hydrogels and Poloxamer 407 hydrogels 
were studied on a tissue-treated surface. 30 µl of freshly mixed PEG-4VS/PEG-4SH solution or 
Poloxamer 407 solution was added to the bottom of tissue-treated 6-well plates, and then placed 
at a 37 °C incubator for 20 min to allow in situ formation of 20% (w/v) hydrogels. To test the 
adhesion of hydrogels to the tissue-treated surface, we scratched the gels with pipette tips. To 
identify the residence time of hydrogels in the solution, pre-warmed PBS was added to the plate 
wells with hydrogels attached to the bottom surface, and the plate was placed on a shaker (20 
rpm) in a 37 °C incubator. Hydrogels was imaged at the desired time points.  
Ex vivo, bioadhesion of PEG hydrogels to fresh tissue with a flat tissue surface and to a fixed 
tissue with structure defect (tympanic cavity) was studied. 10-20 µl of 20% (w/v) of PEG-
4VS/PEG-4SH mixed solution that included 5 molar% of AF488-C5 Maleimide was loaded to the 
hypodermis layer (subcutaneous tissue) of fresh skin, the inner side of the skull or the large 
intestine extracted from BALB/c mice. These gels were then incubated for 20 min to allow in situ 
gel formation at room temperature. Next, we tested the adhesion of gels to the skin by trying to 
separate them with a forceps. In another study, human temporal bones that were preserved in 
formalin solution were rinsed with PBS and dried up by Kimwipe paper. And then ~5 µl of mixed 
solution was applied to the round window niche of each temporal bone, waiting for 20 min to allow 
in situ gel formation at room temperature. We tested the attachment of hydrogels to the tympanic 
cavity with a forceps, and then we immersed the human temporal bones in PBS and rocked on a 
shaker (20 rpm) at room temperature. Fluorescence of AF488-labeled PEG hydrogels were 
imaged by a fluorescence microscope (Nikon) at days 1, 2, 9 after gel formation.  
In vivo Imaging of Hydrogels (Solution vs. PEG hydrogels vs. Poloxamer 407 
hydrogels). PEG-4SH, PEG-4VS and Poloxamer 407 solutions were sterilized by filtering through 
0.22 µm membranes (Millipore). 5 µl of 5 mM FarRed dye was added to 100 µl of ice-cold PBS 
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solution, and freshly mixed 20% (w/v) PEG-4SH/PEG-4VS solution and 20% (w/v) Poloxamer 
407 solution. And then 50 µl of each solution was subcutaneously injected to the back of BALB/c 
mice with 1 ml syringes with 27 G needles (the body temperature of mice is about 36 °C). Each 
mouse received one injection at the right side and another injection at the left side of the back. 
Mice bearing fluorescent hydrogels were imaged at the desired time points by IVIS (PerkinElmer). 
The first imaging was performed 3 hours after injection. The reduction in the fluorescence intensity 
of solutions or hydrogels in vivo was quantified and plotted over time. 
H&E Staining Tissue samples from subcutaneous fat in mice were cryopreserved in 
isopentane and cooled on dry ice, processed, and embedded within OCT embedding medium 
(Tissue-Tek, Sakura Finetech, Torrance, CA). Sections of 14 µm were stained with hematoxylin 
and eosin (H&E). Immunohistochemical stains were fixed with 4% paraformaldehyde for 30 min, 
blocked and permeabilized for 30-min with staining buffer (5% donkey serum, Jackson 
Immunoresearch; 017-000-121) and 0.1% Triton-X 100 (Acros Organics; 327371000 in PBS), 
stained overnight with primary antibodies at 4 °C, stained for 4 h with secondary antibodies at 4 
°C, and treated with mounting solution DAPI Fluoromount-G (SouthernBiotech; 0100-20). Digital 
images were acquired with a MicroFire digital camera (Optronics, Goleta, CA) connected to an 
Olympus BX-41 fluorescence microscope (Olympus, Center Valley, PA, United States). 
Immunofluorescent Staining. Shaved skin tissues (from epidermis to hypodermis) where 
the gel solution or PBS solution was injected to were collected, minced to small pieces and then 
digested in 2 mg/ml Liberase TM (Roche) for 30 min. Liberase was neutralized with FACS buffer, 
PBS containing 0.5% Bovine serum albumin and 2 mM EDTA. And then cells were isolated by 
passing the tissues through 70 µm strainers (BD Bioscience). Red blood cells were lysed using 
0.2% sodium chloride solution, followed by neutralization with 1.6% sodium chloride solution. For 
analysis of immune cell populations, 1 million cells were suspended in 100 µl of FACS solution 
and blocked with 1 µg anti-mouse CD16/32 antibody for 30 min at 4 °C. Cells were then stained 
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with antibody cocktail solution at 4 °C for 1 h, and then fixed with 4% paraformaldehyde (PFA) 
and measured by Bio-Rad ZE5 cell analyzer. 100 µl of antibody cocktail solution included 0.4 µg 
Brilliant Violet 510 anti-mouse/human CD11b antibody, 0.25 µg Brilliant Violet 605 anti-mouse 
CD11c antibody, 0.25 µg FITC anti-mouse Ly6C antibody, 0.25 µg PE anti-mouse Ly6G antibody, 
0.25 µg PE/Cy7 anti-mouse F4/80 antibody, and 0.25 µg Alexa Fluor 700 anti-mouse CD45 
antibody. 
Identification of NT-3-Targeting Peptides by Phage Display The Ph.D.-7 peptide library 
(NEB, New England Biolabs, USA, E8100S) was used to screen for NT-3 binding peptides 
according to the manufacturer’s instructions with slight modifications. In short, 96-well plates were 
coated with 150 μL/well of the recombinant NT-3 protein (Peprotech) at a concentration of 30 
μg/mL. Biopanning was carried out by incubating the phage display library. After washing away 
the unbound phage with Tris-buffered saline (TBS + 0.1% Tween 20), bound phages were eluted 
in TBS and titrated as described in the standard protocol, and then subjected to the next round of 
panning. The second, third and fourth rounds of panning were done under more stringent 
conditions using shorter incubation times (40 min, 25 min and 20 min in the 2, 3 and 4th round, 
respectively). After four rounds of panning, individual clones were randomly picked and amplified 
in E. coli ER2738 strain to prepare their DNA. 
Individual positive phage clones were amplified, and phage single-stranded DNA was 
extracted and purified using M13 Phage DNA Rapid Extraction Kit (Spin-column, Signalway 
Biotechnology, USA). DNA was sequenced by the Genomics Core Facility in the Center for 
Genetic Medicine (Chicago, IL) using the 96 gIII sequencing primer 5′-
CCCTCATAGTTAGCGTAACG-3′ provided by the Ph.D.-7 peptide library kit to identify common 
peptide sequences among the clones and thus the extent of consensus. Amino acid sequences 
were deduced from phage display peptide DNA sequences by ExPASy Translate tool 
(http://web.expasy.org/translate/). Three peptide sequences were randomly picked from this pool. 
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These phages and a non-consensus control peptide, OVA(323–339) containing a C-terminal 
cysteine, were synthesized and purified by Genemed Synthesis (San Antonio, TX). 
Binding Analysis of NT-3-Targeting Peptides The binding kinetics between the selected 
phage display peptides and target protein NT-3 were studied using a Biolayer Interferometry 
based instrument, Octet Red (ForteBio). The biotinylation of NT-3 was prepared by incubating 
NT-3 with EZ-Link NHS‐LC‐LC‐biotin (Pierce) at a 1:1 molar ratio for 2 hours on ice, followed by 
dialysis to remove the excess biotin reagent. Super Streptavidin (SSA) sensors were equilibrated 
for 10 min in black 96-well microplates (VWR, Radnor, PA, USA) containing 200 µL/well of PBS 
buffer. Then, SSA-coated tips were saturated with 10 µg/mL biotinylated NT-3 at capture levels 
of 0.70 ± 0.15 nm. Purified binding phage display peptides at concentrations ranging from 1nM to 
200µM were associated to protein-saturated sensors followed by dissociation in buffer. Reference 
binding sensors containing only the control peptide were corrected for baseline drift. Nanometer 
shift data were analyzed in Data Analysis 6.4 (ForteBio, Menlo Park, CA, USA). To estimate a 
direct binding affinity via the kinetic rate constants (KD = Kon/Koff, where KD = equilibrium 
dissociation rate constant, kon = association rate constant, and koff = dissociation rate constant) 
the buffer-subtracted octet data were fitted globally to a simple 1:1 Langmuir model. 
Cumulative in vitro Drug Release. Transwell permeable inserts that separate two 
chambers were used to mimic the round window membrane. Boyden chambers and Transwell 
inserts (6.5 mm diameter, 8 µm pore size, Corning), were pre-coated with 1% BSA overnight at 
room temperature. Then 30 µl of dextran-loaded or NT-3-loaded PEG hydrogel prepared in the 
mold was transferred to the surface of the Transwell permeable insert and the lower chamber was 
filled 0.5 ml of pre-warmed PBS containing 1% bovine serum albumin (BSA) that blocks 
nonspecific binding to released proteins to well surface. Plates were rocked at 20 rpm in a 37°C 
incubator with full humidity. At the desired time points, 100 µl of solution was collected from the 
lower chamber followed by supplementing 100 µl of PBS containing 1% BSA. Released NT-3 
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proteins were quantified by ELISA (R&D systems) while released FITC-dextran and FITC-casein 
proteins were quantified by their fluorescence intensity measured by a plate reader (BioTek). 
Accumulative released amount of NT-3, dextran and casein was compared with the initial loading 
amount of macromolecules to obtain the drug release ratios. 
8.2.4 Results and Discussion 
Gelation Time of PEG Hydrogels at Different Temperatures 
The injectable PEG hydrogel was prepared by one-step mixing of PEG-4VS and PEG-4SH 
solutions at a 1: 1 molar ratio (Schematic 8.2.1A). By measuring the free unreacted thiols in PEG 
hydrogels using Ellman’s reagent, the conversion of thiol groups in 10%, 15% and 20% (w/v) PEG 
hydrogels was identified to be 99%, 100% and 100%, respectively (Table 8.2.S1), demonstrating 
the high efficiency of the thiol-vinyl sulfone reaction in gel formation, consistent with previous 
reports440.  
We found this Michael addition reaction between thiol (SH) and vinyl sulfone (VS) 
crosslinked PEG polymers at a moderate reaction rate and therefore provided ample time for gel 
handling and allowed the formation of a uniform gel structure. Gelation time of the PEG-4VS/PEG-
4SH mixed solution was further evaluated by changing the polymer concentration and 
temperature. At body temperature (37°C), the gelation times of 60 µl of 10%-20% PEG hydrogels 
ranged from 5 min to 15 min, and their gelation time increased to 18-46 min at room temperature 
(25°C), and further increased to several hours at 4°C (Table 8.2.1). The slow gelation of PEG 
hydrogels at room temperature and 4°C provides sufficient time and convenience for operators to 
prepare, handle and inject the mixed solution and also allows well mixing of two components to 
prepare uniform gels441 (Fig 8.2.S1). The moderate gelation time of PEG hydrogels at 37 °C 
enables the mixed solution to spread out and fill the space in the target site before gel formation 
occurs442.  
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These features are no longer available when the crosslinking is too fast. This was shown 
when we compared SH-VS reaction with SH-maleimide (MAL) Michael addition reaction in the 
preparation of PEG hydrogels using a one-step mixing method. The SH-MAL gelation rate made 
it difficult to uniformly mix PEG-4SH and PEG-4MAL solutions because significant crosslinking 
occurred when the two solutions came into contact. The fast reaction did not provide enough time 
for mixing and gel injection, and poor mixing produced SH-MAL crosslinked PEG gels with non-
uniform internal morphology (Fig 8.2.S1) and lower conversion of thiol groups than VS-SH 
crosslinked hydrogels (e.g. 89% in VS-MAL crosslinking vs. 100% in VS-SH crosslinking, 20% 
hydrogel, Table 8.2.S1). Collectively, the Michael addition reaction between thiol and vinyl sulfone 
efficiently crosslinked 4-arm PEG polymers at a moderate reaction rate, providing PEG hydrogels 
with tunable gelation time at different temperatures. 
 
Schematic 8.2.1. (A) Schematic representation of preparing PEG hydrogel by one-step mixing 
through Micheal addition. (B) Schematic view of phage display to screen peptides that specifically 
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bind to our model drug, human NT-3 proteins. (C) Schematic representation of affinity-controlled 
protein release from PEG hydrogels that are chemically conjugated with NT-3 targeting peptides 
and physically loaded with NT-3 proteins. 
Table 8.2.1: Gelation time of PEG-4SH/PEG-4VS mixed solutions at different conditions. 
PEG concentration 
(w/v) 
10% 15% 20% 
37°C ~15 min ~7 min ~5 min 
25°C ~46 min ~27 min ~18 min 
4°C ~6.5 h ~3.5 h ~2 h 
 
Viscoelastic and Swelling Properties of PEG Hydrogels 
Physicochemical properties of hydrogels determine their diverse in vivo applications421,422,425. 
We subsequently characterized the rheological properties and swelling behaviors of VS-SH 
Michael addition reaction crosslinked PEG hydrogels. We measured the storage modulus (G’) 
and loss modulus (G”) of pre-fabricated 10%, 15% and 20% PEG hydrogels at a constant 2% 
oscillation strain at room temperature in the air (Fig 8.2.1A-B) and in PBS solution (Fig 8.2.1C-
D). Greater G’ values than G” values indicate the elastic property of PEG gels443. The G’ of all 
hydrogels were independent of angular frequency except a slight decrease for 10% gels at a high 
frequency region (30-100 rad/s), demonstrating the good stability of PEG gels. A higher polymer 
concentration increased the G’ values, as seen by the average G’ value of 20% compared to 15% 
and 10% gels between 0.01 and 100 rad/s in the air (684.5, 478.3, and 259.1 Pa, respectively) 
(Table 8.2.2, Fig 8.2.1A,C). This indicates that 20% PEG gels have a higher degree of 
crosslinking and a higher mechanical rigidity than 15% and 10% gels (24).  
The G” of PEG gels also depended on the polymer concentration. The G” values of all PEG 
hydrogels were constant between 0.25 and 30 rad/s, but the average G” values of 20% gels (1.6 
Pa) and 15% gels (1.5 Pa) were greater than that of 10% gels (0.5 Pa) in this frequency region in 
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the air (Table 8.2.2, Fig 8.2.1A). However, the influence of polymer concentration on the G” 
values seemed less significant in the aqueous solution (Fig 8.2.1C). We further plotted the 
damping factor (tan δ), the ratio of G” to G’, as a function of angular frequency (Fig 8.2.1B,D). 
The tan δ values of all hydrogels are independent of frequency between 0.25 and 30 rad/s with 
an average value ranging from 0.002 to 0.003 (Table 8.2.2), an indicator of ideally elastic solid 
materials (tan δ < 0.01)443. When angular frequency is above 30 rad/s, the tan δ values of all 
hydrogels increased rapidly as the angular frequency increased (Fig 8.2.1B,D), suggesting the 
energy dissipation caused by intermolecular friction was proportional to the frequency444.  
Next, we characterized the swelling behavior of the PEG hydrogels. Swelling behavior 
reflects the water diffusion in the matrix and is another indicator of the relative crosslinking density, 
where stiffer networks exhibit lower swelling445. This property is critical for predicting drug release 
behaviors from hydrogels as well as evaluating their use in tissue engineering446,447. We measured 
the weight gain of 10%, 15% and 20% dried PEG hydrogels placed in water at room temperature 
and plotted their swelling ratio (H) and water content (W) as a function of swelling time (t) (Fig 
8.2.1E-F). All three types of PEG hydrogels reached equilibrium at ~120 min. After 24 h, the 
swelling ratios of 10%, 15% and 20% PEG hydrogels were around 2222%, 1993% and 1718% 
(Fig 8.2.1E), respectively, but their water contents were all close to 95% (Fig 8.2.1F). Thus, an 
increase in polymer concentration decreased the swelling ratio of PEG hydrogels but did not 
significantly influence the water content in PEG hydrogels at equilibrium. The decreased swelling 
ratio at a high PEG concentration (20% vs. 15% and 10%) indicated the decreased capacity of 
20% PEG hydrogels to deform themselves due to their more restricted structure with a higher 
degree of crosslinking445, consistent with their higher mechanical rigidity demonstrated in the 
rheological study.  
The time-programed swelling behavior of PEG hydrogels in water (Fig 8.2.1E) shows 
second-order kinetics, which can be expressed as448:  
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𝑑𝑊𝑡
𝑑𝑡
= 𝐾(𝑊𝑖𝑛𝑓𝑖𝑛𝑖𝑡𝑒 − 𝑊𝑡)
2            (3) 
where K is the kinetics rate constant, and Wt and Winfinite denote the water content at time t 
and at infinite time (at equilibrium), respectively. After integration between the limits (t = 0 and Wt 
= 0) and rearranging, the above equation can be also expressed as448: 
𝑡
𝑊𝑡
=  
1
𝐾𝑊𝑖𝑛𝑓𝑖𝑛𝑖𝑡𝑒
2 + 
𝑡
𝑊𝑖𝑛𝑓𝑖𝑛𝑖𝑡𝑒
                  (4) 
We plotted the variation of t/Wt against time in Fig 8.2.1G and then calculated Winfinite and K 
(Table 8.2.2) by linear regression with R2 > 0.99. We found the polymer concentration doesn’t 
significantly change Winfinite, but the kinetics rate constant K decreased from 0.0466 min-1 for 10% 
PEG gels, to 0.0377 min-1 for 15% PEG gels, and 0.0263 min-1 for 20% PEG gels, indicating 
decelerated swelling rate of PEG gels at a higher polymer concentration due to the less flexible 
structure.  
We also studied the rate of water transportation in PEG hydrogels using the following 
empirical Ritger-Peppas equation414,448: 
𝑀𝑡
𝑀𝑖𝑛𝑓𝑖𝑛𝑖𝑡𝑒
=  𝑘𝑡𝑛                       (5) 
which can be written as (3, 29): 
log
𝑀𝑡
𝑀𝑖𝑛𝑓𝑖𝑛𝑖𝑡𝑒
= log 𝑘 + 𝑛 log 𝑡                       (6) 
where Mt and Minfinite denote the water weight diffused into the gel at time t and at infinite 
time, respectively. k is a constant and n is a characteristic exponent that reflects the diffusion 
mechanism. We plotted the variance of log (Mt/Minfinite) as a function of log (t) and obtained the n 
value by linear regression with R2 > 0.99. n values range from 0.54 to 0.56 for 10-20% PEG 
hydrogels (Table 8.2.2), indicating non-Fickian diffusion (0.5 < n < 1) in PEG hydrogels which 
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occurs when the water diffusion and polymer relaxation rates are comparable449. Overall, VS-SH 
crosslinked PEG hydrogels are ideally elastic materials with good mechanical rigidity and high-
water content (95%). In addition, water transportation in PEG hydrogels showed non-Fickian 
diffusion.  
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(A-D) Rheological analysis of 10%, 15% and 20% PEG hydrogels in the air (A, B) or in the PBS 
solution (C, D). Measurements were performed at room temperature. G’: storage modulus; G”: 
loss modulus. tan δ: damping factor, tan δ = G” / G’. (E) Swelling isotherms of 10%, 15% and 
20% PEG hydrogels in water at room temperature; H (%): swelling ratio; (F) Water content in 
different PEG hydrogels over time; Wt (%): water content at time t; (G) Experimental data of 
water content and time t plotted according to Equation (4) for different PEG hydrogels. Three 
curves overlap. (H) Experimental data of water weight and time t plotted according to Equation 
(6) for different PEG hydrogels; Mt: water weight at time t; Minfinite: water weight at equilibrium. 
Table 8.2.2: Characteristics of PEG hydrogels crosslinked by SH-VS Michael addition 
Polymer concentration (w/v) 10% 15% 20% 
1Average G’ (Pa, 0.01-100 rad/s)  259.1 478.3 684.5 
2Average G” (Pa, 0.25-30 rad/s) 0.5 1.4 1.6 
3Average tan δ (0.25-30 rad/s) 0.0020 0.0029 0.0023 
Figure 8.2.1 Rheological properties and swelling behaviors of PEG gels with different polymer 
concentrations. 
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4Winfinite (%) 96.1 95.2 96.2 
5K (min-1) 0.47 0.38 0.25 
6n 0.54 0.55 0.56 
1G’: storage modulus; 2G’: loss modulus; 3tan δ: damping factor, tan δ = G” / G’; 4Winfinite: 
water content when hydrogels reach equilibrium, from equation (4); 5K: kinetic rate 
constant, from equation (4); 6n: diffusion exponent, from equation (6). 
Bioadhesion of PEG Hydrogels and Macromolecular Release from PEG Hydrogels 
In addition to physicochemical properties, the interactions of hydrogels with biological 
tissues through bioadhesion are also important for their in vivo applications432. One challenge with 
using injectable biomaterials is the discontinuity in the interfacial region between biomaterials and 
tissue, which can affect the therapeutic efficacy of the gel433. As a result, our next studies 
assessed the adhesion of gels to a tissue-treated petri dish surface then fresh tissues with a flat 
surface (hypodermis, skull and large intestine) and fixed tissue with structure defects (tympanic 
cavity in the middle ear). We prepared in situ formed PEG gels on a tissue-treated surface and 
then tried to separate the gel using a tip or forceps (Fig 8.2.2A). Mechanical forces failed to 
remove PEG gels from the surface even after a scratch test was performed. Alternatively, the 
Poloxamer gel bound to the tissue-treated surface by physical bioadhesive forces433 but it began 
to detach from the surface after the scratch test due to its low mechanical strength (Fig 8.2.2A).  
Since this study demonstrated the PEG gel’s ability to adhere to a tissue-treated surface, we 
sought to verify these results by testing the gel’s bioadhesion to different tissue samples. The 
surface of the hypodermis (subcutaneous area), skull and large intestine is mainly composed of 
adipose tissue, connective tissue and epithelial tissue, respectively. Similar to the tissue-treated 
petri dish surface, mechanical forces were not able to remove PEG gels from the tissues 
regardless of the tissue type, structure and property of target site (flat vs. cavity, fresh vs. fixed 
tissues), indicating their good bioadhesion (Fig 8.2.2B-C). Tight attachment of PEG gels to 
tissues might result from chemical bonds formed between PEG-VS/PEG-SH and tissue-derived 
biomolecules that includes thiol during in situ chemical crosslinking. Good bioadhesion is 
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associated with long residence time of hydrogels in vivo, which is critical for sustained local drug 
delivery432. We tested gel’s residence time in vitro and ex vivo by immersing PEG gels that were 
attached to tissue-treated surface or fixed tissue in PBS and rocked them at 37 °C or room 
temperature. And we found PEG gels continued to have a consistent size and good attachment 
to both a tissue-treated surface and real tissues over a long time (Fig 8.2.2A,C) while Poloxamer 
407 gels quickly dissolved in PBS (Fig 8.2.2A).  
 Longer residence time of PEG hydrogels in the aqueous solution than Poloxamer 407 gels 
suggests the gels would have a more sustained drug release. In an in vitro drug release model, 
we prepared in situ formed gels on the Transwell insert (6.5 mm in diameter, with 8 µm pores), 
and then filled the lower chamber with PBS solution containing 1% BSA. The release of 40 kD 
FITC-dextran and 24 kD FITC-casein protein from the PEG and Poloxamer gels at the air-liquid 
surface were compared. Due to the dissolving of 20% Poloxamer 407 gels, gels are collapsed 
fast, resulting in > 90% of release of dextran and casein at 8 h (Fig 8.2.2D). In contrast, only 16%, 
27% and 43% of dextran were released from 20%, 15% and 10% PEG gels at 8 h, respectively.  
Similar to the behavior of water diffusion into dried PEG gels (Fig 8.2.1E), the behavior of 
macromolecule release from PEG gels also shows second-order kinetics (Fig 8.2.2D). We then 
defined Rt as the ratio of cumulative released drug at time t vs. total drugs, and then plotted the 
t/Rt over time (Fig 8.2.2E). The kinetics rate constant K of dextran or casein release from PEG 
gels with different polymer concentrations were obtained with linear regression R2 > 0.99 
according to Equation (4) with the replacement of Wt to Rt (Fig 8.2.2E and Tables 8.2.2). Similar 
to the reduced water diffusion into dried 20% PEG gels compared to 10% and 15% gels (K values 
in the swelling of 10%, 15% and 20% PEG gels are 466, 377, 263 min-1, Table 8.2.1), a higher 
polymer concentration in PEG hydrogels also showed slower dextran and casein release from 
20% PEG gels than from 15% and 10% gels. The K values in the release of dextran from 10%, 
15% and 20% PEG gels are 2.3 d-1, 1.9 d-1 and 1.6 d-1, respectively. (Table 8.2.2). Dextran release 
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from 20% Poloxamer gels are 11-fold faster than that from 20% PEG gels, respectively. Strong 
bioadhesion, long residence time and water-insolubility of in situ VS-SH Michael addition reaction 
crosslinked PEG hydrogels imply their suitability for a broad range of in vivo applications. 
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(A) 
Morphology of freshly prepared PEG and Poloxamer 407 hydrogels, gels scratched by a tip and 
gels that were incubated in PBS solution 37 °C for the desired times. In situ formed PEG gels 
bind tightly to tissue-treated surface and continue to have similar size and morphology in PBS 
over 28 days. Poloxamer 407 gels disappeared in pre-warmed PBS solution in 5 min (The arrow 
indicates the original location of the gel). Scale bar = 5 mm. (B) Adhesion of in situ formed AF488-
labeled PEG hydrogels (green, indicated by arrows) to different fresh tissues, including 
hypodermis, skull and large intestine. Gels do not detach the tissue when they are lifted with a 
forceps (the horizontal level is indicated by the water level in the lower panels). Scale bar = 5 mm. 
(C) Residence of AF488-labeled 20% PEG hydrogels (green) in the tympanic cavity over 9 days 
in PBS. The arrow indicates the round window in the tympanic cavity of middle ear. Scale bar = 5 
mm. (D, E) in vitro cumulative release of FITC-dextran (D) from 10%, 15% and 20% PEG 
hydrogels and 20% Poloxamer 407 hydrogels. And the ratio of cumulative released dextran (E) 
to total drugs, Rt, plotted against time t according to Equation (4) for different hydrogels. 
Figure 8.2.2 Bioadhesion and in vitro residence time analysis of PEG hydrogels 
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Table 8.2.3 Quantitative analysis of in vivo Far-Red decay and in vitro NT-3 protein 
release from PEG and Poloxamer 407 hydrogels 
 Far-Red fluorescence reduction  
in vivo 
 Cumulative NT-3 release  
in vitro 
20%  
PEG  
20%  
Poloxamer  
Dye  
solutio
n 
 10%  
PEG 
15%  
PEG 
20%  
PEG 
20% 
PEG 
with 
peptides
2 
20%  
Poloxamer 
1K  1.1 d-1 5.3 d-1 9.7 d-1  4.5 d-1 3.9 d-1 3.1 d-1 1.8 d-1 13.8 d-1 
1K: kinetic rate constant, from equation (4). 2NLKEPYA peptides are conjugated to PEG hydrogels 
at a NT-3: peptides = 1: 50 molar ratio. 
 
In vivo Gel Degradation and Immune Responses to PEG Hydrogels   
The injectability and the superior characteristics of PEG hydrogels to Poloxamer 407 gels 
were further demonstrated by their in vivo behaviors. FarRed dye-loaded 20% PEG-4VS/PEG-
4SH mixed solution and ice-cold 20% Poloxamer 407 solution (control) were subcutaneously 
(s.c.) injected to the back of mice to allow gel formation at the body temperature of mice (~36 °C). 
We observed a fine shape of PEG hydrogels in the subcutaneous area with FarRed fluorescence 
uniformly distributed in the gel after gel formation (Day 0, 3 h after injection), indicating the similar 
thickness of the gel at different areas. The PEG gel showed minimal degradation demonstrated 
by the shape and size of PEG hydrogels not changing over 28 days. This could be due to their 
good mechanical strength and the stability of gels in vivo (Fig 8.2.3A, hydrogels on the right side 
of the mouse back are shown in Fig 8.2.S2).  
In contrast, similar to s.c. injected PBS solution, in situ formed Poloxamer 407 gels had no 
definite shape and no uniform thickness, as seen by the uneven fluorescence distribution of the 
FarRed dye (Day 0). This is partly due to the reversible physical forces driving crosslinking and 
the gels’ low mechanical rigidity. These properties resulted in easy deformation of Poloxamer 407 
gels under the skin during gel formation. In contrast to the PEG hydrogels that had a consistent 
fluorescent shape over a month, fluorescent Poloxamer 407 gels decreased their size and 
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intensity significantly over time (Fig 8.2.3A, 8.2.S2). We extracted gels at day 28 after s.c. 
injection. As shown in Fig 8.2.3B, most Poloxamer 407 gels disappeared due to water-solubility 
or gel degradation430, indicating their short residence time in the s.c. area. In contrast, fluorescent 
PEG gels had a similar size at day 28 vs. as day 0 (Fig 8.2.3B), consistent with in vitro results 
(Fig 8.2.2A).  
Gel’s residence time, degradation and water solubility also influence the drug release 
behavior in vivo. We quantified and compared the decay of the FarRed signal in different gels. In 
vitro, FarRed dyes dissolved in PBS solution are resistant to photo-bleaching over time, as seen 
by the consistent fluorescence intensity of FarRed dye solution preserved in a tube at room 
temperature over a month (Fig 8.2.S3). In vivo, decreased fluorescence of FarRed dye can be 
ascribed to that dyes are adsorbed and quenched by cells and tissues when dyes are diffused 
out the gel or when hydrogels degrade. PEG hydrogels lost ~33% of FarRed fluorescence in the 
first 3 days, following by the slow attenuation of fluorescence. In contrast, Poloxamer 407 
hydrogels and injected PBS solution lost ~82% and ~92% of FarRed fluorescence, respectively, 
in the first 3 days (Fig 8.2.3C). Because the decay of FarRed fluorescence in vivo shows second-
order kinetics in gels or solutions (Fig 8.2.3C), we then defined Ft is the fluorescence reduction 
ratio at day t after s.c. injection, and then plotted the t/Ft vs. t according to Equation (4) with the 
replacement of Wt to Ft. As shown in Fig 8.2.3D, t/Ft vs. t shows linear regression with R2 > 0.99 
in all the three conditions in vivo (Table 8.2.3), and the kinetics rate constant of FarRed loss in 
Poloxamer 407 gels (K = 5.3 d-1) is ~5-fold faster than in PEG gels (K = 1.1 d-1), consistent with 
the in vitro drug release data (Fig 8.2.2D-G, Table 8.2.3). Good mechanical strength, water 
insolubility and non-degradation contribute to the long residence time of PEG hydrogels in vivo, 
resulting in sustained FarRed release from hydrogels.  
We subsequently studied the foreign body responses to in situ formed PEG hydrogels that 
reflect the in vivo biocompatibility of hydrogels450. The frequency of immune cell subsets in the 
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skin tissue surrounding PEG gels at different time points were analyzed and then compared with 
control tissues, such as normal skin and skin tissues that were touched with PBS or Poloxamer 
gel for a month. A total of four major immune cell populations were characterized in this study, 
including CD11b+F4/80+ macrophages, CD11b+Ly6G+ polymorphonuclear neutrophils (pMN), 
F4/80-Ly6C+ monocytes and F4/80-CD11c+ dendritic cells (DCs) (Fig 8.2.S4). In the skin tissue 
touching in situ formed PEG hydrogels, we observed doubled frequency of CD45+ leukocytes at 
day1 after injection compared with normal tissues due to the acute inflammation that occurs after 
s.c. implantation450 (Fig 8.2.3E). Increased leukocytes mainly result from the recruitment of pMN 
and monocytes, as seen by a 6-fold increase in pMN and a 4-fold increase in monocytes relative 
to normal skin (Fig 8.2.3F). But this acute immune response to PEG gels at day1 didn’t cause 
evitable tissue redness or ulceration, indicating the low tissue damage during injection and in situ 
PEG gel formation (Fig 8.2.S5). After alleviating the acute inflammation over a month, leukocytes, 
pMN and monocytes in the skin tissues dropped greatly, and their frequencies (PEG, day28) are 
close to normal skin tissue or tissues treated with PBS solution (Fig 8.2.3F), indicating the good 
biocompatibility of PEG hydrogels in vivo. In contrast to PEG gels, the frequency of DCs in the 
skin tissue surrounding Poloxamer gels is higher than all the other groups at day28 (Fig 8.2.3F), 
resulting in a slightly higher leukocytes population (Fig 8.2.3E). This is probably because 
gradually degraded Poloxamer gels were regarded as foreign objects and hence were taken up 
by DCs for antigen-presenting, which stimulates the recruitment of DCs to gel sites over a long 
time451. Overall, in situ formed PEG hydrogels initiate acute inflammation after injection, which is 
common for s.c. implants450, but the immune responses were greatly alleviated in a month, 
demonstrating the good biocompatibility of PEG hydrogels in vivo. 
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(A) Whole-animal images of s. c. injected solutions or hydrogels on the left back of mice. (B) 
Morphology of FarRed-loaded gels at day 28 post s.c. injection; solid line distinguishes the PEG 
gel edge or FarRed traces at day 28 while dash line indicates the original size the gel/solution at 
day 0. Scale bar = 5 mm. (C) Quantitative image analysis of fluorescence reduction over time; Ft: 
fluorescence reduction at day t. Ft values were averaged by the two gels at the mouse back. (D) 
Experimental data of the fluorescence reduction Ft and time t plotted according to Equation (4) 
for different hydrogels. (E, F) Flow analysis of the frequency of immune cell subsets in the skin 
tissues surrounding the PEG gel at day 1 and day 28 after injection.  
 
Screening and Identifying NT-3 Binding Peptides  
We employed an affinity-controlled NT-3 release system from the injectable in situ 
crosslinking PEG hydrogel to prevent a significant burst release while providing sustained release 
profiles. Unlike Poloxamer 407 hydrogels, the SH and VS groups on PEG allow chemically 
conjugation to thiol-functionalized peptides that can reversibly associate with NT-3 to control 
release. We screened short peptides that can selectively bind NT-3 using a Ph.D.-7™ phage 
Figure 8.2. 3 In vivo fluorescence analysis of FarRed-loaded PBS solution, PEG hydrogels and 
Poloxamer hydrogels over time. 
 
Figure 8.2. 4 In vivo fluorescence analysis of FarRed-loaded PBS solution, PEG hydrogels and 
Poloxamer hydrogels over time. 
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display peptide library (Schematic 8.2.1B). Following four rounds of biopanning, the amounts of 
output phages on NT-3 coated wells vs. control proteins (bovine serum albumin (BSA) and casein) 
were determined by titration (Fig 8.2.4A). The output for NT-3 coated well was at approximately 
105-fold higher than BSA and casein (from 1.3 × 108 to 1.4 × 104 and 2.0 x 103, respectively), 
suggesting that the phages had a specific affinity to NT-3. After the fourth round of panning, a 
total of 17 phage clones were randomly selected and amplified, and the DNA of these selected 
clones was extracted and sequenced (Table 8.2.4). Three peptides, including NLKEPYA, 
ADARYKS, and SLTEPSS were picked from the fourth-round phage pool, and all three showed 
strong NT-3 binding in a monoclonal phage ELISA assay compared to casein proteins (control) 
(Fig 8.2.4B). 
The affinity and binding kinetics of the three peptides were quantified by binding analysis 
using Octet RED platform that is based on bioluminescence imaging (BLI) to evaluate biomaterial 
interactions. In this test, NT-3 proteins were immobilized to the super streptavidin coated 
biosensor surface, and soluble peptides were injected at concentrations ranging from 10 to 200 
µM. Real-time association and dissociation of these peptides to immobilized NT-3 are shown in 
Fig 8.2.4C and the association rate kon, the dissociation rate koff and the binding affinity KD (KD = 
koff / kon) are summarized in Table 8.2.5. The binding analysis identified that NLKEPYA peptides 
(KD = 2.8 µM) and SLTEPSS (KD = 7.5 µM) show superior binding affinity for NT-3 than the 
ADARYKS peptide (KD = 24.0 µM). Although the ADARYKS peptide had a similar kon value to the 
other two peptides, its koff value was much greater, resulting in a higher KD value that indicates its 
poor affinity for NT-3 (Table 8.2.5).    
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(A) Plots of round 4 phage output on plates coated overnight with NT-3, BSA, or casein. (B) ELISA 
measurements of NLKEPYA, ADARYKS and SLTEPSS peptides or control Ph.D.TM-7 peptide 
binding to NT-3 or casein (control). (C) Binding kinetics for NLKEPYA, ADARYKS and SLTEPSS 
peptides at 10, 100 and 200 µM concentrations to NT-3 proteins. kon, koff and KD are summarized 
in Table 8.2.5. 
 
Table 8.2.4: Sequencing results of 17 positive phage colonies that show specific binding 
to NT-3 proteins. 
Round Sample Sequence 
4 1 DHINLTR 
4 2 THNKLLV 
4 3 LLAPPYW 
4 4 ANPTFFS 
4 5 FHSTDPS 
4 6 SPLHSNY 
4 7 AWPYVTL 
Figure 8.2.5 Identification of NT-3 binding peptides. 
 
Figure 8.2.6 Bioadhesion and in vitro residence time analysis of 
PEG hydrogelsFigure 8.2.7 Identification of NT-3 binding 
peptides. 
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4 8 LSAFGTH 
4 9 NLKEPYA 
4 10 TQMWAMG 
4 11 ADARYKS 
4 12 LITNGHL 
4 13 GSTSFSK 
4 14 MNDAFRN 
4 15 NQRVDKV 
4 16 YRAIPSP 
4 17 SLTEPSS 
 
Table 8.2.5: Binding kinetics and binding affinity of NT-3 targeting peptides 
Peptides kon (×103, M-1s-1) koff (×10-2, s-1) KD (µM) 
NLKEPYA 3.99 1.37 2.8 
ADARYKS 5.24 15.5 24.0 
SLTEPSS 3.37 3.39 7.5 
 
Peptide-Conjugated PEG Hydrogels Show Affinity-Controlled NT-3 Release 
The kinetics and pattern of NT-3 release from unmodified PEG hydrogels, at multiple 
percentages of PEG, was initially evaluated. We added 1 µM of NT-3 proteins in PEG-4SH/PEG-
4VS solutions to allow physical protein loading during gel formation. Protein loading does not 
significantly change the gelation time of PEG (data not shown). Protein release was studied at 
the air-liquid surface in a Boyden chamber that mimics the round window membrane. In this 
model, protein-loaded hydrogels were in situ formed on the Transwell membrane insert in the 
upper Boyden chamber while the lower chamber was filled with PBS buffer containing 1% BSA. 
NT-3 proteins are released from gels that are placed at the air-liquid surface, and then diffuse 
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through the membrane to the buffer in the lower chamber. We quantified the amount of NT-3 
accumulated in the lower chamber at different time points with ELISA, and then plotted time-
programmed cumulative NT-3 release from 10%, 15%, and 20% unmodified PEG hydrogels or 
Poloxamer 407 hydrogels. NT-3 release from PEG hydrogels showed second-order kinetics, 
including the burst release in the first 24 hours followed by the slow release afterwards (Fig 
8.2.5A). We defined Rt as the ratio of cumulative released NT-3 amount at t time vs. total NT-3 
loaded in the gel, and then plotted t/Rt against time (Fig 8.2.5B). The kinetic rate constant (K) of 
NT-3 release from PEG gels was obtained according to Equation (4) where Wt was replaced to 
Rt, with linear regression R2 > 0.98. A correlation between release rates and polymer 
concentrations were observed with higher polymer concentration decelerating the NT-3 release. 
Specifically, K values for NT-3 release from 10%, 15% and 20% PEG hydrogels are 4.5 d-1, 3.9 
d-1 and 3.1 d-1, respectively (Table 8.2.3). These results are consistent with the observation that 
water diffusion into dried 20% PEG hydrogels is slower than 10% and 15% hydrogels (Table 
8.2.2) because 20% hydrogels have a more constrained structure and a relatively smaller pore 
size inside the hydrogels, which limit the payloads or solutions to diffuse in or out. In contrast to 
stable PEG hydrogels, Poloxamer 407 hydrogels gradually dissolve and collapse at the air-liquid 
surface, causing a > 90% of release of payloads in 8 hours, while at this time point, only 8% of 
NT-3 proteins were released from 20% PEG hydrogels. Afterwards, NT-3 was continuously 
released from PEG hydrogels and 25% of NT-3 is released from 20% PEG hydrogels in a week 
(Fig 8.2.5A). NT-3 release from 20% Poloxamer hydrogels (K = 13.8 d-1) is ~4.5-fold faster than 
from 20% PEG hydrogels (K = 3.1 d-1, Table 8.2.3), comparable to the ~5-fold faster loss of Far-
Red fluorescence from Poloxamer hydrogels than from PEG hydrogels in vivo.  
Next, release from the affinity PEG hydrogels was analyzed using the three peptides with 
varying affinity for NT-3 (Table 8.2.5) that were separately conjugated to 20% PEG hydrogels at 
a protein: peptide = 1:50 molar ratio. NLKEPYA and SLTEPSS peptides, which have high affinity 
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to NT-3 (KD < 10 µM, Table 8.2.5), suppressed protein release in the first 8 hours and 2 days , 
while the lower affinity ADARYK (KD = 24 µM) did not significantly change NT-3 release in the first 
2 days (Fig 8.2.5C). For the NLKEPYA-conjugated PEG hydrogels, release exhibited second-
order kinetics similar to the unmodified PEG hydrogels, except for a slower release profile (Fig 
8.2.5D). Quantitatively, the kinetic constant K calculated from Equation (4) for NT-3 release from 
20% PEG hydrogels decreased from 3.2 d-1 to 1.1 d-1 after conjugation with NLKEPYA peptides 
at a protein: peptide = 1: 50 molar ratio (Fig 8.2.5E, Table 8.2.3), suggesting a ~3-fold lower NT-
3 release by peptides and thus demonstrating that reversible binding within the gel can 
successfully control the release of NT-3 (Schematic 8.2.1C). In addition to peptide affinity, we 
also observed that a higher protein-to-peptide ratio in the gel can further decelerate the NT-3 
release, yet it plateaus at protein-to-peptide ratios below 1/100 (Fig 8.2.5F) 
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(A) Cumulative NT-3 release from 10%, 15% and 20% of unmodified PEG hydrogels and 20% 
Poloxamer 407 hydrogels over 7 days. Rt: released ratio, Rt = released protein amount at t time / 
total protein amount. (B) Experimental data of Rt in (A) and time t plotted according to Equation 
(4). (C) Cumulative NT-3 release from 20% PEG hydrogels conjugated with NLKEPYA, 
ADARYKS, or SLTEPSS at a protein: peptide = 1: 50 molar ratio in 8 hours and 2 days. (D) 
Cumulative NT-3 release from 20% PEG hydrogels conjugated with NLKEPYA at a protein: 
peptide = 1: 50 molar ratio over a week. (E)  Experimental data of Rt in (C) and time t plotted 
according to Equation (4). (F) Cumulative NT-3 release from 20% PEG hydrogels conjugated with 
NLKEPYA at different protein: peptide molar ratios in 2 days. 
 
8.2.5 Conclusions 
In this study, we identified a one-step mixing formulation to prepare injectable in situ 
crosslinking PEG hydrogels by using SH-VS Michael addition that has a moderate reaction rate. 
Tunable gelation time of this PEG-4SH/PEG-4VS formulation, depending on temperature and 
polymer concentrations, provides time for handling at room temperature, yet efficient gelation at 
body temperature. PEG hydrogels crosslinked by SH-VS Michael addition were elastic and stable, 
with good mechanical rigidity and high-water content. Water transportation in PEG hydrogels 
showed non-Fickian diffusion. The gels have better bioadhesion, longer in vivo residence time 
and better biocompatibility compared to physically crosslinked Poloxamer 407 hydrogels.  
This injectable chemically crosslinked PEG hydrogel formulation is suitable for delivering 
drugs to biological sites that have irregular structure and require low cytotoxicity, such as the 
tympanic cavity in the middle ear. We verified the potential of this formulation to deliver NT-3 
protein to the round window membrane in the middle ear. Unmodified PEG hydrogels release NT-
3 proteins at second-order kinetics. The affinity PEG hydrogels, which were conjugated with 
peptides that specifically bind NT-3, suppressed the burst release. NT-3 release from PEG 
hydrogels separately conjugated with three peptides of varying affinity demonstrated sustained 
protein release from the hydrogels, with tuning of the affinity-controlled release possible through 
the protein-to-peptide ratio.  
 
Figure 8.2.8 in vitro NT-3 protein release from unmodified or peptide-conjugated PEG 
hydrogels 
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8.2.6 Supporting Information 
P E G -4 V S /P E G -4 S H
(1 / 1 )
P E G -4 M A L /P E G -4 S H
(1 / 1 )
2 0 %  P o lo x a m e r  4 0 7
h y d r o g e l
2 0 %  P E G  h y d r o g e l
A B C
 
Figure 8.2.S1 Hydrogel morphology observed under the microscope showing the uniform 
internal structure (A, C) and non-uniform internal structure (B). Scale bar = 5 µm. 
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Figure 8.2.S2 Whole-animal images of s. c. injected hydrogels or solutions on right back of 
mice. 
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Figure 8.2.S3 Fluorescence intensity of the FarRed solution that was preserved in a tube at 
room temperature over a month. 
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Singlets gated by side scatter, CD45+ leukocytes gated as AF700+, CD11b+F4/80+ macrophages 
gated as BV510+PE/Cy7+, CD11b+Ly6G+ polymorphnuclear neutrophils (pMN) gated as 
BV510+PE+, F4/80-Ly6C+ monocytes gated as PE/Cy7-FITC+, and F4/80-CD11c+ dendritic cells 
gated as PE/Cy7-BV605+. All gates were set according to appropriate positive and negative 
controls. Each arrow indicates a nested gate where the positive population from the previous plot 
is represented on the subsequent plot. BV: brilliant violet. 
c e l ls
s in g le ts
C D 4 5 +
C D 4 5 + C D 1 1 b +
C D 4 5 + C D 1 1 b + F 4 /8 0 +
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Figure 8.2.S4 Gating strategies for flow cytometric analysis of immune cell markers showing 
identification of cells 
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Figure 8.2.S5 Morphology of FarRed-loaded PEG gel at day 1 post s.c. injection. Solid line 
distinguishes the gel edge. Scale bar = 5 mm. 
 
Table 8.2.S1: Thiol conversation in PEG hydrogels 
PEG 
concentration 
(w/v) 
 
Formulation (molar ratio) 
 
Thiol Conversation 
10% PEG-4VS/PEG-4SH (1: 1) 99% 
15% PEG-4VS/PEG-4SH (1: 1) 100% 
20% PEG-4VS/PEG-4SH (1: 1) 100% 
20% PEG-4MAL/PEG-4SH (1: 1) 89% 
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